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The receptor for advanced glycation end products (RAGE) is a multiligand, cell surface receptor. 
Isolated from lung, the organ in which it is most abundant, RAGE has since been shown to be a 
pro-inflammatory mediator in the pathogenesis of diabetes, atherosclerosis, rheumatic and 
neurodegenerative syndromes, and cancer. However, despite its localization, the role of RAGE in 
asthma and allergic airway disease is largely unknown. 
The studies described herein explore RAGE’s effect on disease phenotype using several 
different models of allergic airway disease/asthma in mice, with house dust mite extract or 
ovalbumin as the provoking allergen. Respiratory mechanics were assessed using mechanical 
ventilation and the forced oscillation technique; bronchovascular architecture and airway 
remodeling were evaluated using general histochemical stains. Expression of RAGE, 
immunoglobulin, and relevant cytokines was characterized by standard protein detection 
methods and/or real-time PCR, while immunohistofluorescence microscopy was used to 
determine the cellular localization of proteins of interest. 
In both house dust mite and ovalbumin models of chronic allergic airway disease/asthma, 
the absence of RAGE abolishes most assessed measures of pathology, including airway 
hypersensitivity (resistance, tissue damping, and elastance), eosinophilic inflammation, and 
mucus hypersecretion. IL-17 demonstrates complex regulation, with elevated baseline expression 
in RAGE knockouts, but no induction in response to allergen challenge. IL-4 and IL-25 
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 v 
secretion, immunoglobulin isotype class switching and antigen recognition are intact in the 
absence of RAGE. In contrast, allergen-induced up-regulation of eotaxin, eotaxin-2, IL-5, IL-13, 
and IL-33 is abrogated in RAGE’s absence. 
RAGE’s soluble isoform is a decoy receptor that impedes ligand binding to the 
membrane isoform and thus downstream signaling. Soluble RAGE (sRAGE) has been 
efficacious in ameliorating disease in a broad array of models in which the membrane RAGE 
isoform is thought to be involved. Because few studies have explored the use of this agent in the 
lung, clearance and biodistribution studies were performed, exploring three common routes of 
administration; intratracheal delivery was found to be substantially superior to other modes. 
sRAGE was used as a therapeutic in an animal model of asthma and was shown to markedly 
reduce inflammation, suggesting that inhibition of RAGE may serve as a promising therapeutic 
strategy. 
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1.0  INTRODUCTION 
What’s in a name? When it dictates the first two decades of one’s life, much apparently. Such is 
the story of the protein RAGE, whose name and circumstances of discovery have had a 
prevailing influence on the subsequent course of research. More than just a commentary on the 
extraordinary power of language, the history of RAGE research illustrates the triumph of 
biochemistry as a discipline and biochemical mechanism in particular over more archaic 
teleological thought patterns, within the modern biological research enterprise. Thus, it is 
RAGE’s putative molecular interactions that have captivated the scientific discourse since its 
discovery in 1992; the organ in which it is predominantly expressed – the lung – and the obvious 
implications with regard to pulmonary homeostasis and pathophysiology, have been neglected as 
tangential details. The studies set forth herein seek to redress this imbalance, as it were, by 
shedding light on the role of RAGE in one of the most important diseases of the lung: asthma. 
1.1 RAGE BIOLOGY 
1.1.1 RAGE structure and function 
The receptor for advanced glycation end products (RAGE) is a multiligand receptor of the 
immunoglobulin superfamily of surface-expressed receptors.1 The discoverers of RAGE 
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identified it as a 35 kDa advanced glycation end product-binding protein isolated from bovine 
lung, but noted that expression of RAGE from cDNA transfected into cell lines demonstrated a 
50 kDa protein. They attributed the discrepancy to multiple isoforms and variable post-
translation glycosylation. The extracellular domain is composed of three immunoglobulin-like 
domains: V, C1, and C2, named for their resemblance to the corresponding variable and constant 
domains of immunoglobulin.1 The extracellular domain, and specifically the V-C1 functional 
domain (which acts as single unit2), is responsible for ligand binding.3 A single hydrophobic 
transmembrane domain links the ligand-binding extracellular portion to a cytoplasmic domain, 
which is essential for downstream signal transduction.4-6 RAGE is glycosylated at two 
asparagine residues,7 a property known to be critical in RAGE ligand binding and function.3,8,9 In 
view of this, it is worth pointing out at this juncture that unfortunately many of the biochemical 
studies of RAGE have been performed on protein expressed in bacteria, yeast, or insect cells, in 
which glycosylation is either absent or at any rate markedly less complex than in higher 
eukaryotes. 
RAGE comes in two flavors: a membrane isoform (mRAGE) and essentially two soluble 
isoforms. The soluble isoforms include the entire extracellular portion of the protein (thus 
inheriting the ligand binding capacity of the membrane isoform), while lacking the 
transmembrane and cytosolic domains. Soluble isoforms of RAGE may arise via alternative pre-
mRNA splicing10 (there may be some variability in splicing, such that multiple products are 
possible) or proteolytic cleavage of the membrane isoform. The former is sometimes called 
endogenous secretory RAGE11 (esRAGE) whereas the latter is named sRAGE, a term that 
sometimes subsumes all soluble RAGE isoforms. Matrix metalloproteinases have been found to 
mediate proteolytic cleavage of RAGE12,13; the majority of soluble RAGE in the circulation is 
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sRAGE, the cleaved form. As alluded to previously, the cytoplasmic signaling domain is critical 
to RAGE’s function as a pro-inflammatory receptor. Synthetic isoforms lacking this domain, 
termed DN-RAGE, act in a dominant negative fashion to inhibit the function of normal RAGE,4 
as well as of any other receptors binding to RAGE’s ligands. It is not surprising, therefore, that 
soluble RAGE isoforms (regardless of their origin as cleavage product or secreted protein), 
which of course do not possess a signal transduction apparatus, antagonize the function of 
membrane RAGE. sRAGE (in the sense of all soluble isoforms of RAGE) does this by 
sequestering pro-inflammatory ligands, thus acting as a decoy receptor. It is important to state 
here that, as many RAGE ligands are also ligands of other pro-inflammatory receptors, some 
effects of sRAGE may be attributable to antagonism of non-RAGE signaling axes. 
Agonistic ligation of RAGE is believed to activate multiple signal transduction pathways, 
including, but not limited to, p38 mitogen activated protein kinase (MAPK),14 p42/p44 MAPK 
(extracellular-signal-regulated kinase 1/2 (ERK 1/2)),15 and p21 (Ras) MAPK.16 This eventuates 
in the release of NF-κB from cytosolic sequestration and translocation into the nucleus to induce 
transcription of genes encoding pro-inflammatory mediators.17 RAGE activation by application 
of ligands frequently induces up-regulated RAGE expression, a positive regulatory feedback 
loop that may be rationalized by the existence of three putative NF-κB-like binding sites in the 
promoter region of RAGE itself.18 Additionally, sustained RAGE activation induces increased 
transcription of the p65 subunit of NF-κB, a phenomenon that amplifies the reserve of this pro-
inflammatory transcription factor and thus the dynamic range of the downstream response.19 
On the basis of history and overarching hypotheses, RAGE ligands may be partitioned 
into three categories. The first of these is comprised of the advanced glycation end products 
(AGEs), which continue to bear such a strong mark in the field of RAGE research by virtue of 
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historic primacy. To summarize briefly, AGEs are proteins or lipids with sugar moieties 
incorporated via non-enzymatic organic reactions, such as the Maillard reaction. While AGEs are 
normally generated endogenously at low levels, the hyperglycemic and oxidative state in 
diabetes promotes production of elevated levels of AGEs. Although receptors for the uptake of 
AGEs exist on phagocytic cells,20,21 it was only with the discovery of putatively endothelium-
expressed RAGE that an elegant mechanism connecting elevated AGEs to vascular 
complications of diabetes was in place.1 However, recognizing the implicit absurdity of a 
receptor whose apparent sole purpose is to lie in wait for diabetes to arise (with no obvious 
adaptive role in that disease), and perhaps because of considerations related to RAGE’s 
molecular architecture, the authors suggested that AGEs may not be the natural ligands of 
RAGE. This set the stage for the ensuing years of research devoted to other RAGE ligands. 
The main body of research on RAGE ligands explored RAGE’s role as a pattern 
recognition receptor (PRR). PRRs were identified as the key sensors of the innate immune 
system, detecting microbial pathogens based on conserved molecular patterns, termed pathogen 
associated molecular patterns (PAMPs).22 PAMPs are general molecular motifs unique to 
pathogens (e.g. cell wall components in bacteria or viral-type nuclei acid), whose role is so 
fundamental to the pathogen’s survival and propagation that mutation attributable to drift or 
selection pressure is practically impossible. In succeeding years, it was recognized that many 
sterile disease processes, such as tissue injury or infarction, involved a prominent inflammatory 
component. The postulated and later discovered endogenous mediators driving this response 
were termed damage associated molecular patterns (DAMPs).23 These mediators may be released 
from necrotic cells by passive leakage (e.g. high mobility group protein B1 (HMGB1)) or 
secreted in a regulated fashion from inflammatory effector cells at sites of injury (e.g. 
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calgranulins released by neutrophils). It should be noted here that although amyloid β peptide (a 
known ligand and activator of RAGE24) is not one of the classic DAMPs, it may be categorized 
with the latter in that it is frequently associated with a disease state. 
HMGB1, also known as amphoterin, is constitutively expressed in the nucleus, where it 
facilitates nucleosome assembly. During necrosis (but not apoptosis) and in certain states of 
activation, HMGB1 is released into the extracellular space, where it binds and activates several 
pro-inflammatory PRRs, including Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4), and 
RAGE.25,26 The HMGB1-RAGE interaction has been implicated in a number of inflammatory 
disease processes, including neoplasm metastasis,27 arthritis,28 colitis,29 and ischemia-reperfusion 
injury.30 Even so, reflection on the fact that other HMGB1-binding receptors, such as TLR2 and 
TLR4, are bound and agonized or antagonized by a vast array of exogenous substances (from 
bacterial lipopolysaccharide (LPS) and fungal zymosan to measles hemagglutinin, opioid 
analgesics, and nickel ions), should lead one to accept the thesis that HMGB1 is the definitive 
ligand of RAGE with caution. 
Members of the calgranulin family are also known to bind to RAGE and have been 
implicated in diseases and pathophysiologic phenomena such as cardiomyopathy,31 
neurodegeneration,32 and tumor invasion.33 Known also as S100 proteins, these small calcium-
binding proteins are structurally similar to calmodulin, but in contrast to the latter they 
demonstrate a considerably narrower cell and tissue distribution. RAGE has been shown to bind 
and respond to S100A8/S100A9,9,34 S100B, S100A4, S100A6, S100A11, and S100A12.35 As 
S100 proteins are named for their complete (100%) solubility in ammonium sulfate at neutral pH 
– which is a reflection of biochemistry rather than physiology – and as the distribution, 
expression pattern, and apparent function differs markedly for each member of the family, the 
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fact that so many bind to RAGE may be less indicative of true biological relevance of these 
interactions than of promiscuous binding owing to large, labile, or low-complexity interaction 
domains. 
The last category of RAGE ligands is comprised of those largely ignored by the bulk of 
the research community. They have been investigated primarily by those who found RAGE’s 
localization to the lung compelling, and wished to understand its homeostatic function better. 
Glycosaminoglycans such as heparan sulfate36 and heparin37 (whose affinity is exploited in 
RAGE purification) are among these, as are collagen I and IV and laminin.38 RAGE has been 
observed to be important in mediating adherence and spreading of transfected cells to collagen-
coated surfaces,39 lending physiologic support to results obtained from in vitro binding studies, 
and suggesting that RAGE may be involved in adhering pulmonary epithelium to underlying 
basement membrane. Within this vein, RAGE has also been shown to act as a binding partner of 
the macrophage β2 integrin Mac-1, which may indicate a role as a facilitator of leukocyte 
adhesion and trafficking.40,41 
Having briefly outlined some of the RAGE ligands, it difficult to discern how to go about 
determining the biological relevance of any particular interaction, as much of the work on RAGE 
ligands has been performed in rather artificial systems: mixtures of purified protein, cell lines 
over-expressing RAGE, administration of supraphysiologic quantities of exogenous protein, etc. 
Moreover, it may be a mistake in this case to give primacy to protein ahead of cell, tissue, and 
organ: it would be curious, indeed, to go about defining the primary role of collagen through 
enumeration of its many binding partners! To better understand RAGE function, its expression 
and localization must be considered. 
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1.1.2 RAGE expression 
The first survey of RAGE expression was conducted shortly after its discovery and demonstrated 
a low level of transcript expression (as assessed by Northern blot) in all organs excepting the 
lung, where it was shown to be expressed at very high levels.42 There was a notable discrepancy 
between the mRNA and protein expression profiles, such that not only was the lung not the 
dominant organ source of RAGE, it was not even first ranked among all the organs assayed. 
Although the transcript data was later confirmed by other investigators,39 confirmation of the 
protein data was not readily forthcoming, and over the subsequent years most research has 
indicated that basal expression of RAGE protein is indeed greatest in the lung.43-45 
The lung is a heterogeneous organ, consisting of many different cell types whose 
functions range from ensuring adequate ventilation and perfusion to facilitating gas exchange 
and mediating defense mechanisms against pathogens. The cellular localization of RAGE within 
the lung was at first somewhat unclear, in part because the discoverers of RAGE and authors of 
the original survey of its organ distribution suggested that endothelium was the primary source, 
but also because of an excessive reliance by some on immunohistofluorescence microscopy data 
(all too often presented without accompanying controls) in the absence of confirmatory 
biochemical studies. Included among these are studies suggesting that RAGE is expressed by 
bronchial epithelium,46,47 findings that have not been confirmed by the vast majority of 
investigators. Elegant in situ hybridization studies were performed to demonstrate that 
pulmonary RAGE transcript is localized to type II alveolar epithelial cells48; biochemical 
analysis of type II alveolar epithelial cell primary culture was confirmatory. RAGE transcript 
localization to type II pneumocytes was not reflected in the numerous protein localization studies 
that followed, which consistently demonstrated that RAGE protein is expressed by type I 
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alveolar epithelial cells, the main cell type across which gas exchange occurs.39,49-51 Furthermore, 
a number of these studies39,50 incorporated microanatomical dissection by immunoelectron 
microscopy, which consistently demonstrated that RAGE expression was confined to the 
basolateral surface of type I pneumocytes. Expression of RAGE transcript primarily by type II 
pneumocytes is not inconsistent with protein expression primarily by type I pneumocytes, as the 
latter population arises by differentiation of the former. A unique function of RAGE mRNA 
apart from its canonical role as a template for protein synthesis is unknown. 
Because many diseases, including those of the lung, involve a prominent inflammatory 
component, it is important to consider RAGE expression in cells of the hematopoietic 
compartment. Indeed, multiple studies have indicated that cells of the monocyte/macrophage 
lineage express RAGE,52-55 although much of this data has been indirect and functional (e.g. 
demonstration of inhibited uptake of AGE-albumin by monocytes in the presence of anti-RAGE 
antibodies or co-expressed DN-RAGE). More recently, RAGE has also been linked to T cells,56-
58 with some data suggesting a role in T cell activation and cytokine secretion. Limited evidence 
has been presented demonstrating RAGE expression by eosinophils,59 with the suggestion that it 
may be involved in eosinophil chemotaxis by direct recognition of elaborated RAGE ligands.60 
Despite the existence of considerable functional and immunocytofluorescence data, apart from 
one study in human eosinophils59 rigorous demonstration of RAGE transcript and protein 
expression in specific inflammatory cell populations has been lacking.  
1.1.3 RAGE in pulmonary disease 
Relatively few studies have investigated the relevance of RAGE to pulmonary disease, a fact 
rendered all the more remarkable given the protein’s organ distribution. RAGE has been studied 
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in cancer, hyperoxic lung injury, sepsis, acute lung injury, chronic obstructive pulmonary disease 
(COPD), and pulmonary fibrotic disease. RAGE was found to be markedly down-regulated or 
even totally abrogated in cancerous lung (specifically non-small cell lung cancer, NSCLC), a 
finding confirmed by multiple groups of investigators.61-64 Although the authors infer that this is 
demonstrative of reduced expression in tumor cells, given the dearth of RAGE in normal 
bronchus and the proliferative nature of neoplastic disease, it is not unreasonable to attribute 
decreased global expression either to dysregulated alveolar expression in response to tumor 
encroachment, or to tumor burden reducing the proportion of RAGE-expressing alveolar 
epithelial cells in whole lung. Furthermore, while it is unclear whether reduced pulmonary 
RAGE expression in lung cancer facilitates tumor progression or is merely a bystander effect of 
disease, the finding that a genetic polymorphism in the RAGE promoter is associated with 
increased incidence of NSCLC65 would tend to support a more mechanistic role. 
RAGE has a pernicious pro-inflammatory role in animal models of viral pneumonia, 
specifically in primary respiratory syncytial virus66 and influenza A46 infection. The absence of 
RAGE was found to have a protective effect in mouse models of pneumococcal67 and E. coli68 
pneumonia as well as in a cecal ligation and puncture mouse model of sepsis.45,69 In contrast, 
RAGE was found to have a beneficial role in the clearance of mycobacterial lung infection in 
mice.70 Collectively, these studies suggest that pulmonary RAGE has a consistently pro-
inflammatory function in the context of bacterial and viral infection. 
Limited data is available regarding the role of RAGE in COPD. Soluble RAGE was 
found to be decreased in lung and in the circulation in patients with COPD with prominent 
neutrophilic component.71 Another study demonstrated decreased levels of sRAGE in patients 
with COPD as compared to controls, with sRAGE levels inversely correlated to emphysema 
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severity.72 Contrastingly, RAGE was also found to be increased in the lungs of COPD patients as 
compared to those of controls,73 a finding not inconsistent with the sRAGE data. The progressive 
destruction of lung tissue in COPD may account for the decline in secreted or shed sRAGE, 
whereas degraded lung architecture and obstructed airflow may drive compensatory up-
regulation of RAGE in order to enhance epithelial adhesion to remaining basement membrane. 
RAGE’s role in pulmonary fibrosis is complex and model-dependent. Mice lacking 
RAGE were found to develop spontaneous pulmonary fibrosis with age.44 RAGE was found to 
have a deleterious role in bleomycin-induced pulmonary fibrosis in mice.74,75 In contrast, RAGE 
appeared to have no role in silica-induced pulmonary fibrosis,76 and in asbestos-induced 
pulmonary fibrosis the absence of RAGE had an aggravating effect on disease phenotype.44,74 In 
patients with idiopathic pulmonary fibrosis, a disease whose pathogenesis is poorly understood, 
all RAGE isoforms have been found to be markedly diminished.44,77,78 Due to the lack of 
longitudinal data, it is unclear if loss of RAGE in this disease is causal or consequential. The 
complex, sometimes seemingly contradictory, roles of RAGE in pulmonary fibrosis in particular 
and pulmonary disease in general appear to emerge from RAGE’s dual function as both a 
promoter of epithelial adhesion to basement membrane and a pro-inflammatory multiligand 
receptor.  
1.1.4 sRAGE as a therapeutic 
As RAGE is thought to be involved as a pro-inflammatory mediator in a variety of disease 
processes, and sRAGE is known to antagonize ligation of the membrane isoform of RAGE by 
sequestration of cognate ligands,79  sRAGE has been employed as a therapeutic modality in a 
variety of experimental models of diseases thought to involve RAGE ligands, including 
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atherosclerosis,80,81 wound healing,82 ischemia/reperfusion injury,83,84 arthritis,85, stroke,86 and 
diabetic nephropathy.87 Because the vast majority of studies explored sRAGE’s therapeutic 
potential in non-pulmonary disease, it is quite natural that most used intraperitoneal or 
intravenous modes of delivery. There is reason to suspect that, at least in some cases, purified 
proteins used in treatment studies may have been contaminated with endotoxin; contaminating 
endotoxin may have the potential to reroute inflammatory processes away from established 
inflammatory loci to the site of administration (e.g. the peritoneal cavity), thus simulating a 
therapeutic effect when in fact there is none. The use of sRAGE synthesized in prokaryotic or 
simple eukaryotic expression systems, and thus lacking species-appropriate glycosylation, is also 
a matter of significant concern in evaluating the significance of studies utilizing therapeutic 
sRAGE. 
A graver problem in studies that use sRAGE as a treatment modality is the dearth of 
pharmacokinetic and pharmacodynamic data. One study in rats using recombinant sRAGE found 
a plasma half-life of approximately 26 hours when administered intravenously, and a plasma 
half-life approximately twice as great when sRAGE was administered intraperitoneally.88 
Appreciable biodistribution to the liver, kidney, and spleen was detected, but no irrelevant 
protein was used to control for nonspecific effects. Additionally, the large bolus of protein 
administered (~50-65 µg of sRAGE) may have recruited or induced uptake and clearance 
mechanisms that are not usually involved basally or in disease states (where circulating sRAGE 
may be dysregulated). No studies have been conducted with the aim of determining the most 
efficacious mode of sRAGE delivery to any particular organ, including the lung. Nor has the 
possibility that sRAGE has roles beyond that of a decoy receptor been explored. 
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1.2 ASTHMA 
1.2.1 Clinical asthma 
Asthma is a chronic inflammatory disease of the airways characterized by variable and episodic 
airflow obstruction, bronchial hyperresponsiveness, and longstanding inflammation that presents 
with clinical manifestations of wheezing, cough, and dyspnea.89 Although both a chronic and 
obstructive disease, asthma is usually not grouped with COPD, with distinction between the two 
being made easily on the basis of historic features (e.g. cigarette smoking in COPD) and 
reversibility. Save in severe cases, airflow obstruction in asthma is largely reversible, whereas in 
COPD it is minimally so. In addition to reversibility, the existence of characteristic 
environmental triggers of acute symptoms, such as exercise or exposure to cold air or allergens, 
is suggestive of asthma. Other historic features that assist in the diagnosis of asthma are early age 
of onset, a family history positive for allergic diseases, and a history of improvement in 
symptoms following bronchodilator and corticosteroid therapy. 
The non-specificity of symptoms associated with asthma necessitates the use of 
pulmonary function testing in making a diagnosis.90 A series of function tests is usually required. 
The most commonly employed are the peak expiratory flow rate (PEFR), the forced expiratory 
volume in 1 second (FEV(1)), and the ratio between FEV(1) and the forced vital capacity (FVC), 
which relates flow to volume.91 PEFR is measured during a rapid forceful exhalation 
immediately following a maximal inhalation; it is most useful in tracking trends in lung function 
longitudinally.92 By itself, a reduction in PEFR is of limited usefulness in making a diagnosis, 
because it is not specific to asthma or even obstructive lung disease (it is decreased in restrictive 
lung disease as well), and because it depends largely on patient effort.93 Spirometry provides a 
 13 
controlled method for assessing airflow and lung volumes and may be utilized to determine 
numerous indices of pulmonary function. Three are most commonly used in practice: FEV(1), 
FVC, and the ratio between the two, FEV(1)/FVC. The ratio FEV(1)/FVC is of particular 
importance in distinguishing between obstructive and restrictive disease, in that while the ratio is 
reduced in obstructive airway disease, it is commonly normal or even increased in restrictive 
disease. Measurements of other spirometrically-determined lung volumes and diffusing capacity 
may be of use in the diagnosis of certain cases of asthma, or in better characterizing physiologic 
abnormalities in patients already diagnosed. 
Due to the episodic nature of symptoms in asthma, two treatment-response tests are often 
useful in making a diagnosis where the clinical picture, historical features, laboratory test data, 
and baseline spirometric indices are not definitive. The bronchodilator response test employs a 
short-acting bronchodilator, such as albuterol, which relieves the reversible airway constriction 
and airflow obstruction in patients with asthma, which registers as a significant increase in 
FEV(1) value from baseline. In the event of the patient being already at a true physiologic 
baseline with minimal constriction at the time of testing, no marked increase in FEV(1) will be 
detected. Bronchoprovocation testing addresses this possibility: airflow obstruction is induced 
using a provocative stimulus, such as methacholine. Due to the enhanced bronchial 
responsiveness in asthmatics, markedly lower doses of methacholine suffice to elicit the same 
degree of bronchial constriction (as measured by FEV(1) decreased from baseline) in a patient 
with asthma than a healthy patient or one with non-reversible obstructive disease. Additional 
tests utilized in the diagnosis or treatment of asthma include assessment of levels of exhaled 
nitric oxide (which directly correlates with eosinophilic airway inflammation), skin prick testing 
to determine allergen sensitivity, and chest imaging.89 
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1.2.2 Pathophysiology of asthma 
Asthma is a condition characterized by chronic inflammation accompanied by acute 
symptomatic episodes of reduced airflow that is usually reversible. It is treated as a single 
disease entity, but in fact consists of multiple subtypes, each with its own distinct 
pathophysiologic mechanism. However, despite somewhat substantial differences in etiology, 
triggers, pattern of exacerbation, and responsiveness to therapy, a central common mechanism is 
thought to be involved, which is the antigen-triggered degranulation of mast cells. Mast cells are 
innate immune cells resident in the tissues, most frequently in those that interface with the 
outside environment (i.e. respiratory tract, gastrointestinal tract, etc.)94;their primary role is in 
defense against pathogens. IgE is the key antibody isotype involved in asthma, including both 
allergic and non-allergic asthma95; circulating IgE binds to its high-affinity cognate Fc receptor 
(FcεRI) on mast cells, thus priming these innate immune cells for specific responses to allergen 
challenge. Once allergen binds multiple IgE molecules expressed on the surface of mast cells, 
FcεRI cross-linking takes place and the mast cells degranulate, releasing histamine, serotonin, 
heparin, eicosanoids, and other inflammatory mediators.96,97 Antibody-producing B lymphocytes 
are induced to shift immunoglobulin production from IgM to IgE by inputs from T lymphocytes 
in the form of cell-cell contact and soluble cytokines. Interestingly, although intrinsic asthma 
(which accounts for ~10% of the total number) does not register an identifiable allergen on skin 
prick test or assays of serum IgE, the pattern of eosinophilic inflammation and expression of IgE 
at sites of inflammation is remarkably similar to that seen in atopic asthma,98 underscoring the 
centrality of the IgE antibody response and its downstream cellular effectors in asthma. 
Furthermore, elevated total serum IgE levels were associated with both atopic and intrinsic 
asthma, although in the latter case the provoking antigen could not be identified.95 It is 
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hypothesized that in intrinsic asthma it is non-classical staphylococcal superantigens (which 
bypass the usual antigen-IgE antibody-Fc receptor pathway to activate mast cells in a more direct 
fashion) that drive mast cell degranulation.98,99 
Once mast cells degranulate upon encounter of allergen, early and late phase reactions are 
initiated. The early phase response is mediated by histamine, bradykinin, prostaglandin D2 and 
leukotrienes LTC4, D4, and E4. The early phase reaction rapidly results in contraction of airway 
smooth muscle leading to bronchoconstriction,100-102 which is largely relieved with 
bronchodilators. The late phase reaction occurs several hours later, involves leukotriene LTB4, 
and recruits inflammatory cells to the site of allergen insult. During the late phase, 
bronchoconstriction mediated by airway smooth muscle may also occur but is somewhat less 
responsive to bronchodilator therapy than bronchoconstriction in the early phase.103 The cells 
recruited during the late phase response include T lymphocytes, dendritic cells, neutrophils, 
basophils, and eosinophils. 
T lymphocytes are obviously crucial in the asthmatic inflammatory response, and are the 
subject of extensive discussion in a subsequent section. In connection with this, it is notable that 
non-classical T lymphocytes, including invariant natural killer T cells104 (iNKTs) and γδ T 
cells,105 are thought to play an important role in asthma pathogenesis. Dendritic cells are 
professional antigen-presenting cells (APCs) involved in processing allergen and presenting it in 
a pro-inflammatory context to naïve T lymphocytes, thus activating them. By contrast, resident 
alveolar macrophages, although professional APCs as well, appear to have an anti-inflammatory 
effect.106,107 Neutrophils have a poorly understood role in asthma; they are primarily associated 
with more severe phenotypes, which also tend to be more resistant to corticosteroid therapy. As 
neutrophils are far less susceptible to corticosteroids than eosinophils and many other immune 
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effector cells,108 it is possible that severe asthma is often associated with neutrophilia because 
disease progression and clinical decline occurs more rapidly in the absence of effective 
corticosteroid inhibition of neutrophils.109,110 Basophils are very similar in function to mast cells 
but may be more important in asthma for their capacity to secrete critical pro-allergic 
cytokines111 than their ability to degranulate as mast cells do. Eosinophils produce effector 
molecules such as leukotrienes, platelet activating factor (PAF), eosinophil cationic protein 
(ECP), eosinophil peroxidase (EPO), and major basic protein (MBP).112 Eosinophils also 
produce cytokines such as GM-CSF and IL-5, which in turn promote further eosinophil 
generation and recruitment to the site of inflammation. 
The stromal cells of the lung – bronchial and alveolar epithelial cells, smooth muscle 
cells, fibroblasts, and vascular endothelial cells – are known to play an important role in the 
pathogenesis of asthma.113 Epithelium produces eosinophil chemokines RANTES, MIP-1α, 
MCP-4, and eotaxin, as well as neutrophil-recruiting IL-8 and pro-fibrogenic TGF-β. In asthma, 
bronchial epithelial cells also release a variety of growth factors that promote extracellular 
matrix deposition, including basic fibroblastic growth factor (FGF-2), insulin-like growth factor 
1 (IGF-1), platelet-derived growth factor (PDGF), and endothelin-1 (ET-1).114 In asthmatics, 
airway smooth muscle cells and fibroblasts produce stem cell factor (SCF), which is an 
important growth factor for mast cells; these structural cells are therefore competent to expand 
the niche available to mast cells in the lung compartment, thus further promoting the type I 
hypersensitivity mechanism central to asthma pathogenesis.115 Thus, in the context of asthmatic 
inflammation, structural cells seem to be involved primarily in secreting chemokines that recruit 
inflammatory effectors such as mast cells and eosinophils, or in releasing growth factors or 
enzymes that facilitate remodeling of the airway architecture. 
 17 
Airway remodeling is a concept that refers to architectural changes in the airways that 
subsequently superimpose with the underlying inflammation and reversible bronchoconstriction 
to contribute to irreversible physiologic deficits.116 There are many ways in which this might 
occur: sloughing of layered epithelium of the bronchus, submucosal gland and goblet cell 
hypertrophy and hyperplasia leading to excessive mucus occluding the airways, smooth muscle 
thickening,117 matrix deposition in the subepithelial reticular basement membrane,118,119 and 
aberrant angiogenesis and vascular hypertrophy.120 The mechanisms by which each of these 
forms of airway remodeling lead to functional decline vary: excessive mucus can lead to mucus 
inspissation and further narrowed or totally occluded airways, whereas deposition of matrix 
around airways may reduce baseline caliber and thus impede the effect of parenchymal tethering 
(which maintains airway patency). Regardless of the specific effect on lung structure, airway 
remodeling occurring over many years leads to progressive decline in measures of lung function 
both at baseline and during acute bronchoconstrictive episodes. 
Airflow obstruction in asthma is primarily reversible and attributable to peribronchial 
smooth muscle contraction. Bronchoconstriction may be heightened due to intrinsic changes in 
the smooth muscle cells, neural reflex,121 or provoking stimuli such as cysteinyl leukotrienes,122 
prostaglandins, histamine, and tryptase123 released from mast cells, basophils, and eosinophils. 
Aspirin-induced asthma may also involve these mediators, which then act directly on smooth 
muscle.124 Other less reversible forms of airflow obstruction includes mucus plugging, airway 
smooth muscle hypertrophy and hyperplasia, and airway edema. Nevertheless, smooth muscle 
airway constriction constitutes the main source of airflow obstruction. While obstruction occurs 
throughout the conducting airways, it is the small bronchi that are believed to undergo the bulk 
of constriction in asthma.125 This is not particularly surprising, as physical arguments would 
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suggest that local airway resistance, the definitive measure of airflow obstruction, is inversely 
proportional to the radius to the fourth power. Naturally, with equivalent circumferential 
constriction of smaller and larger bore airways, the smaller bore airways increase in resistance 
far more rapidly than the larger bore airways. Bronchial hyperresponsiveness arises due to the 
inflammatory milieu in the pulmonary compartment and is mediated by smooth muscle in 
response to stimuli such as histamine or methacholine. While it is well known that a number of 
cytokines are pivotally-involved in bronchial hyperresponsiveness in humans and animal models 
(discussed subsequently), neither the mechanism by which the smooth muscle hypersensitivity 
response occurs, not the potential adaptive effect of that hyperresponsiveness in combatting 
infection, is known. 
1.2.3 Etiopathogenesis of asthma 
Asthma is a multifactorial disease thought to arise from complex interactions between 
endogenous and external factors.89 In discussing etiology, it is important to note that asthma 
consists of many subtypes, e.g. brittle asthma, intrinsic asthma, atopic asthma, aspirin-intolerant 
asthma, etc.126,127 Atopy, which may be understood as the predisposition to develop type I 
allergic hypersensitivity reactions, is the single most important risk factor in asthma.128 Although 
there is substantial overlap between atopy and asthma, only a fraction of atopic patients develop 
frank asthma, suggesting that genes involved in asthma risk and asthma severity and those 
predisposing to atopy are distinct,127 a fact attested to by the existence of a distinct population of 
asthma patients (~10%) who do not demonstrate atopy (intrinsic asthma).129 Even so, there is 
high concordance for asthma in monozygotic twins, indicating that the genetic contribution, 
although distributed over many loci, is quite strong. The most consistent genetic associations 
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have been made to polymorphisms in the genes encoding the cytokines IL-4, IL-5, and IL-
13.130,131 Associations with other genes, such as ADAM-33,132 mammalian chitinases,133 and the 
β2 adrenergic receptor,134 have been made, but the mechanism by which these genes influence 
asthma pathogenesis is in many cases unclear. 
Environmental factors have long been recognized to have a key role in many variants of 
asthma. One major factor is viral infection.135 The role of viral infections in increasing risk of 
subsequent asthma is complex and depends on the type and site of infection. One study found 
that RSV bronchiolitis in infancy (that required hospitalization) was associated with early onset 
asthma.136 A second very recent study has demonstrated that risk of later developing asthma was 
particularly great in children with up-regulated levels of RANTES (an important eosinophil 
chemokine) in nasal epithelium during RSV bronchiolitis.137 This may indicate that RSV 
bronchiolitis triggers subsequent allergic airway disease in those already predisposed towards 
eosinophilic inflammatory responses. By contrast, multiple viral infections in early childhood 
(outside the lower respiratory tract) were associated with decreased risk of developing asthma.138 
This suggests that whereas early infection of the lower respiratory tract may prime the immune 
system for subsequent allergic inflammation, the exposure to certain pathogens outside the lung 
in early life shifts the immune system away from atopic-type inflammation towards a more 
adaptive immunity. 
While it is obvious that allergens are important in triggering symptoms of (atopic) 
asthma, it is not immediately apparent that they play a significant role in promoting the 
development of asthma. As it turns out, exposure to certain (primarily indoor) allergens early in 
life is a major risk factor in the pathogenesis of asthma. In one study, the level of house dust mite 
and cockroach antigen to which children were exposed was directly related to sensitization 
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risk.139 Exposure to higher levels of cockroach allergen was shown to be associated with greater 
risk of sensitization and subsequent development of asthma in a study in inner-city children.140 
Other investigators found that exposure to one of the main house dust mite allergens, Der p 1, 
was demonstrated to be a determinant of the risk of subsequent asthma development.141 Even 
exposure to low levels of allergen is sufficient to increase asthma risk: sensitization to the 
outdoor fungus Alternaria was found to be an important independent risk factor for asthma in 
children.142 Collectively, these data suggest that increased exposure to certain allergens (with 
presumably intrinsic pro-allergenic characteristics) increases risk of sensitization; as many 
subtypes of asthma are marked by prominent atopy, increased risk of sensitization implies an 
increased risk of subsequent development of asthma as well. Other important environmental 
factors thought to contribute to asthma pathogenesis include exposure to tobacco smoke143,144 
and air pollution,145 vitamin D deficiency146 and a diet low in omega-3 fatty acids,147 exposure to 
organic solvents,148 and maternal use of paracetamol during pregnancy.149 
1.2.4 Allergic mechanisms of asthma 
That allergic inflammation is central to the pathogenesis of atopic asthma was first appreciated 
from autopsy specimens from patients with fatal asthma.123 Biopsies from patients with less 
severe disease confirmed this finding, with the degree of inflammation often directly correlated 
with severity of disease.150,151 Since then, these observations and those gleaned from other 
diseases encouraged research into the mechanisms of innate and adaptive immunity mediating 
allergy. Immunologists had long recognized that the inflammatory processes involved in acute 
infection and allergic hypersensitivity are markedly different: whereas acute bacterial and viral 
infections involve predominantly neutrophilic, lymphocytic, and monocytic inflammation with 
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associated opsonizing IgG and IgA antibodies and cytotoxic lymphocytes, in allergic 
hypersensitivity reactions it is degranulating mast cells, infiltrating eosinophils, and non-
opsonizing IgE antibodies that are most prominent. Interestingly, the inflammatory pattern in 
allergic disease is remarkably similar to that observed in parasite and helminth infections,152-154 
suggesting that this type of inflammation – so pernicious in response to innocuous allergens – is 
in fact adaptive in combating infection by large extracellular pathogens. 
Biologists seeking to understand the role of T cells in the immune response (whose 
importance in antigen recognition and the host response was then only beginning to be fully 
appreciated with the discovery of MHC restriction155) discovered that non-cytotoxic (helper) T 
cell clones from mice demonstrated two major patterns of cytokine secretion.156 They named 
these two types of helper T cell responses T-helper 1 (Th1) and T helper 2 (Th2). Th1 has since 
come to be recognized as mediating adaptive immune responses to intracellular pathogens as 
well as certain kinds of autoimmune diseases, with a secretory profile notable for IFN-γ and 
TNF-β and effectors such as cytotoxic T cells, activated macrophages and opsonizing IgG 
antibodies.157 Th2 is thought to mediate responses to extracellular pathogens such as parasites 
and helminths as well as atopic disease, via effectors such as IgE, eosinophils, basophils and 
mast cells, and changes in tissue architecture (e.g. mucus hypersecretion) believed to facilitate 
expulsion of such pathogens.157 Much of the work that contributed to this understanding of 
fundamental T cell biology was initially performed in mice. The finding that polymorphisms in 
IL-4,158 IL-5,159 and IL-13160 or their cognate receptors are linked to human asthma therefore lent 
support to the thesis that atopic asthma is mediated primarily by a Th2 process. Further 
confirmation was provided by the observation that these cytokines are expressed at sites of 
inflammation in the lungs of patients with allergic asthma.161-163 
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The finding that Th1 and Th2 immune responses appear to be reciprocally-inhibitory of 
each other,164 as well as the observation that asthma prevalence is drastically increasing in the 
developed world165 (where childhood incidence and severity of infection has declined) promoted 
the formulation of the so-called ‘hygiene hypothesis.’166,167 This hypothesis holds that humans 
are skewed towards Th2-type responses early in life. Encounters with Th1-inducing pathogens, 
such as bacteria and viruses, redirect the baseline immune response towards a more Th1-type 
phenotype, thus reducing the risk of Th2-mediated diseases, such as atopic asthma. As more 
developed countries have improved sanitation, better patient education, and better access to 
antibiotics, the incidence and severity of infections that elicit a Th1 response has markedly 
declined, thus maintaining more individuals in a Th2-skewed state, with a greater predisposition 
towards developing asthma. There is some direct support for the hypothesis in the form of 
reduced risk of asthma in those who have experienced infections with hepatitis A virus168 or 
Mycobacterium tuberculosis.169 The hypothesis also potentially explains the association between 
daycare attendance, later birth order and larger family size with decreased incidence of 
asthma.170,171 Although intellectually compelling, the hygiene hypothesis fails to explain the 
increased incidence of Th1-mediated autoimmune diseases, such as type 1 diabetes mellitus172 
and multiple sclerosis,173 in the industrialized world,174 nor the fact that helminth and parasite 
infection – rather than stabilizing an innate Th2 bias and thereby increasing predisposition to 
atopic asthma, as would be expected – appears to be negatively associated with subsequent 
development of atopy and asthma.175 
The Th2 immune response is coordinated by a canonical triad of cytokines: IL-4, IL-5, 
and IL-13. IL-4 appears to have a crucial role in the sensitization process that primes naïve cells 
to differentiate into Th2 cells: loss of IL-4 at the gene level leads to attenuation of allergic 
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inflammation,176 while administration of antibodies against IL-4, but not IL-5, during the 
sensitization process leads to impeded differentiation to Th2 and secretion of downstream 
cytokines.177,178 However, inflammation is intact when IL-4 was antagonized during the 
challenge phase, after sensitization has taken place.177,178 This indicates that IL-4 is involved in 
the early part of Th2 inflammation, but is not necessary for continued maintenance of allergic 
inflammation once T cells have been primed.179-181 IL-4 is also crucial for the generation of an 
IgE antibody response.182-186 IL-4 is necessary for priming and activation of T cells to express the 
co-stimulatory molecule CD154; subsequent IL-4 ligation of its cognate receptor on B cells, as 
well as T cell CD154 ligation of B cell CD40, induces B cells to undergo antibody isotype class 
switching from IgM to IgE and differentiation to long-lasting plasma cells. The source of early 
IL-4 was for some time a mystery, as IL-4 is necessary for Th2 differentiation, but non-Th2 cell 
sources of this cytokine were unknown. It appears that early IL-4 is derived from innate immune 
cells, such as basophils, which are increasingly being recognized as key players in the initiation 
of the allergic immune response.187-189 
The second member of the classic Th2 cytokine triad, IL-5 is the cytokine principally 
responsible for eosinophil generation, differentiation, maturation, recruitment, survival, and 
activation. IL-5 is also involved in terminal differentiation of B cells to IgE-producing plasma 
cells.190,191 Administration of antibodies against IL-5 markedly reduces the eosinophilic 
component of inflammation in animal models of asthma.192 Furthermore, mice lacking IL-5 were 
found to have abolished eosinophilia, airway damage, and airway hyperreactivity.193 Conversely, 
overexpression of IL-5 in airway epithelium194 or administration of exogenous IL-5195 were 
found to induce pronounced tissue eosinophilia, suggesting that IL-5 is both necessary and 
sufficient for eosinophil recruitment. IL-5 has been long considered to be primarily produced by 
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Th2 cells: IL-4 ligation of its cognate receptor on T cells activates STAT6 and induces 
expression of the GATA-3 transcription factor, which is the central regulator of Th2 
differentiation and coordinates expression of IL-4, IL-5, and IL-13.196,197 This simplistic view is 
undergoing revision, as it is increasingly recognized that many innate effector cells produce IL-5 
as well, including eosinophils themselves,198 mast cells,199 and a novel class of innate 
lymphocytes called nuocytes.200 The transcriptional regulation of IL-5 production in these cell 
types is not well understood. 
Eosinophil recruitment is mediated by a diverse group of chemokines, including but not 
limited to RANTES (CCL5), MCP-3 (CCL7), MCP-4 (CCL13), MIP-1α (CCL3), TARC 
(CCL17), eotaxin (CCL11), and eotaxin-2 (CCL24).201 Of the aforementioned, however, only 
eotaxin and eotaxin-2 (and eotaxin-3 (CCL26), in humans) exhibit eosinophil-specific 
chemotactic activity through the chemokine receptor CCR3. Indeed, eotaxin has no effect on 
neutrophils and macrophages, which do not express CCR3,202,203 and only a weak effect on 
conditioned lymphocytes.204 Eotaxin-2 is chemotactic for lymphocytes, but only weakly-so for 
neutrophils.205 Eotaxins are synthesized and secreted by structural cells of the lung, including 
fibroblasts206,207 and smooth muscle cells.208-210 
Transmigration of eosinophils into the interstitium and peribronchial and perivascular 
spaces requires the expression of adhesion molecules mediating eosinophil extravasation. One of 
the key endothelial binding partners of the eosinophil-expressed integrin VLA-4 (expressed on 
many cell types, but apparently the dominant integrin expressed on eosinophils)211 is vascular 
cell adhesion molecule 1 (VCAM-1).212-214 Absence of VCAM-1 seriously impairs eosinophil 
migration into the lung in response to allergic stimulus215 and Th2 cytokines associated with 
asthma, in turn, drive up-regulated expression of VCAM-1.216,217 Another key endothelial 
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binding partner of eosinophils is P-selectin, which interacts with eosinophil P-selectin 
glycoprotein ligand 1 (PSGL-1).211 While both eosinophils and neutrophils express PSGL-1, 
eosinophils demonstrate enhanced efficiency of initial binding to P-selectin and thus are 
selectively recruited.218 Interestingly, platelet-expressed P-selectin also mediates eosinophil 
recruitment through the formation of transient platelet-eosinophil circulating aggregates that 
promote adhesion to vessel walls and subsequent transmigration.219 
IL-13 is the third member of the set of canonical Th2 cytokines. It acts in a 
complementary fashion to IL-5 by inducing expression of the eotaxins.206,220-222 Furthermore, the 
receptor for IL-13 shares its IL-4Rα subunit with the IL-4 receptor, which leads to a degree of 
overlap in the actions of the two cytokines. For instance, IL-13 is necessary for basal IgE 
production, but does not play the decisive role in inducing class switching (which is mediated by 
IL-4). IL-13 has been recognized as having a vital role in the genesis of airway 
hyperreactivity.223 This was demonstrated through global deletion of IL-13 abrogating airway 
hyperresponsiveness, despite the presence of eosinophilic inflammation; supplementation of 
exogenous IL-13 to knockout animals restored airway hyperresponsiveness. These findings were 
previously seen with antibody-mediated antagonism of IL-13.224 IL-13 is also believed to drive 
aspects of airway remodeling, such as subepithelial fibrosis,225 which may be attributable to IL-
13 induction of TGF-β synthesis by stromal cells.226 The role of IL-13 in promoting mucus 
hypersecretion in allergic inflammation is critical.224,225,227 Th2 cells in the absence of IL-13 have 
been shown to be incapable of inducing mucus secretion in mouse models of asthma; 
furthermore, IL-9’s effect on mucus secretion has been found to be mediated via IL-13.228 
Inhibition of IL-13 using antagonistic antibodies was found to markedly attenuate mucus 
secretion, whereas administration of exogenous IL-13 was sufficient to induce it.229 Collectively, 
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these observations suggest that just as IL-4 and IL-5 have unique roles in mediating isotype class 
switching and eosinophil recruitment, respectively, IL-13 is the main Th2 cytokine involved in 
tissue changes in allergic inflammation (the adaptive role is presumably to condition the 
respiratory and gastrointestinal tracts for easier expulsion of parasites secondary to eosinophil 
attack and mast cell degranulation). IL-13 was initially thought to be produced primarily or 
entirely by Th2 cells, but it has since been appreciated that innate cells called nuocytes also 
produce the cytokine in a STAT6/GATA-3-dependent manner.230 
Initially grouped with the Th2 cytokines, IL-9 demonstrates a complex expression 
pattern, with some secretion by Th2 cells but most expression being driven by a separate 
differentiated class of T lymphocytes, Th9 cells.157 IL-9 overexpression in pulmonary epithelium 
in mice leads to mucus hypersecretion and eosinophilia, airway hyperresponsiveness to 
methacholine challenge, and subepithelial fibrosis. IL-9 overexpression is also uniquely 
accompanied by prominent mast cell infiltrates.231 IL-9 over-expressed in pulmonary epithelium 
apparently mediates its role through classic Th2 cytokines, up-regulating their expression; 
conversely, blockade of the downstream cytokines IL-4, IL-5, and IL-13 attenuates or 
completely abolishes the effects of IL-9 on eosinophilia and mucus production.232 However, 
deletion of IL-9 does not abrogate allergic inflammation, with IgE, IL-4, IL-5, and IL-13 intact, 
along with their usual effects on mucus production and eosinophilic inflammation.233 This 
suggests that IL-9 is not as fundamental to Th2 immunity as the classic triad and that it acts more 
as an ancillary cytokine of allergic inflammation, with the capacity to drive inflammation but not 
central to it. 
Although not a classic cytokine of the Th2 immune response, IL-17 has been suggested 
to be a molecular mediator relevant to asthma, particularly in subtypes with a prominent 
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neutrophilic component.234,235 While IL-17 has been shown to play a role in neutrophilic 
asthma,236 it has also been shown to be a negative regulator of established allergic asthma.237,238 
Furthermore, the level of IL-17 expression in asthmatics has been shown to associate with 
bronchial hyperresponsiveness.239 A number of mouse models of allergic airway disease/asthma, 
including T cell adoptive transfer models, have recapitulated this observation, with IL-17 
inhibition effected with antagonistic antibodies leading to attenuation in airway 
hyperresponsiveness.240,241 IL-17 is of particular interest for its potential role in steroid-resistant 
asthma242 and severe asthma.109 
1.2.5 Initiation of allergy 
Although the last two decades of research have elucidated much about the mechanisms 
underlying allergic inflammation downstream of the T cell, the factors initiating Th2 immune 
responses remain poorly understood. Recently, a set of innate immune cytokines involved in 
initiation of Th2 inflammation has been identified, and their potential role in atopic asthma is a 
matter of great interest. The first of these, thymic stromal lymphopoietin (TSLP), is synthesized 
and secreted by epithelium,243 basophils, and mast cells244 in response to activation by a protease 
receptor, PAR-2.245 Activation of the receptor is mediated by protease activity, which is a 
common feature in allergens, including house dust mite and fungus. This places TSLP very early 
in the immune response at the level of allergen recognition, considerably upstream of T cell 
differentiation. Antibody-mediated inhibition of TSLP or deletion of its cognate receptor 
(TSLPR) attenuates allergic inflammation.246 The observations from animal models and in vitro 
studies attesting to the importance of TSLP are supported by the finding that polymorphisms in 
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this gene are linked to susceptibility to bronchial asthma in humans.247 TSLP is thought to be 
important for the synthesis and secretion of IL-4, IL-5, IL-13, IL-10, and IgE.248,249 
IL-25 (IL-17E) is gaining increasing prominence as a potent stroma-derived Th2-
promoting cytokine. IL-25 is structurally related to IL-17, but in contrast to the latter, which is 
primarily secreted by T lymphocytes and coordinates the adaptive immune response and its 
neutrophil effectors, IL-25 is released by structural cells (specifically pulmonary epithelium) and 
induces pathologic changes and cytokine profiles consistent with Th2 immunity.250-252 Moreover, 
IL-25 exerts its effects in an IL-4- and GATA-3-dependent manner in T cells,253 but most of the 
IL-5 and IL-13 generated in response to IL-25 originates from innate lymphocytes called 
nuocytes.254 Administration of exogenous IL-25 induces expression of IL-4, IL-5, and IL-13 in 
the absence of allergen.250 Conversely, inhibition of IL-25 action through the use of blocking 
antibodies diminishes the Th2 response and airway hyperresponsiveness in models of allergic 
asthma, even when blockade is initiated after sensitization has already occurred (indicating 
effects beyond a role in the initiation of Th2 differentiation).255 
The third member of the recently-identified group of stroma-derived pre-Th2 cytokines, 
IL-33 is constitutively expressed in endothelium, lung, colon, and brain, among other tissues.256 
IL-33 is structurally related to IL-1 and IL-18, but does not require cleavage by caspase-1 to be 
activated.257,258 It has a dual function: normally it acts as a negative regulator of transcription, 
localizing primarily to the nucleus and associating with heterochromatin.259 In response to 
insults, however, IL-33 is released either passively due to loss of integrity of the nuclear 
envelope and cell membrane or in a regulated fashion. In this sense, it appears to act as an 
alarmin,256 analogous to HMGB1 and IL-1α. Endogenously-released IL-33 can bind to its 
cognate receptor (ST2) on inflammatory cells to induce a Th2-type response.260,261 IL-33 is able 
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to do so even in SCID mice (which lack an adaptive T cell response) suggesting that it is able to 
exert its cytokine-inducing function purely through innate immune cell and structural cell 
targets.262 Lack of IL-33 leads to markedly attenuated Th2 immune responses to allergen, 
indicating that it is critical in the development of a competent allergic response.263 Furthermore, 
exogenous IL-33 drives induction of Th2 cytokines, indicating that it is a central mediator in a 
common pathway leading to allergic inflammation and does not depend on PAMPs or DAMPs 
for activity. IL-33-induced IL-5 and IL-13 are primarily secreted by innate lymphocytes called 
nuocytes.254 
Nuocytes have been recently identified as having a crucial role in the development of Th2 
inflammation in animal models of pulmonary and gastrointestinal disease.264 Although they do 
not bear lineage markers of T cells or B cells, they bear CD45 and the IL-7 receptor, which 
suggests a lymphoid origin. In addition to these markers, nuocytes bear the receptors for IL-10, 
IL-12, and IL-17, as well as IL-25 and IL-33 (ST2). IL-33 together with IL-7 has the capacity to 
induce nuocyte proliferation, whereas IL-25 and IL-33 can independently induce secretion of IL-
5 and IL-13. Nuocytes were shown to have the capacity to induce IL-13-mediated expulsion of 
gastrointestinal nematodes in the absence of T cells; by contrast, competent Th2 cells alone, in 
the absence of nuocytes, were not able to clear the parasites.254 In another study in mice with 
global deletion of IL-13 (and thus resistant to the development of airway hyperresponsiveness 
and inflammation more generally), adoptive transfer of nuocytes expressing IL-13 could restore 
susceptibility to IL-25-induced bronchial hyperreactivity and pulmonary inflammation.265 This 
suggests that nuocytes alone produce sufficient quantities of IL-13 to reconstitute the entire IL-
13 axis in models of Th2-mediated disease. In connection with this, in a mouse model of 
helminth infection it was found that all nuocytes express IL-13, 70% express IL-5, and less than 
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5% express IL-4.254 This would suggest that nuocytes are involved in coordinating innate 
immune cell and structural cell responses without significantly driving T cell differentiation to 
Th2, this latter function presumably being relegated to IL-4-producing basophils. 
This discussion of allergic mechanisms of asthma is summarized schematically below 
(Figure 1). 
 
Figure 1. A schematic representation depicting major pathways of Th2 immunity. 
Allergen along with danger signals elicits secretion or release of TLSP, IL-25, and IL-33. TSLP induces IL-4 from 
basophils and T cells. IL-25 induces IL-4, IL-5, and IL-13 in T cells and nuocytes. IL-33 induces IL-5 and IL-13 in 
nuocytes. IL-4 drives Th2 differentiation and isotype class switching in B cells. IL-5 drives eosinophil generation, 
proliferation, survival, and recruitment (also mediated by eotaxins). IL-9 promotes mast cell hyperplasia and mucus 
hypersecretion. IL-13 induces airway hyperreactivity (AHR), airway remodeling and smooth muscle hyperplasia, 
goblet cell hyperplasia and mucus hypersecretion, eotaxin expression, and up-regulation of adhesion molecules in 
vasculature to promote eosinophil transmigration. 
 31 
1.2.6 Asthma therapy 
Asthma treatment must address both the underlying pathogenic process driving the disease, as 
well as the episodic symptoms arising from acute constriction of the airways. The mainstay of 
asthma therapy is long-term suppression of inflammatory airway disease with low- or medium-
dose inhaled corticosteroids. Short-acting aerosolized β2-agonists, which target airway smooth 
muscle, are used to control bronchoconstriction.123 In patients with more severe asthma, the dose 
of inhaled corticosteroids must be ramped up, short-acting bronchodilators may need to be 
exchanged for longer-acting agonists, and occasionally oral corticosteroids may be introduced as 
well.266 In patients that do not tolerate steroids well or have disease refractory to these 
conventional treatment regimens, alternative therapies must be considered. Steroids are quite 
effective in most patients precisely because they target so many genes and cell types involved in 
inflammation.267,268 Therefore, when a maximal steroid dose has been found to be inadequately 
effective, agents targeting specific molecular or cellular players in asthma are used. These have 
conventionally included the cromoglycates, which are thought to target mast cell function, as 
well as the leukotriene modulators.267 The cromoglycates have declined in popularity due to no 
added benefit beyond inhaled corticosteroids, whereas the leukotriene modifiers have become the 
main non-steroidal therapy for control of inflammation in asthma. These drugs block leukotriene 
access to the cognate type 1 cysteinyl leukotriene receptor.269 Leukotriene modulators may be 
most effective in mild persistent asthma as an alternative to corticosteroids, and may offer some 
additional benefit in patients with severe asthma already treated with high-dose 
corticosteroids,270 but the combination of corticosteroids and long-acting bronchodilators 
remains superior.271 
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Although a heterogeneous disorder, several central molecular mediators of asthma have 
been identified, and targeting them via small molecule inhibitors or antagonistic antibodies 
would appear to be a viable approach in the treatment of asthma in which steroids, 
bronchodilators, and leukotriene modifiers are inadequate. Anti-IgE therapy (omalizumab) is the 
first of these biological immunoregulatory agents to have entered the mainstream, and has been 
shown to reduce the frequency of exacerbations in severe allergic asthmatics.272,273 Anti-IL-5 
therapy (mepolizumab) has also had modest success in reducing exacerbation frequency and 
permitting steroid dose reduction in patients with eosinophilic asthma.274,275 Antagonism of the 
IL-4 receptor α chain (which is part of both the IL-4 receptor and IL-13 receptor) failed to 
demonstrated clinical efficacy in asthmatics276; interestingly, inhibition of solely the IL-13 
signaling pathway with an antibody against the cytokine (lebrikizumab) demonstrates very 
modest but statistically significant improvement in lung function in patients with asthma, 
particularly those with high IL-13 activity.277 
The results seen in the use of biological agents against cytokines, their receptors, and 
cellular effectors (despite the eminent rationality in their being targeted) have been less than 
satisfactory, as these agents are often accompanied by exorbitant cost in exchange for modest 
benefit, risk of additional morbidities, and are confined in their effectiveness to narrow subsets of 
asthmatics (e.g. asthma with prominent atopic component for omalizumab and eosinophilic 
asthma for mepolizumab). Redundancy in the system may render targeting of any specific 
downstream effector cell type or terminal cytokine relatively ineffective at ameliorating disease 
in the majority of patients. Identification of fundamental nodes higher up in the molecular 
hierarchy coordinating the pathogenesis of allergy and asthma may be a prerequisite for the 
development of the next generation of broadly effective therapeutics. 
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1.3 RAGE IN ASTHMA 
1.3.1 Genome-wide association studies 
Genome-wide association studies (GWAS) are epidemiologic analyses that link common genetic 
variants, most often single-nucleotide polymorphisms (SNPs), to traits such as disease status, 
biomarker level, or a physiologic measure. As such, they are powerful tools in the assembly of 
working hypotheses that would not have been otherwise apparent based on current knowledge; 
these hypotheses can then be explored in depth in humans or animal models. Two recent GWAS 
analyses were performed,278,279 studying genetic loci linked to the spirometric parameter FEV(1) 
and the FEV(1)/FVC ratio. Reduced FEV(1)/FVC ratio is indicative of obstructed airflow, 
whereas FEV(1) serves as an indicator of severity of obstruction and may be used longitudinally 
to track progression of  disease.280 Both meta-analyses were conducted on two different consortia 
of European patients. The first group,278 working on the SpiroMeta consortium, identified six 
loci linked to reduced FEV(1) or FEV(1)/FVC, whereas the second group,279 working on the 
CHARGE consortium, identified eight loci linked to reduced FEV(1)/FVC ratio and one to 
FEV(1). In both studies, the association between reduced FEV(1)/FVC and RAGE (termed 
AGER in their studies) was strong. RAGE was a notable finding in both studies, in that the first 
study278 stated that it was the strongest association to FEV(1)/FVC of all the loci identified, 
whereas the other study279 pointed out that a RAGE SNP was one of a small group of three (out 
of nearly 120 in total) SNPs that was localized to the exonic region of the implicated genes and 
thus could exert its effects through altered protein structure. 
That SNP, rs2070600, is a glycine-to-serine missense mutation at the codon for residue 
82 (G82S), which places the mutation precisely at the second of two N-glycosylation sites 
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(asparagine at position 81).8 As previously discussed, glycosylation plays an important role in 
RAGE function, and a mutation introducing bulkier and hydrophilic serine in place of glycine 
might be expected to interfere with that post-translational modification and thus impede RAGE 
function. In fact, the contrary appears to be the case. It was recently shown that RAGE bearing 
the G82S polymorphism expressed in HEK 293 cells, in comparison to wild type RAGE 
expressed in the same system, demonstrates preferential glycosylation of the asparagine at 
residue 81.281 Using the same in vitro system, the authors also demonstrated enhanced nuclear 
translocation of NF-κB in response to S100B stimulus in HEK 293 cells expressing RAGE 
bearing the rs2070600 SNP as compared to those transfected with wild type RAGE, confirming 
the results of an earlier study exploring the same polymorphism’s role on RAGE function.282 In 
the event that these in vitro observations hold true in the lung, it would appear that enhanced 
RAGE function correlates with increased risk of obstructive lung disease. 
1.3.2 Clinical studies 
A very few preliminary studies have explored the expression of RAGE or RAGE ligands in 
patients with asthma. S100A12, a RAGE ligand, was recently shown to be expressed in 
eosinophils and up-regulated in sputum from patients with eosinophilic asthma (as compared to 
patients with other asthma subtypes and normal controls).283 HMGB1 was shown by one group 
to be up-regulated in induced sputum from patients with asthma in general and those with 
neutrophilic asthma in particular, a finding confirmed by other investigators.284 The same group 
demonstrated significantly higher levels of esRAGE in asthmatics, but no correlation between 
esRAGE level and disease severity.285 However, another group studying sRAGE and HMGB1 in 
asthma found that while sRAGE was unchanged from the normal baseline in most asthma 
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subtypes, it was decreased in those with neutrophilic asthma, a phenomenon they attributed to 
increased degradation by neutrophils.71 This group also found no difference in HMGB1 
expression between asthmatics (regardless of subtype) and healthy controls. No attempt by the 
latter group to reconcile their data with the work of others was made. Such inconsistency in a 
very small body of literature is worrisome; moreover, these studies have failed to provide 
mechanistic insight as to the role, if any, of RAGE or RAGE ligands in asthma. 
1.3.3 sRAGE-induced pulmonary inflammation 
Previous work has suggested that exogenous sRAGE delivered to the lung may induce monocyte 
and neutrophil286 or eosinophil38 ingress. In the first study, a bolus of up to 100 µg of 
recombinant baculovirus-expressed sRAGE, ostensibly depleted of endotoxin, was administered 
intratracheally to individual mice. One or two days later, lungs were harvested and examined, 
demonstrating an influx of monocytes and neutrophils into the pulmonary compartment. The 
authors apparently infer that the fact that purified sRAGE was more effective than endotoxin at 
recruiting monocytes and less effective than endotoxin at recruiting neutrophils was evidence 
that contaminating endotoxin was not responsible for the phenomena seen.286 Another study38 
suggested that bovine sRAGE administered intratracheally (as a therapeutic in a bleomycin 
model of pulmonary fibrosis) had the capacity to recruit eosinophils to the lung, even in control 
mice that were not receiving the chemotherapeutic agent. At first mistaking eosinophils for 
neutrophils, the investigators repeatedly endotoxin-depleted their preparations of sRAGE, 
believing it to be the cause of the unanticipated granulocytic inflammation they were seeing. It is 
notable that two instillations of sRAGE to the lungs, spaced out over several days, were 
markedly more effective at inducing eosinophil chemotaxis than a single instillation. 
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2.0  RATIONALE AND HYPOTHESIS 
The receptor for advanced glycation end products (RAGE) was first identified as a potential pro-
inflammatory mediatory of vascular disease in diabetes.1 The putative role in diabetes and 
inflammation, as well as the various ligand identifications made, had the effect of steering RAGE 
biology research away from questions of homeostasis and almost exclusively towards those of 
pathogenesis. Curiously enough, the fact that RAGE is expressed in the lung (and in the 
structural cells of the lung, at that) at levels overwhelmingly greater than in any other organ 
appeared for many to be a very distant consideration. Although hypotheses referential to 
purposes rather than means or mechanisms are no longer acceptable in mainstream scientific 
discourse, such a specific distribution is undeniably compelling and mandates further 
investigation. 
RAGE’s capacity as a pro-inflammatory multiligand receptor suggests that it may be 
involved in the recognition of pathogens. Distribution across broad surfaces of alveolar 
epithelium would lend RAGE the capacity to sense large-scale pathogen motifs, such as the 
repeat motifs found in parasite glycocalyx and helminth tegument; this is a particularly 
interesting possibility, as the immune response to parasites and helminths appears to be related in 
a fundamental way to atopic diseases such as asthma. Remarkably, however, no investigators 
have published studies of RAGE in animal models of allergic airway disease/asthma. 
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Recent whole genome association studies have demonstrated a strong correlation between 
a decline in the ratio FEV(1)/FVC and the RAGE gene.278,279 Although such an association is not 
specific with respect to the type of obstructive disease, asthma is certainly consistent with such a 
change in lung function. In connection with this, it would appear that at this time there are only 
two studies dealing directly with RAGE in patients with asthma71,285 (additional studies address 
RAGE ligands S100A12283 and HMGB1284). The findings of the two studies are mutually 
contradictory, primarily concerned with the neutrophilic subtype of asthma, and provide no 
mechanistic insight into the role of RAGE and specifically sRAGE in the disease. A better 
understanding of the potential role of RAGE in allergic airway disease/asthma requires more 
invasive studies in humans or at the very least the use of animal models, where genetic 
heterogeneity and environmental non-uniformity are minimized, genetic engineering techniques 
are available, and pharmacologic agents may be easily tested. 
The arguments and observations described above led to the formulation of the hypothesis 
that pulmonary RAGE is an important mediator of allergic airway disease/asthma and impeding 
its effect, either through complete elimination of the encoding gene or via pharmacologic 
blockade, attenuates or abolishes one or more key features of the asthmatic phenotype. 
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3.0  MATERIALS AND METHODS 
3.1 ANIMAL STUDIES 
3.1.1 Animals 
Wild type male C57BL/6 mice were purchased from Taconic or Chares River. Founder RAGE 
knockout (RAGE KO) mice were provided by Dr. A. Bierhaus (University of Heidelberg) and 
from these a breeding colony was initiated.44,76,287 These mice are congenic with the C57BL/6 
background. RAGE KO mice were age- and sex-matched to wild type mice for each experiment. 
In all cases mice were housed in the animal care facility of the University of Pittsburgh and 
experimental protocols were approved by the University’s Institutional Animal Care and Use 
Committee.  
3.1.2 Protein preparations 
Soluble RAGE (sRAGE) was purified from mouse lung tissue and endotoxin was removed with 
a Detoxi-Gel column (Pierce) as described previously.7,37 Purity was confirmed by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie Brilliant Blue 
staining. Specific binding of the purified sRAGE to a known RAGE ligand, HMGB1, was 
assessed as described elsewhere39 to ensure ligand binding was intact in the purified protein. 
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Chromatographically purified mouse serum albumin (MSA) and ovalbumin (OVA) were 
purchased from Sigma. House dust mite (HDM) extract was obtained from Greer Laboratories. 
HMGB1 was kindly provided by Dr. K. Tracey (Feinstein Institute for Medical Research). 
3.1.3 Radiolabeling of proteins 
Purified mouse serum albumin and mouse sRAGE were labeled with Na125I (Perkin Elmer) using 
the chloramine T method (Iodination Beads, Pierce) per manufacturer’s instructions. To remove 
residual iodine, both samples were run over Bio-Spin 6 (Bio-Rad) centrifugation columns and 
the eluate was collected. Protein concentration was determined using the absorbance at a 
wavelength of 280 nm, the experimentally-determined mass extinction coefficient of mouse 
sRAGE of 1.89 x 10-3 mL µg-1 cm-1, and the commonly reported mass extinction coefficient of 
serum albumin of 0.52 x 10-3 mL µg-1 cm-1. Gamma counting was performed on a Cobra II auto 
gamma counter (Packard, Perkin-Elmer) and activity calculated from disintegrations per minute 
and the apparatus’ counting efficiency. Samples were analyzed by SDS-PAGE and gel 
autoradiography to estimate purity. 
3.1.4 Delivery of radiolabeled proteins 
Eight-week-old male wild type mice were administered radioiodinated MSA or mouse sRAGE 
via intratracheal (i.t.), intraperitoneal (i.p.), or intravenous (i.v.) routes. Each animal received 1 
µCi of radiolabeled protein, which corresponded to ~0.6-0.9 µg of mouse serum albumin or 
~0.7-1.4 µg of mouse sRAGE (the range is due to the time over which the experiments were 
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performed and the radioactive decay of the 125I isotope), diluted in 0.9% saline; for i.t. and 
i.p./i.v.  treatments, the treatment volumes were 70 µL and 200 µL, respectively. 
3.1.5 Processing of animals following radiolabeled protein biodistribution 
Mice were sacrificed at 1, 2, 4, and 12 hours after the administration of radiolabeled protein, and 
4-5 mice were used per treatment group (where a treatment group was defined by administration 
route, protein administered, and time point). Mice were euthanized with sodium pentobarbital 
i.p., urine was collected, and blood drawn from the right ventricle of the heart. The lungs were 
perfused with saline through the right ventricle until they blanched. Next, the systemic 
circulation was perfused with saline through the left ventricle until the liver and kidneys had 
blanched noticeably. Out of each group of 4-5 mice, 1-2 had their organs removed at this point; 
the remaining three of each group had their lungs inflation-fixed with 0.8 mL of 10% neutral 
buffered formalin (NBF), whereas the systemic circulation was subsequently perfused with 10% 
NBF to fix the other organs, after which these organs were removed as well. The contents of the 
stomach, small intestine, and colon were thoroughly flushed out with saline before weighing and 
gamma counting. 
The following tissues, fluids, and organs were assayed: blood, urine, stomach, small 
intestine, colon, bladder, kidneys, pancreas, spleen, liver, skeletal muscle, bone (femur), thymus, 
heart, lungs, and brain. These were dispensed into previously-tared gamma counting vials and 
weighed. Samples were kept on ice until ready for counting. Radiolabeled protein biodistribution 
at various time points and routes of administration was reported as the ratio between organ 
radioactivity and organ weight (microcuries per gram, µCi/g). For lung, the clearance kinetics of 
the i.t.-administered radioactive tracer were determined by mono-exponential fit of the organ 
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radioactivity/weight ratios. Following gamma counting, unfixed samples were transferred to 
tubes and flash frozen in liquid nitrogen, then transferred to -80°C for long term storage; fixed 
organs, excepting bone, were placed in cassettes and agitated in a large volume of 10% NBF 
overnight; bone was simultaneously decalcified and fixed in Cal-Rite (Richard Allen scientific) 
overnight. Following fixation, cassettes were transferred into 85% ethanol and thus stored until 
ready for paraffin embedding. 
3.1.6 Exogenous sRAGE-induced eosinophil chemotaxis study 
To test the potential eosinophil-recruiting effect of sRAGE, eight-week-old male wild type mice 
were treated i.t. with 50 µg of MSA or an equal mass of sRAGE dissolved in 70 µL of PBS. 
Mice were sacrificed at 24, 48, and 96 hours after treatment. To test for the possibility that an 
induction dose is necessary to prime the lung compartment for enhanced responsiveness to 
subsequent doses, mice were also treated on days 0 and 1 with 50 µg of MSA or sRAGE (on 
each treatment day) and sacrificed on day 3. 
3.1.7 Models of allergic airway disease/asthma 
Allergic airway disease/asthma was induced in eight-week-old male wild type or RAGE KO 
mice using one of three protocols (Figure 2). In the first protocol (Figure 2A), mice were treated 
intranasally (i.n.) four times per week for seven weeks with 40 µg of house dust mite (HDM) 
extract in 25 µL of saline. Control mice were treated with saline vehicle alone. Mice were 
sacrificed 48 hours after the last treatment. 
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The second protocol (Figure 2B) used ovalbumin (OVA) as the sensitization/challenge 
antigen. Sensitization was effected by i.p. treatment with 50 µg of ovalbumin with 2 mg of 
aluminum hydroxide gel (alum, Brenntag) in 0.5 mL of saline on days 0 and 7. Control mice 
were given alum with saline alone during the sensitization phase. Intranasal challenge 
commenced at day 14 with 10 µg of ovalbumin in 25 µL of saline, continuing on alternate days 
for a total of three treatments per week for three weeks. Control mice were given saline alone 
during the challenge phase. Mice were sacrificed 24 hours after the last treatment. 
In the third protocol (Figure 2C), wild type mice were treated i.n. five times per week for 
three weeks with one of the following six treatments (in each case prepared in 25 µL of 
phosphate buffered saline (PBS)): saline control, 25 µg MSA alone, 25 µg mouse sRAGE alone, 
40 µg HDM extract alone, 40 µg HDM extract with 25 µg MSA, or 40 µg HDM extract with 25 
µg sRAGE. Mice were sacrificed 24 hours after the final treatment. Pulmonary function testing 
was performed in these mice. 
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Figure 2. Experimental asthma mouse model sensitization/challenge protocols.  
(A) A seven-week house dust mite (HDM) extract sensitization/challenge protocol. (B) A five-week ovalbumin 
(OVA) sensitization and challenge protocol. (C) A three-week HDM extract sensitization/challenge protocol 
involving the use of co-administered purified proteins. 
3.1.8 Generation of bone marrow chimeras 
Eight-week-old male wild type or congenic RAGE KO recipient mice were administered 0.032 
mg/mL of enrofloxacin (Bayer) in drinking water two days prior to bone marrow transplant and 
kept on antibiotics until seven days post-transplant. Donor wild type and RAGE KO mice were 
euthanized and tibias and femurs harvested into cold Hank’s balanced salts solution (HBSS) 
containing penicillin and streptomycin. The marrow was flushed out of the bones with a needle 
and syringe, and the marrow cells were disrupted into a suspension, then strained to remove bone 
fragments and undisrupted marrow, and washed several times with antibiotics- and serum-free 
cold HBSS, then counted. Recipient mice were given 10 Gy (1000 R) of whole-body ionizing 
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radiation in one dose and received 15-20 x 106 bone marrow cells in ~200 µL HBSS by tail vein 
injection within 8 hours of the irradiation. 
Four weeks following the bone marrow transplantation, mice were given liposomal 
clodronate i.t. to ablate any radioresistant pulmonary macrophages in the recipients. 
3.1.9 Ablation of pulmonary macrophages with liposomal clodronate 
Bisphosphonate dichloromethylenediphosphonic acid disodium (clodronate) encapsulated in 
liposomes was administered to selectively ablate pulmonary macrophages that had possibly 
survived irradiation.288 Eight milligrams (8 mg) of cholesterol (Sigma) and 86 mg of 1,2-
dioleoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids) were dissolved in chloroform in a 
glass vial. The solvent was allowed to evaporate by bubbling nitrogen into the solution over 
several hours to generate a dry hydrophobic cake on the inside surface of the vial. One gram (1 
g) of clodronate (Sigma) was prepared in 5 mL of sterile PBS and added to the lipophilic 
contents of the vial. Liposomes were generated by vortexing the vial contents for 30 minutes and 
then sonicating for 5 minutes. Centrifugation for 1 hour at 125,000 x g effected phase separation, 
with liposomes floating at the surface. The clodronate solution was aspirated and the liposomes 
were washed by resuspension and mixing into 5 mL of sterile PBS. Centrifugation was repeated 
as previously, and the PBS supernatant was aspirated. The liposomes were then reconstituted in 4 
mL of sterile PBS and administered i.t. at a volume of 75 µL to each of the bone marrow 
chimeric mice. 
Four weeks following the treatment with liposomal clodronate, the mice were subject to 
the first of the three protocols outlined in the subsection above (Figure 2A). Pulmonary function 
testing was performed in these mice. 
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3.1.10 IL-33 release study 
To test the capacity of HDM extract to induce release of IL-33 from intracellular stores, eight-
week-old male wild type mice were treated i.t. with 40, 80, or 120 µg of HDM extract dissolved 
in 70 µL of PBS, with PBS vehicle as the control treatment. Mice were sacrificed at one of the 
following time points after treatment: 30 minutes, 1, 2, 3, or 4 hours. 
3.1.11 Pulmonary function testing 
Pulmonary function was assayed using the forced oscillation technique on a flexiVent apparatus 
as described elsewhere.289 Briefly, mice were anesthetized with sodium pentobarbital (~100 
mg/kg), tracheostomized, cannulated and coupled to a flexiVent ventilator apparatus (SCIREQ). 
Mice were ventilated with a 0.2 mL tidal volume and PEEP of ~3 cm H2O. Pressure and volume 
were measured to generate pressure-volume curves, which were then fit by multiple linear 
regression to a mathematical model of the lung. Methacholine (Sigma) was delivered via a 
nebulizer; following each dose, the response was measured by applying 2-second perturbations 
at 10-second intervals for a total of 3 minutes. Dose-response curves were then determined for 
each of three parameters measuring lung function: Newtonian resistance (Rn), tissue damping 
(G), and elastance (H).  
3.1.12 Processing of animals in studies not involving radioactive substances 
In studies in which pulmonary function testing was not performed, the mice were first euthanized 
with sodium pentobarbital (~250 mg/kg), tracheostomized, and cannulated (in studies involving 
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pulmonary function testing, mice were already anesthetized and cannulated in order to test 
pulmonary mechanics). 
Mice were exsanguinated and sera prepared using serum separator tubes (Becton 
Dickinson); following coagulation, serum tubes were centrifuged at 15,000 x g for 5 minutes, 
and the serum was collected and transferred to fresh tubes. 
Eight hundred microliters (0.8 mL) of saline was instilled in the lungs via the trachea and 
withdrawn. Bronchoalveolar lavage fluid (BALF) was diluted twofold for cell counts and 
cytospin slides were prepared for differential cell counting using a cytocentrifuge (Shandon). 
Slides were air dried, stained with Diff-Quik (Siemens), air dried again, and coverslipped with 
Permount (Fisher). Cells per milliliter of BALF were determined manually by counting all 
hematopoietic cells in each of eight high power fields, determining the average number of cells 
per field, multiplying by a factor relating the area of a high power field to the total area of the 
cytospin disk (x144), and finally multiplying by an appropriate dilution factor taking into 
account the dilution of BALF (x2) and the quantity of diluted BALF loaded for each cytospin 
slide (100 µL, hence x10 for cells/mL). The relative percentage of each of monocytes, 
eosinophils, neutrophils, and lymphocytes was determined by counting five high power fields. 
Remaining BALF was centrifuged at 10,000 x g for 10 minutes to sediment cells suspended in 
BALF, and the BALF supernatant was transferred to fresh tubes. 
The right lung was tied off with suture, removed, divided in several pieces into separate 
tubes (for various downstream analyses, e.g. immunoblotting, frozen tissue embedding and 
sectioning or quantitative reverse transcription polymerase chain reaction (qRT-PCR)), and flash 
frozen in liquid nitrogen. The left lung was inflation fixed in the chest cavity with 0.6 mL of 10% 
NBF for ~10 minutes, excised and transferred to tissue cassettes for 4 hrs of fixation in NBF, 
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then transferred to 70% ethanol until ready for paraffin embedding by the University of 
Pittsburgh’s Research Histology Services. 
BALF supernatants, BALF cell pellets, sera, and lungs that had previously been flash 
frozen in liquid nitrogen were stored at -80°C for downstream analyses. 
3.2 BIOCHEMICAL ANALYSES 
3.2.1 Tissue homogenization for protein analyses 
Lung homogenates were used in a variety of downstream applications, including SDS-PAGE 
followed by gel autoradiography, SDS-PAGE followed by membrane transfer and 
immunoblotting, sRAGE affinity chromatography, and immunoglobulin or cytokine enzyme-
linked immunosorbent assay (ELISA). 
For lung homogenates in which membrane proteins as well as soluble proteins were 
desired, frozen lungs were homogenized in cold CHAPS buffer (150 mM NaCl, 50 mM Tris-
HCl, 10 mM CHAPS, pH 7.4) with protease inhibitors (all from Sigma: 100 µM 3,4-
dichloroisocoumarin (DCI), 10 µM trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane (E-
64), 2 mM o-phenanthroline monohydrate), followed by brief sonication, and then protein 
extraction over 2-4 hours at 4°C. For lung homogenates in which only soluble proteins were 
desired, CHAPS detergent was withheld from the buffer and sonication was omitted. Following 
extraction, insoluble substances were sedimented by centrifugation at 20,000 x g for 20 minutes 
at 4°C. The supernatants were transferred to fresh tubes and stored at -80°C until further use. 
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3.2.2 Determination of protein content 
Total protein content in lung homogenates was determined using the Bradford method using 
Bradford reagent (Thermo Fisher), serially-diluted bovine serum albumin (BSA) standard protein 
(Pierce) to generate a standard curve, and a SpectraMax plate reader (Molecular Devices). 
Briefly, fixed volumes of protein samples were mixed with fixed volumes of Bradford reagent in 
96-well plates, incubated, and absorbances read at 595 nm on the plate reader. Total protein 
concentrations of samples were determined by comparison of measured absorbances to the 
standard curve relating known concentrations of BSA to absorbances at the same wavelength. 
3.2.3 sRAGE affinity chromatography 
Cyanogen bromide-activated Sepharose 4B resin (Sigma) was reconstituted in cold 1 mM HCl, 
then washed five times with a 10X volume of distilled water. The resin was then washed into 
coupling buffer (0.1 M NaHCO3, 0.5 M NaCl, pH 8.5) and incubated with concentrated purified 
mouse sRAGE in coupling buffer overnight at 4°C. The resin was then sedimented, washed in 
coupling buffer, and incubated in 0.2 M glycine, pH 8.0, overnight at 4°C to quench unreacted 
cyanogen bromide sites. Finally, the resin was washed four times with alternating 20X volumes 
of coupling buffer and acetate buffer (0.1 M sodium acetate, 0.5 M NaCl, pH 4.0), loaded into a 
glass column fitted with a glass frit, and stored in 1 M NaCl at 4°C until further use. The resin-
coupled sRAGE was shown to retain specific HMGB1 binding activity. 
To probe HDM extract for RAGE ligands, 15 mg of HDM extract (corresponding to ~5 
mg of HDM extract protein) was diluted in loading buffer (50 mM HEPES, 50 mM NaCl, pH 
7.4) and passed over the sRAGE-coupled resin. To probe lung homogenates derived from mouse 
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models of allergic airway disease/asthma for RAGE ligands, ~2-3 mg of total protein from 
pooled lung homogenate (lacking CHAPS detergent) from each strain/treatment group was 
diluted into loading buffer and passed over the sRAGE-coupled resin. To elute loosely-bound 
molecules, a more physiologic washing buffer (50 mM HEPES, 150 mM NaCl, pH 7.4) was 
used to wash the resin. Finally, to elute the sRAGE-bound molecules, high salt elution buffer (50 
mM HEPES, 1 M NaCl, pH 7.4) was applied to the resin. The eluate was concentrated using 
3000 kDa molecular weight cutoff centrifugal filter units (Amicon). 
3.2.4 Identification of RAGE ligands by mass spectrometry 
Samples were denatured with 6 M urea and reduced with 5 mM dithiothreitol (DTT) in a 20 mM 
Tris-HCl, pH 8 buffer. Alkylation was performed with 15 mM iodoacetamide and following 
dilution in 20 mM ammonium bicarbonate buffer the samples were digested with trypsin (w/w: 
1:25) at 37°C for 16 hours. Tryptic peptides were purified per manufacturer instructions on 
StageTips (Thermo Scientific) and then lyophilized. Nano-electrospray ionization tandem mass 
spectrometry (nanoESI-MS/MS) was performed on an EASY-nLC II system (Thermo Scientific) 
coupled to a TripleTOF 5600 mass spectrometer (AB Sciex), equipped with a NanoSpray III 
source (AB Sciex) under Analyst TF 1.5.1 control. The tryptic digests were suspended in 0.1% 
formic acid and injected, trapped and desalted on a ReproSil-Pur C18-AQ column (5 µm, 2 cm x 
100 µm I.D; Thermo Scientific). Peptides were eluted from the trap column and separated on a 
ReproSil-Pur C18-AQ capillary column (3 µm, 10 cm x 75 µm I.D; Thermo Scientific) 
connected in-line to the mass spectrometer at 250 nl/min, using a 50-minute gradient from 5% to 
35% phase B (0.1% formic acid and 90% acetonitrile). Data processing was performed using 
Peakview 1.0 to generate MGF files. Files were searched using the Mascot search engine (Matrix 
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Science) against an in-house database with MS/MS tolerance set to 0.1 Da and peptide tolerance 
set to 10 ppm. 
To lend the data a semi-quantitative footing, exponentially-modified protein abundance 
index (emPAI) was used for comparison between samples. Protein abundance index (PAI) 
normalizes the number of observed peptides to the number of observable peptides for each 
protein species.290 emPAI, which is defined as 10PAI – 1, in turn, is proportional to the abundance 
of a protein species in a mixture.291 Because of intersample variations in the initial pooled raw 
homogenate total protein content loaded over the sRAGE-conjugated resin, further analysis of 
emPAI values was performed, such that the sum of emPAI values for each pooled sample was 
determined (this estimates total protein loaded) and individual emPAI values for each species 
were normalized to this sum. This is briefly summarized in the formula below (where i 
represents an individual protein species, N represents the total number of peptides (actually 
observed or theoretically observable), and n represents the total number of protein species 
detected in the mixture). 
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3.2.5 SDS-PAGE, gel staining, and gel autoradiography 
For SDS-PAGE analysis of purified unlabeled MSA or sRAGE, samples were adjusted to an 
equal concentration and volume, whereas radiolabeled MSA or sRAGE were assessed by gamma 
counting and adjusted to an equal activity and volume prior to gel separation. Frozen lungs from 
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mice that had been treated i.t. with radiolabeled MSA or sRAGE were homogenized in 1.5 mL 
cold buffer lacking CHAPS detergent and containing protease inhibitors, as described 
previously; sixty microliters (60 µL) of each sample was used for SDS-PAGE separation. 
For SDS-PAGE separation of HDM extract components, 100 µg of HDM extract was 
used for each lane. For animal studies that did not employ radioactive substances, uniform 
quantities (5-35 µg) of total lung homogenate protein, 65 µL of undiluted BALF, and/or 65 µL 
of tenfold diluted (in PBS) serum samples were applied to each lane. 
For SDS-PAGE analysis of RAGE-binding molecules, whether derived from HDM 
extract or from lung homogenates, the complete eluates, which had first been concentrated by 
centrifugal filtration, were used. 
Samples were denatured and reduced with SDS and 50 mM DTT, then boiled for 5 
minutes and shock-cooled on ice. DTT was omitted in some cases when HDM extract was 
prepared for SDS-PAGE under non-reducing conditions. Samples were separated on 5-15% 2-
amino-2-methyl-1,3-propanediol-buffered polyacrylamide gradient gels as described 
previously.292 Gels with known or anticipated microgram quantities of protein were stained with 
Coomassie Brilliant Blue and destained in a methanol/acetic acid-containing solution; gels were 
imaged with simple white light transillumination. For gel autoradiography, gels were incubated 
in a 3% glycerol-containing destain solution for 1 hour, then dried overnight on cellulose 
membranes. Dried gels were incubated at -80°C in a metal cassette with photographic film 
(Amersham Biosciences), and exposed film was thereafter developed and scanned. Gels with 
known or anticipated nanogram quantities of protein were stained with SYPRO Ruby protein gel 
stain (Invitrogen) and destained per manufacturer instructions; gels were imaged with UV 
transillumination using a 595 nm emission filter. Gels were visualized on a Kodak Gel Logic 
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2200 Imaging System and recorded using Kodak Molecular Imaging software (both from 
Kodak). 
3.2.6 Immunoblotting 
Gels were equilibrated and transferred to PVDF membranes in immunoblotting transfer buffer 
containing 6-aminohexanoic acid and methanol at 500 mAmps for 1 hr with cooling. Following 
transfer, membranes were incubated in Ponceau S staining solution, destained in methanol/acetic 
acid-containing solution, and recorded by scanning. Membranes were reactivated with methanol, 
and acetic acid was washed out with PBS containing Tween-20 (PBST) three times, at 10 
minutes per wash. Following overnight blocking in 5% milk in PBST at 4°C, membranes were 
washed three times with PBST at 5 minutes per wash, and then probed with one of the following 
(1 hour for each primary anti-mouse antibody incubation at room temperature, unless noted 
otherwise, and three washes in PBST at 5 minutes per wash after each antibody incubation): 
1:5000 rabbit anti-RAGE polyclonal antibody (GenScript 95131-9B) in PBST followed by 
1:5000 secondary horseradish peroxidase (HRP)-conjugated donkey anti-rabbit IgG antibody 
(Jackson ImmunoResearch) in 1% milk in PBST; 1:5000 mouse anti-β-actin monoclonal 
antibody (Sigma A5316) in PBST followed by 1:10000 secondary HRP-conjugated rabbit anti-
mouse IgG antibody (Jackson ImmunoResearch) in PBST; 1:20 diluted (into PBST) pooled 
serum, obtained from wild type or RAGE KO mice sensitized/challenged with HDM extract, 
overnight at 4°C, followed by 1:5000 secondary HRP-conjugated rabbit anti-mouse IgG 
antibody in 1% milk in PBST; 1:500 goat anti-mouse IL-33 polyclonal antibody (R&D Systems 
AF3626) in PBST followed by 1:5000 secondary HRP-conjugated donkey anti-mouse IgG 
antibody (Jackson ImmunoResearch) in 1% milk in PBST. 
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Membranes were developed using enhanced chemiluminescent detection (Thermo-
Fisher). Developed membranes in all cases were visualized on a Kodak Gel Logic 2200 Imaging 
System and recorded using Kodak Molecular Imaging software. Loading was controlled using 
Ponceau S staining for BALF and serum, and for lung homogenate blots by membrane stripping, 
overnight blocking, and re-probing for β-actin as described above. Membrane stripping was 
performed by incubating the membrane twice in succession for 30 minutes in stripping buffer (25 
mM glycine, 1% SDS, pH 2), followed by three washes at 10 minutes per wash in PBST prior to 
blocking overnight. 
Densitometric analysis was performed using the same software used to record the images. 
For each sample, net signal intensity was determined for both RAGE (or IL-33) bands and the 
respective β-actin bands. The RAGE:β-actin (or IL-33:β-actin) signal intensity ratios for each 
sample were determined (in the case of RAGE, for each individual isoform), with the mean ratio 
for saline-treated controls arbitrarily set to 1.0 and used to normalize all other ratios.  
3.2.7 RNA isolation and qRT-PCR 
RNA was prepared from whole lung using an RNeasy Mini Kit (Qiagen), per manufacturer 
instructions. Nuclei acid concentration was determined using the following formula: absorbance 
at 260 nm x dilution factor x 40; the degree of protein contamination was evaluated using the 
ratio of absorbance at 260 nm to absorbance at 280 nm. Reverse transcription (RT) was 
performed with 1 µg of each sample’s RNA, using the following mastermix: 2.5 U MuLV 
reverse transcriptase, 5 mM MgCl2, 1X PCR Buffer II, and 1 mM dNTPs (all from Applied 
Biosystems) in a thermocycler (Techne). The following program was used: 42°C for 40 minutes, 
99°C for 5 minutes, and 5°C for 5 minutes. Quantitative PCR (qRT-PCR) was performed using 
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2X universal TaqMan PCR buffer and TaqMan primer/probe assay reagent (both from Applied 
Biosystems) with primers for RAGE (Mm00545815_m1), IL-5 (Mm00439646_m1), IL-13 
(Mm00505403_m1), TSLP (Mm00498739_m1), IL-33 (Mm00505403_m1), and GAPDH 
control (Mm99999915_g1). The following sequence was performed on an ABI Prism 7300 
machine (Applied Biosystems): 50°C (2 minutes), 95°C (10 minutes), and then 40 cycles of 
95°C (15 seconds) followed by 60°C (1 minute). The fold change in RAGE, IL-5, IL-13, TSLP, 
or IL-33 mRNA expression, as compared to GAPDH mRNA housekeeping control, was 
determined using the ΔΔCt method, with wild type saline-treated control mice set at a fold 
change of 1.0. 
3.2.8 ELISA 
ELISA was used to assess either the immunoglobulin response or cytokine expression in mouse 
models of allergic airway disease/asthma. HDM-specific IgG1 ELISA was performed by coating 
high-binding polystyrene 96 well plates with 2 µg/mL HDM extract in coating buffer (100 mM 
NaHCO3, 30 mM Na2CO3, pH 9.5) overnight at 4°C. Between each step, washes were 
performed with PBST. After blocking with 1% BSA for 2 hours, 1:100 diluted serum or neat 
lung homogenate (containing CHAPS detergent) were applied and incubated at 4°C overnight. 
Detection was performed by probing with 1:1000 secondary HRP-conjugated goat anti-mouse 
IgG1 (Jackson ImmunoResearch) for 1 hour at room temperature, and then incubating with o-
phenylenediamine (OPD) substrate (Sigma) for 30 minutes. Plates were read at 450 nm and data 
are recorded as absolute absorbances. Total IgE ELISA was performed using 1:20-diluted serum 
and an OptEIA IgE ELISA kit (BD Biosciences) per manufacturer instructions. To detect HDM-
binding IgE, first HDM extract was biotinylated using biotin-X,SSE (Invitrogen); then, free 
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biotin was removed using a Sephadex G-25 quick spin column (Roche) and biotinylated HDM 
extract was eluted and stored at -80°C until further use. HDM-specific IgE ELISA was 
performed by first using the OptEIA IgE ELISA kit to capture total IgE in 1:5-diluted serum, 
overnight at 4°C. Then, biotinylated HDM extract was applied for 2 hours at room temperature, 
followed by washing, application of HRP-conjugated streptavidin from the IgE ELISA kit for 1 
hour, and then detection by incubating with OPD substrate for 30 minutes. For all 
immunoglobulin ELISAs the plates were read at 450 nm and data were recorded as absolute 
absorbances or, in the case of total IgE, the concentration of immunoglobulin was determined by 
comparing sample absorbances to a standard curve relating known concentrations of 
manufacturer-supplied IgE standard to absorbances at the same wavelength. 
ELISAs for eotaxin and eotaxin-2 (both from Abcam); IL-4 and IL-5 (both from BD 
Biosciences); IL-17 (R&D Systems); IL-13, IL-25, TSLP, and IL-33 (all from eBioscience) were 
performed per manufacturer instructions, using neat or diluted BALF in all cases except for IL-
17 and TSLP, which utilized neat lung homogenate. Samples were incubated overnight at 4°C, 
with agitation. Blocking and detection antibody incubation steps were generally performed for 1-
2 hours at room temperature, whereas colorimetric detection incubation steps (whether with OPD 
or 3,3’,5,5’-tetramethylbenzidine (TMB)) were performed for 15-30 minutes in the dark. The 
plates were read at 450 nm and absolute concentrations of cytokines were determined by 
comparing sample absorbances to a standard curve relating known concentrations of 
manufacturer-supplied cytokine standard to absorbances at the same wavelength. 
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3.3 HISTOLOGIC ANALYSES 
3.3.1 Tissue embedding, sectioning, and preparation for downstream applications 
Tissue embedding in paraffin was performed in the lab for specimens containing radioactive 
substances. For specimens not containing radioactive substances, formalin-fixed lungs stored in 
ethanol were submitted to the University of Pittsburgh’s Research Histology Services for 
dehydration through ethanol, pre-clearing in xylenes, and embedding in paraffin. For 
immunohistofluorescence staining, blocks were sectioned on a microtome to a 5-µm thickness, 
adsorbed to Superfrost Plus glass slides (Fisher Scientific), dried, incubated at 60°C to improve 
adherence to the slide, deparaffinized in three 10-minute washes in xylenes, and rehydrated 
through a series of 100%, 95%, 90%, 85%, and 70% ethanol to water. 
For frozen tissue embedding, flash frozen lung was immersed in optimal cutting 
temperature (OCT) media (Tissue-Tek) and frozen with liquid nitrogen into molds suitable for 
mounting blocks into a cryomicrotome. Cryosections were obtained at an 8-µm thickness and 
adsorbed to Superfrost Plus glass slides and stored at -80°C with desiccant until further use. To 
prepare sections for immunofluorescence staining, slides were allowed to equilibrate to room 
temperature for 20 minutes, then fixed for 5 minutes in dry 75% acetone/25% ethanol that had 
previously been cooled to -20°C, and then left to dry again at room temperature. 
3.3.2 Tissue section autoradiography 
All steps were undertaken under very low (red) light conditions until the fixation step. 
Autoradiography emulsion NBT (Kodak) was melted at 42°C in a warm water bath. Five 
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micrometer-thickness lung sections previously mounted on slides, deparaffinized, and 
rehydrated, were dipped in molten emulsion, briefly air dried, and stored in light-insulated slide 
boxes with desiccant. The boxes were sealed to prevent entry of water, wrapped in foil, and 
stored at 4°C in the dark for 3-5 weeks. Following incubation, the slides were developed in D-19 
developer and fixed in fixer (both from Kodak), then washed in water, and counterstained, as 
described in the subsequent subsection. 
3.3.3 Histochemical staining 
For hematoxylin and eosin (H&E) counterstaining of NTB emulsion-dipped radioactive lung 
sections (silver grains having been already developed and fixed), specimens were dipped into 
Gill’s hematoxylin (Vector Labs) for up to 15 minutes to generate an adequate counterstain, then 
dehydrated through ethanol, briefly dipped in eosin Y for several seconds, pre-cleared in xylenes, 
and coverslipped with Permount hydrophobic mounting media (Fisher Scientific). 
For histochemical staining of non-radioactive specimens, paraffin blocks were submitted 
to the University of Pittsburgh’s Research Histology Services for sectioning, slide adsorption, 
deparaffinization, and rehydration. Sections were stained with H&E stain and in some cases 
periodic acid-Schiff (PAS) stain. In all cases, sections were examined by light microscopy on an 
Olympus BH-2 microscope and photomicrographs were obtained using an Olympus DP12 
camera. All images were processed using ImageJ software.293 Images were light background-
subtracted; in all cases a rolling ball radius of 50.0 pixels was used.  
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3.3.4 Immunofluorescence microscopy 
Lung sections were mounted, dried, melted, deparaffinized, and hydrated as described 
previously. Whenever possible, RAGE KO sections were used as controls for RAGE staining, 
and isotype matched antibodies against irrelevant antigens and pre-immune sera were used as 
controls for staining of other markers. For immunofluorescence detection of RAGE (in frozen 
sections) and the T lymphocyte marker CD4, no antigen retrieval was necessary. For 
immunofluoresence detection of RAGE in paraffin sections, the basement membrane collagen 
IV, the eosinophil marker major basic protein (MBP), and the macrophage marker F4/80, antigen 
retrieval was performed in 0.2 N HCl with 1 mg/mL pepsin (Fisher) at 37°C for 10 minutes. For 
immunofluorescence detection of VCAM-1, IL-33, the bronchial epithelial cell marker 
uteroglobin/Clara cell secretory protein (CCSP), the endothelial cell marker CD31/PECAM-1, 
the type I alveolar epithelial cell marker aquaporin 5 (AQP5), the type II alveolar epithelial cell 
marker prosurfactant protein C (proSP-C), or the smooth muscle cell marker α-smooth muscle 
actin (α-SMA), antigen retrieval was performed in boiling citrate buffer (Dako) at pH 6 for 30 
minutes. Following antigen retrieval (or, for frozen sections post-fixation drying), sections were 
washed twice in PBS at 5 minutes per wash, and a hydrophobic barrier pen was used to encircle 
each of the sections, which were then blocked with 2% BSA in PBST for 1 hour at room 
temperature. 
Following blocking, sections were washed three times with PBST at 5 minutes per wash, 
and then probed with one or two of the following primary antibodies (incubation conditions of 1 
hour at room temperature or overnight at 4°C for each primary anti-mouse antibody (diluted in 
0.5% BSA in PBST)): 1:500 goat anti-RAGE antiserum (GenScript), 1:500 rabbit anti-RAGE 
polyclonal antibody (GenScript 35131-9B), 1:500 rabbit anti-collagen IV polyclonal antibody 
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(Pierce PA1-26148) 1:500 rat anti-MBP monoclonal antibody (kindly provided by the Dr. J. Lee, 
Mayo Clinic), 1:50 rat anti-CD4 monoclonal antibody (clone RM4-5, eBioscience 14-0042), 
1:100 rat anti-F4/80 monoclonal antibody (clone A3-1, Abcam ab6640), 1:500 goat anti-VCAM-
1 polyclonal antibody (R&D Systems AF643), 1:100 anti-IL-33 polyclonal antibody (R&D 
Systems AF3626), 1:2000 rabbit anti-CCSP antiserum (Millipore 07-623), 1:50 rabbit anti-CD31 
polyclonal antibody (Abcam ab28364), 1:100 rabbit anti-AQP5 polyclonal antibody (Millipore 
AB15858 ), 1:4000 rabbit anti-proSP-C polyclonal antibody (Millipore AB3786), or rabbit anti-
α-SMA polyclonal antibody (Abcam ab5694). 
Following single or dual primary antibody incubation, sections were washed three times 
with PBST at 5 minutes per wash, and then probed with appropriate single secondary antibody or 
pairs of secondary antibody (diluted in 0.5% BSA in PBST) for 1 hr at room temperature in the 
dark: DyLight 488 (henceforth “DL488”)- or AlexaFluor 488 (henceforth “AF488”)- or Cyanine 
3 (Cy3)-conjugated anti-rabbit or anti-goat or anti-rat polyclonal antibody (all from Jackson 
ImmunoResearch). In all cases secondary antibodies were raised in donkey and, particularly for 
those raised against rat IgG, care was taken to purchase antibodies that exhibit minimal cross-
reactivity to mouse IgG. Following secondary antibody incubation, sections were washed three 
times with PBST and then twice with PBS at 5 minutes per wash. Nuclei were stained using a 
brief application of Hoechst stain (10 mg/mL), and free Hoechst stain was washed out with three 
washes of PBS at 1 minute per wash. Sections were coverslipped with gelvatol (recipe from the 
Center for Biologic Imaging at the University of Pittsburgh: 21 g of polyvinyl alcohol, 42 mL of 
glycerol, 52 mL of water, 106 mL of 0.2 M Tris-HCl at pH 8.5, and a few crystals of sodium 
azide; reagents dissolved by heat and agitation; viscosity adjusted by the addition of glycerol or 
polyvinyl alcohol; clarified by centrifugation at 5,000 x g for 15 minutes; stored at 4°C), 
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examined by an Olympus IX71 inverted microscope, and representative photomicrographs 
obtained. All images were processed using ImageJ software, with images background-subtracted 
as individual colors, followed by color channels being merged; in all cases a rolling ball radius of 
50.0 pixels was used. 
3.3.5 Histologic scoring 
H&E-stained lung sections from wild type mice subjected to the third of the enumerated 
sensitization/challenge protocols modeling allergic airway disease/asthma (Figure 2C), were 
examined by a board certified pathologist (Tim D. Oury, MD, PhD), who had been blinded to the 
identity of the samples. The total number of bronchovascular bundles in each lung section was 
determined and inflammation was scored. Inflammation in each bronchovascular bundle was 
graded as 0 (none), 1 (mild), 2 (moderate), or 3 (severe). The results are expressed as the 
percentage of all bronchovascular bundles that involve any inflammatory infiltrates (score of 1 or 
above), and additionally as an average severity score obtainable by dividing the pan-section sum 
of the bronchovascular bundle inflammation scores by the total number of bronchovascular 
bundles in that section. 
Lung sections from wild type or RAGE KO mice subjected to the first of the allergic 
airway disease/asthma model sensitization/challenge protocols summarized previously (Figure 
2A), stained for the presence of IL-33 and visualized by immunofluorescence microscopy, as 
described previously, were scored for the density of IL-33+ nuclei/cells. Staining conditions, and 
the parameters of imaging and image processing were identical for all samples. Briefly, five 
randomly-selected primarily-parenchymal areas of lung section from each individual mouse lung 
specimen were inspected at 10X magnification and recorded separately for both Cy3 signal 
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(corresponding to IL-33+ nuclei/cells) and Hoechst signal (corresponding to all nuclei). The 
photomicrographs were background-subtracted on ImageJ software as previously described, 
color-inverted, and converted to 8-bit grayscale files. These images, in turn, were analyzed using 
the Image-Based Tool for Counting Nuclei (ITCN) plug-in (Center for Bio-Image Informatics, 
University of California, Santa Barbara, CA) in ImageJ. For each corresponding pair of IL-33 
signal and Hoechst signal images, the ratio between the number of IL-33+ nuclei/cells and the 
total number of nuclei/cells was determined. From these ratios, the mean for each sample was 
determined, and from these latter values, the mean for each strain/treatment group was 
determined. The mean ratio for wild type saline control-treated mice was arbitrarily set at 1.0 and 
was used to normalize the other strain/treatment group ratios. 
3.4 REGRESSION AND STATISTICAL ANALYSES 
Quantitative data were analyzed using GraphPad Prism 5 (GraphPad Software Inc., La Jolla, 
CA). Linear regression for standard curves and exponential decay fitting for radioactive tracer 
clearance were performed using this program, as were statistical analyses. Comparisons 
involving one variable were conducted with Student’s t-test, whereas comparisons involving two 
variables, such as those pertaining to experiments varying both strain and treatment, were 
performed with 2-way analysis of variance (2-way ANOVA) followed by post-hoc t-test. All 
values are reported as mean±standard error of the mean (S.E.M.). A p-value of p < 0.05 was 
considered statistically significant. Sample sizes are indicated in figure captions. 
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4.0  RESULTS 
4.1 INTRATRACHEAL INSTILLATION, BUT NOT INTRAVENOUS OR 
INTRAPERITONEAL INJECTION, DELIVERS SOLUBLE RAGE TO THE LUNG 
To determine the most efficacious means of delivery of sRAGE to the lung, biodistribution and 
clearance studies were performed with radiolabeled sRAGE or MSA (as a protein control) given 
via three common routes of administration: i.v. injection, i.p. injection, or i.t. instillation. To 
confirm that the proteins being administered were relatively pure, SDS-PAGE and Coomassie 
Brilliant Blue gel staining were performed and indeed failed to demonstrate the presence of 
proteins other than MSA (~69 kDa) and sRAGE (~37-42 kDa), which migrated as expected 
(Figure 3A). Following labeling with 125I, SDS-PAGE and gel autoradiography was performed to 
confirm incorporation of the label into sRAGE or MSA and removal of free radiolabel (Figure 
3B). Some slight radiolabeled impurities are evident, particularly in the sRAGE preparation, but 
are unlikely to account for more than a few percents of the total protein given. 
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Figure 3. sRAGE and MSA used in biodistribution and clearance studies are relatively pure. 
(A) SDS-PAGE separation and Coomassie Brilliant Blue staining of ~2.5 µg of MSA or sRAGE preparations used 
for radioiodination, and in later experiments, testing the potential eosinophil-recruiting effect of sRAGE. (B) SDS-
PAGE separation and gel autoradiography of 125I-labeled MSA and sRAGE. 
 
Small quantities of radiotracer were used so as to minimize any potential effect of these 
bioactive proteins on the baseline physiology of the animals. Intravenous and intraperitoneal 
injection failed to deliver an appreciable quantity of sRAGE or MSA protein control to the lung 
(Figures 4 and 5, respectively). Distribution to the lung failed to occur within the 12-hour 
window of investigation, by which time extensive renal clearance had already occurred. In 
contrast, intratracheal instillation was very efficacious at delivering sRAGE and MSA to the 
lung, and was in fact the only feasible means of doing so (Figure 6). 
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Figure 4. Organ biodistribution of intravenously-administered sRAGE or MSA in mice. 
Biodistribution of sRAGE or MSA (A) 1 hour, (B) 2 hours, (C) 4 hours, and (D) 12 hours after i.v. injection. 
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Figure 5. Organ biodistribution of intraperitoneally-administered sRAGE or MSA in mice. 
Biodistribution of sRAGE or MSA (A) 1 hour, (B) 2 hours, (C) 4 hours, and (D) 12 hours after i.p. injection. 
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Figure 6. Organ biodistribution of intratracheally-administered sRAGE or MSA in mice. 
Biodistribution of sRAGE or MSA (A) 1 hour, (B) 2 hours, (C) 4 hours, and (D) 12 hours after i.t. instillation. 
4.2 SOLUBLE RAGE IS RAPIDLY CLEARED FROM THE LUNG, INTACT AND 
AT THE ALVEOLAR-CAPILLARY INTERFACE 
To investigate the kinetics of sRAGE clearance from the lung, the biodistribution data for i.t. 
administration was plotted with respect to time and mono-exponential decay fitting was 
performed. Bi-exponential and multi-exponential fitting was not taken into consideration because 
there is insufficient mechanistic understanding at the microscopic level of the processes by 
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which either MSA or sRAGE are cleared from lung, and because the mono-exponential fit 
provides an adequate understanding of the residence time of exogenously-administered MSA and 
sRAGE in lung. Because the 125I-labeled MSA radioactivity in lung at the 1-hour time point was 
substantially lower than the radioactivity of 125I-labeled sRAGE in lung at the same time point, it 
was reasoned that this discrepancy was due to error in the i.t. instillation procedure and the data 
for MSA at 1 hour following treatment were excluded from the mono-exponential fit. Both MSA 
and sRAGE were cleared rapidly from the lung, with half-lives of 2.29 and 2.95 hours, 
respectively (Figure 7A). 
Catabolism is one of many possible mechanisms of protein clearance. To test whether 
sRAGE is removed from the lung by degradation, lung homogenates from animals that had 
received MSA or sRAGE by i.t. instillation were separated by SDS-PAGE and gel 
autoradiography was subsequently performed to detect the various radiolabeled species present. 
Comparison with the gel autoradiograph of the original electrophoretically-separated 125I-labeled 
purified proteins (Figure 3B) indicates that, while the higher- and lower-molecular weight 
impurities persist, neither protein undergoes appreciable proteolysis as it is eliminated from 
normal healthy lung (Figure 7B). 
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Figure 7. Clearance of intratracheally-administered sRAGE or MSA from the lung is rapid and non-
proteolytic. 
(A) Exogenous sRAGE or MSA persistence in the lung over time. (B) SDS-PAGE separation and gel 
autoradiography of lung homogenates from mice given sRAGE or MSA i.t. and sacrificed at the indicated time 
points thereafter. 
 
To determine the cell and tissue sites at which sRAGE egress from the lung occurs, 
autoradiography was performed on sections of lung from mice give sRAGE by i.t. instillation. 
sRAGE (and MSA, results not shown) rapidly reaches the alveolar compartment (there is no 
apparent predilection for the bronchial epithelium, type II alveolar epithelial cells, or alveolar 
macrophages) and thence the circulation (Figure 8). 
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Figure 8. Clearance of intratracheally-administered sRAGE from the lung occurs at the alveolar-
capillary interface. 
Representative light micrographs/autoradiographs recorded at 20X magnification of sections of lung from mice 
given sRAGE (or MSA, shown for comparison) i.t. and sacrificed at the indicated time points thereafter. Lung from 
untreated mice serves as autoradiography background control. 
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4.3 EXOGENOUS SOLUBLE RAGE DOES NOT RECRUIT EOSINOPHILS TO THE 
LUNG 
To test the capacity of sRAGE to recruit eosinophils, endotoxin-depleted sRAGE or MSA was 
administered by i.t. instillation and mice were sacrificed at various time points thereafter. 
Eosinophil infiltration was assessed by immunofluorescence microscopy on lung sections, using 
collagen IV to discriminate pulmonary architecture and major basic protein (MBP) to detect 
eosinophils. Although these results were not quantified, no appreciable difference in eosinophil 
burden in response to MSA vs. sRAGE was apparent. Even when sRAGE was given on two 
consecutive days, no difference from MSA treatment was observed (Figure 9). 
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MSA, 48 hrs post-treatment i.t. sRAGE, 48 hrs post-treatment i.t. 
MSA, 96 hrs post-treatment i.t. sRAGE, 96 hrs post-treatment i.t. 
MSA, D4 post-treatment i.t. D1,2 sRAGE, D4 post-treatment i.t. D1,2 
 
Figure 9. Intratracheally-administered sRAGE does not draw eosinophils into the lung. 
Representative immunofluorescence photomicrographs recorded at 10X magnification of sections of lung from mice 
treated with 50 µg MSA or 50 µg sRAGE, then sacrificed at the indicated time points thereafter. Green – collagen 
IV; red – MBP; blue – nuclei. 
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4.4 ALLERGIC AIRWAY DISEASE DOES NOT ALTER PULMONARY RAGE 
EXPRESSION 
Dysregulated expression or localization of one or more molecular mediators implicated in a 
pathogenic process is a common feature of disease. To investigate the regulation of RAGE 
expression in response to allergens or the allergic disease state itself, mice were subjected to a 
house dust mite (HDM) model of allergic airway disease/asthma (the protocol outlined in Figure 
2A) and assayed for RAGE transcript and protein expression. qRT-PCR indicated a modest 
down-regulation in RAGE transcript expression in response to HDM extract as compared to 
saline control (Figure 10A), although this difference was not statistically significant. Nor was 
any change observed in the total expression level of RAGE protein or the relative proportions of 
sRAGE as compared to its two membrane-bound isoforms, xRAGE294 and mRAGE (Figure 
10B).  
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Figure 10. Pulmonary RAGE expression is not altered in an HDM model of allergic airway 
disease/asthma. 
(A) qRT-PCR (GAPDH used as housekeeping control) and (B) immunoblot (β-actin serves as loading control) 
probing for RAGE, in whole lung homogenates of mice treated intranasally with HDM extract or saline control. 
Densitometry analysis shows normalized RAGE isoform:β-actin ratios for each strain/treatment group. n=3-5 per 
treatment group. 
4.5 ALLERGIC AIRWAY DISEASE DOES NOT INDUCE SHEDDING OF 
SOLUBLE RAGE 
sRAGE shedding has been demonstrated to occur in the context of acute pulmonary injury 
Moreover, sRAGE has been found by other investigators to be elevated in the BALF of asthma 
patients.285 To determine if such shedding into the airspaces or circulation was occurring, BALF 
(~10% of the total volume recovered from both lungs) and serum from mice subjected to an 
HDM model of allergic airway disease/asthma (Figure 2A) were assayed by immunoblotting for 
the presence of sRAGE. sRAGE could be detected in neither BALF nor serum (Figure 11). 
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Figure 11. sRAGE is not shed into the airspaces or the circulation in an HDM model of allergic 
airway disease/asthma. 
Immunoblot probing for RAGE in (A) BALF and (B) serum samples of mice treated intranasally with HDM extract 
or saline control. Ponceau S stain serves as loading control, and purified sRAGE as positive control. 
4.6 ALLERGIC AIRWAY DISEASE DOES NOT ALTER PULMONARY RAGE 
LOCALIZATION 
As RAGE is abundantly expressed by type I alveolar epithelial cells, it was thought that subtle 
changes in RAGE expression in other cell types more closely associated with allergic airway 
disease/asthma, such as bronchial epithelial cells or inflammatory cells, might be undetectable by 
whole lung expression assays. To address this question, immunofluorescence microscopy studies 
of lung sections from mice subjected to an HDM model of allergic airway disease/asthma 
(Figure 2A) were performed, using collagen IV to delineate the basement membrane, which 
approximates the basolateral aspect of RAGE-expressing alveolar epithelium. No appreciable 
change in bronchial, vascular, or alveolar RAGE expression in response to HDM extract 
sensitization and challenge could be detected (Figure 12). 
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Figure 12. Pulmonary RAGE localization is not altered in an HDM model of allergic airway 
disease/asthma. 
Representative immunofluorescence photomicrographs recorded at 10X magnification of sections of lung from mice 
treated with HDM extract or saline control. Green – collagen IV; red – RAGE; blue – nuclei; yellow – co-
localization. 
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Because asthma is a chronic inflammatory disease and because RAGE has been reported 
to be expressed on hematopoietic cells, notably monocytes-macrophages,34,295,296 eosinophils,59 
and T cells,56,58 lung sections from mice subjected to an HDM model of allergic airway 
disease/asthma (Figure 2A) were inspected by immunofluorescence microscopy for the 
expression of RAGE by cells of the hematopoietic compartment. Eosinophils and CD4+ helper T 
cells do not express RAGE (Figure 13A,B), whereas alveolar macrophages appear to express 
RAGE at low levels at baseline (Figure 13C, middle). RAGE expression appears to co-localize 
with F4/80 expression at the cell surface in saline controls but has a more punctate and 
intracellular distribution in lungs of mice treated with HDM extract (Figure 13C, right). 
B A 
C 
Eosinophils (WT) CD4+ T cells (WT) 
Macrophages (RAGE KO) Macrophages (WT, saline-treated) Macrophages (WT, HDM-treated) 
 
Figure 13. Eosinophils and helper T lymphocytes do not express RAGE, whereas macrophages 
express low levels of RAGE. 
Representative immunofluorescence photomicrographs recorded at 20X magnification of pulmonary (A) 
eosinophils, (B) CD4+ T lymphocytes, or (C) macrophages: left, RAGE KO control; middle, saline-treated lung; 
right, HDM extract-treated lung. Green – RAGE; red – MPB (eosinophils), CD4 (helper T lymphocytes), or F4/80 
(macrophages); blue – nuclei; yellow – co-localization. 
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4.7 IN THE ABSENCE OF RAGE, CHANGES IN PULMONARY FUNCTION 
PARAMETERS CONSISTENT WITH ASTHMA DO NOT DEVELOP IN RESPONSE 
TO HDM ALLERGEN 
Expression of a pathogenetic mediator need not be altered in a disease state, particularly when 
the mediator in question is a receptor with multiple, potentially mutually-antagonistic, roles. 
Therefore, to explore whether the absence of RAGE affects the physiologic response to allergen 
sensitization and challenge, wild type or RAGE KO mice were subjected to an HDM model of 
allergic airway disease/asthma (Figure 2A). Pulmonary function testing performed using forced 
oscillation technique on a flexiVent apparatus demonstrated significant alterations in airway 
function in wild type mice treated with HDM extract, consistent with an asthmatic profile 
(Figure 14). These changes in responsiveness to methacholine challenge were evident in the 
parameters corresponding to central airway resistance (Rn), small airway tissue damping or 
resistance (G), and tissue elastance (H), respectively. The modest change in Rn (Figure 15A), as 
compared to what is often seen in studies in BALB/c mice, is consistent with findings of 
previous studies in the C57BL/6 strain.297 The picture with the Rn parameter is somewhat 
complex, with a slightly elevated responsiveness to methacholine in naïve RAGE KO mice as 
compared to wild type counterparts, but no difference between saline-treated versus HDM 
extract-treated RAGE KO mice is demonstrable. However, it is important to note that RAGE KO 
mice treated with HDM extract demonstrate G and H parameters (Figure 15B,C) 
indistinguishable from those of naïve wild type and RAGE KO mice. 
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Figure 14. Mice lacking RAGE do not develop airway hypersensitivity to methacholine challenge in 
response to HDM allergen. 
Dose-response curves of parameters of (A) central airway resistance (Rn), (B) tissue damping (G), and (C) tissue 
elastance (H), in response to methacholine challenge, in mice treated with HDM extract or saline control. n=6-10 per 
strain/treatment group. 
4.8 IN THE ABSENCE OF RAGE, HDM ALLERGEN DOES NOT EFFECT 
PULMONARY EOSINOPHILIA 
There is a prominent eosinophilic inflammatory component in allergic airway disease/asthma, 
and to assess this aspect of disease wild type and RAGE KO mice were subjected to an HDM 
model of allergic airway disease/asthma (Figure 2A). Modified Romanowsky staining of BALF 
cells illustrated markedly elevated cell counts and eosinophilia in the allergic wild type mice 
compared to saline-treated controls (Figure 15). 
 79 
 
Figure 15. Mice lacking RAGE do not develop airway eosinophilia in response to HDM allergen. 
(A) Representative photomicrographs recorded at 40X magnification and (B) graphical summaries of cell counts and 
differentials, of Romanowsky-stained cytospins prepared from BALF from mice treated with HDM extract or saline 
control. n=6-10 per strain/treatment group. 
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Histologic evaluation of lung sections by H&E stain revealed peribronchial, perivascular, 
and interstitial eosinophilia in lungs of allergic wild type mice but not in controls (Figure 16). In 
contrast, RAGE KO mice sensitized and challenged with HDM extract had essentially no 
inflammatory infiltrates, suggesting that RAGE has an important role in drawing eosinophils to 
the lung in response to HDM allergen. 
WT, saline-treated RAGE KO, saline-treated 
WT, HDM extract-treated RAGE KO, HDM extract-treated 
 
Figure 16. Mice lacking RAGE do not develop peribronchial, perivascular, and interstitial 
eosinophilia in response to HDM allergen. 
Representative photomicrographs recorded at 20X magnification off H&E-stained lung sections from mice treated 
with HDM extract or saline control. n=6-10 per strain/treatment group. 
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4.9 IN THE ABSENCE OF RAGE, HDM ALLERGEN DOES NOT INDUCE MUCUS 
HYPERSECRETION 
Mucus hypersecretion is a hallmark feature of asthma. To assess for goblet cell hyperplasia, lung 
sections from wild type or RAGE KO mice subjected to an HDM model of allergic airway 
disease/asthma (Figure 2A) were evaluated for expression of mucin by periodic acid-Schiff 
(PAS) stain. As anticipated, wild type mice showed goblet cell hyperplasia and elevated 
expression of mucin in numerous bronchi of the allergic wild type mice compared to saline-
treated controls (Figure 17). However, RAGE KO mice did not demonstrate enhanced mucus 
expression when treated with HDM extract, suggesting that RAGE is involved in key changes in 
airway structure and function characteristic of allergic airway disease/asthma. 
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Figure 17. Mice lacking RAGE do not develop elevated mucin expression in response to HDM 
allergen. 
Representative photomicrographs recorded at 20X magnification of PAS-stained lung sections from mice 
treated with HDM extract or saline control. n=6-10 per strain/treatment group. 
4.10 ENDOGENOUS RAGE BINDING PARTNERS ARE DIFFERENTIALLY 
EXPRESSED IN RESPONSE TO ALLERGIC AIRWAY DISEASE 
A key question arising from studies of the role of RAGE in an HDM model of allergic airway 
disease/asthma concerns the identity of the RAGE ligand(s) mediating the pro-allergic function 
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of RAGE. This question was addressed both by studying an ovalbumin model of allergic airway 
disease/asthma, as well as the direct approach of probing for RAGE binding partners. HDM 
extract was passed over an sRAGE-conjugated resin under gentle low-salt conditions, and then 
adsorbed binding partners were eluted by increasing the salt concentration. The eluted proteins 
were concentrated, separated by electrophoresis and visualization was attempted using 
Coomassie Brilliant Blue stain (Figure 18A), which has a detection limit of ~50 ng. Because no 
bands could be detected on this attempt, the entire experiment was repeated, with visualization 
achieved using SYPRO Ruby gel stain (Figure 18B), which has a detection limit of below 1 ng. 
There is therefore a >100,000-fold difference between the estimated quantity of HDM extract 
protein passed over the column (~5 mg) and the minimum quantity detectable by Coomassie 
Brilliant blue stain (~50 ng). Despite the fact that such scarce binding partners are of dubious 
biological relevance, the eluted proteins were submitted for identification by mass spectrometry. 
The spectrum of RAGE-binding HDM extract proteins (Table 1, appendix) is unremarkable (as 
no species-restriction to Dermatophagoides pteronyssinus was possible in the peptide matching 
database, homologs in other arthropod species are erroneously identified as matches), and none 
have been suggested to have particular relevance to the development of allergic airway 
disease/asthma in mice or humans. 
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Figure 18. RAGE binding partners are scarce in HDM extract. 
SDS-PAGE separation and (A) Coomassie Brilliant Blue gel staining or (B) SYPRO Ruby gel staining, of whole 
HDM extract proteins, non-adsorbed (“flow-through”) HDM extract proteins from sRAGE affinity chromatography, 
and eluate containing sRAGE-binding proteins in HDM extract 
 
 As HDM extract did not prove to be a major source of RAGE binding partners, and those 
identified are not particularly compelling, an alternative mechanism was considered: endogenous 
RAGE ligands, elaborated by one or more unknown cellular players in response to exogenous 
allergen stimulus, drive RAGE signaling and thereby allergic disease. To explore this possibility, 
equal quantities of lung homogenate protein from mice subjected to an HDM model of allergic 
airway disease/asthma (Figure 2A) were passed over an sRAGE-conjugated matrix; the matrix 
was washed and ligands eluted in a high-salt buffer and concentrated. SDS-PAGE and SYPRO 
Ruby gel staining demonstrated numerous RAGE-interacting proteins in lung homogenates from 
all strain/treatment groups. Differential regulation (primarily up-regulation, but also down-
regulation) of RAGE binding partners in wild type mice in response to HDM allergen, as 
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compared to saline-treated controls, was readily apparent (Figure 19). The same expression 
pattern was not seen in RAGE KO mice treated with HDM extract, which is perhaps indicative 
of a feed-forward mechanism in which early RAGE ligands act via RAGE to induce the 
enhanced expression of the additional RAGE ligands. Mass spectrometry identified numerous 
RAGE-binding proteins (Table 2, appendix), a number of which (e.g. decorin and biglycan) have 
been reported to have significance in asthma.298-301 It is also notable that HMGB1 is not among 
the RAGE ligands identified in any of the lung homogenates. Semi-quantitative analysis was 
performed to compare HDM extract-treated versus saline control-treated wild type or RAGE KO 
mice (comparison of treatments within individual strains, but not betweens strains). A summary 
of those RAGE binding partners for which the total-protein-normalized emPAI value (defined 
previously) is greater in the HDM extract-treated group than in the saline control-treated group in 
at least one of the strains, is given (Table 3, appendix). This gives a rough estimate of which 
RAGE-interacting proteins demonstrate increased expression in response to HDM extract 
treatment. 
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Figure 19. RAGE binding partners are differentially expressed in response to HDM allergen. 
SDS-PAGE separation and SYPRO Ruby gel staining of RAGE binding partners isolated by sRAGE affinity 
chromatography from lung homogenates of wild type and RAGE KO mice subjected to an HDM model of allergic 
airway disease/asthma. 
4.11 IN THE ABSENCE OF RAGE, CHANGES IN PULMONARY FUNCTION 
PARAMETERS CONSISTENT WITH ASTHMA DO NOT DEVELOP IN RESPONSE 
TO OVALBUMIN ALLERGEN 
To explore the relevance of antigen to the role of RAGE in allergic airway disease/asthma, an 
ovalbumin model (Figure 2B) was used for comparison to the HDM model. Sensitization differs 
markedly between the HDM and OVA models, both with respect to location (lung and 
mediastinal lymph nodes vs. mesentery, respectively) and allergen structure (a blend of 
arthropod proteins, some with protease activity vs. a chicken egg protein adsorbed to aluminum 
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hydroxide). Pulmonary function testing indicated alterations in the Rn, G, and H parameters in 
wild type mice treated with ovalbumin as compared to those treated with saline (Figure 20), 
analogously to findings in the HDM model. While the change in the Rn parameter did not reach 
statistical significance, the changes in the G and H parameters did. 
 
Figure 20. Mice lacking RAGE do not develop airway hypersensitivity to methacholine challenge in 
response to ovalbumin allergen. 
Dose-response curves of parameters of (A) central airway resistance (Rn), (B) tissue damping (G), and (C) tissue 
elastance (H), in response to methacholine challenge, in mice treated with ovalbumin or saline control. n=8-10 per 
strain/treatment group. 
4.12 IN THE ABSENCE OF RAGE, OVALBUMIN ALLERGEN DOES NOT EFFECT 
PULMONARY EOSINOPHILIA 
To assess for eosinophilic inflammation in an OVA model of allergic airway disease/asthma 
(Figure 2B), modified Romanowsky staining of BALF cells was performed, illustrating 
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markedly elevated cell counts and eosinophilia in the allergic wild type mice compared to saline-
treated controls (Figure 21). Peribronchial, perivascular, and interstitial eosinophilic 
inflammation, as assessed by H&E stain, was evident (Figure 22). In contrast, RAGE KO mice 
sensitized and challenged with ovalbumin had essentially no inflammatory infiltrates, suggesting 
that the RAGE effect on eosinophil recruitment to the lung observed in an HDM model 
maintains in the ovalbumin model of allergic airway disease/asthma. 
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Figure 21. Mice lacking RAGE do not develop airway eosinophilia in response to ovalbumin allergen. 
(A) Representative photomicrographs recorded at 40X magnification and (B) graphical summaries of cell counts and 
differentials, of Romanowsky-stained cytospins prepared from BALF from mice treated with ovalbumin or saline 
control. n=8-10 per strain/treatment group. 
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Figure 22. Mice lacking RAGE do not develop peribronchial, perivascular, and interstitial 
eosinophilia in response to ovalbumin allergen. 
Representative photomicrographs recorded at 20X magnification of H&E-stained lung sections from mice treated 
with ovalbumin extract or saline control. n=8-10 per strain/treatment group. 
4.13 IN THE ABSENCE OF RAGE, OVALBUMIN ALLERGEN DOES NOT INDUCE 
MUCUS HYPERSECRETION 
Lung sections from wild type or RAGE KO mice subjected to an OVA model of allergic airway 
disease/asthma (Figure 2B) were evaluated for expression of mucin by PAS stain. As anticipated, 
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wild type mice showed goblet cell hyperplasia and elevated expression of mucin in numerous 
bronchi of the allergic wild type mice compared to saline-treated controls (Figure 23). However, 
RAGE KO mice did not demonstrate enhanced mucus expression when treated with ovalbumin, 
suggesting that the RAGE effect on allergic up-regulation of bronchial mucin observed in an 
HDM model maintains in the ovalbumin model of allergic airway disease/asthma. 
WT, saline-treated RAGE KO, saline-treated 
WT, ovalbumin-treated RAGE KO, ovalbumin-treated 
 
Figure 23. Mice lacking RAGE do not develop elevated mucin expression in response to ovalbumin 
allergen. 
Representative photomicrographs recorded at 20X magnification of PAS-stained lung sections from mice treated 
with ovalbumin or saline control. n=8-10 per strain/treatment group. 
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4.14 EXOGENOUS SOLUBLE RAGE HAS NO EFFECT ON HDM ALLERGEN-
INDUCED CHANGES IN PULMONARY FUNCTION PARAMETERS 
Numerous studies of RAGE in animal models of inflammatory disease have suggested that 
sRAGE has an anti-inflammatory and generally salutary effect, likely by virtue of its 
sequestration of RAGE ligands away from the pro-inflammatory membrane isoform.82,302,303 To 
determine which of the two isoforms - mRAGE or sRAGE - is driving the allergic process in the 
HDM murine model of allergic airway disease/asthma, and to explore whether sRAGE has a 
therapeutic effect in this disease model, sRAGE (Figure 24) was co-administered i.n. alongside 
HDM extract; MSA served as a protein control for sRAGE (the protocol is outlined in Figure 
2C). 
 
Figure 24. sRAGE and MSA co-administered with HDM allergen are relatively pure. 
SDS-PAGE separation and Coomassie Brilliant Blue staining of ~5 µg of MSA or sRAGE preparations used for i.n. 
administration alone or alongside HDM extract. 
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Pulmonary function testing did not demonstrate significant differences in parameters Rn, 
G, or H in mice co-administered sRAGE alongside HDM extract, as compared to those co-
administered MSA alongside HDM extract or those receiving HDM extract alone (Figure 25). 
 
Figure 25. Exogenous sRAGE does not ameliorate airway hypersensitivity to methacholine challenge 
in response to HDM allergen. 
Dose-response curves of parameters of (A) central airway resistance (Rn), (B) tissue damping (G), and (C) tissue 
elastance (H), in response to methacholine challenge, in mice treated with HDM extract or saline control, alongside 
sRAGE, MSA, or no additional protein. n=3-4 per treatment group. 
4.15 EXOGENOUS SOLUBLE RAGE ATTENUATES PULMONARY 
EOSINOPHILIC INFLAMMATION ELICITED BY HDM ALLERGEN 
Because of the possibility that changes in pulmonary function parameters occur at a low 
threshold of eosinophil density (thus masking any sRAGE effect on the underlying inflammation 
(sensitization/challenge protocol outlined in Figure 2C)), modified Romanowsky staining of 
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BALF cells was performed, illustrating markedly reduced total cell counts and percentage 
eosinophils in mice co-administered sRAGE alongside HDM extract as compared to either the 
HDM extract alone or HDM extract alongside MSA (Figure 26). Hematoxylin and eosin stained 
lung sections (Figure 27A) were evaluated by a pathologist blinded to treatment group for the 
total number of bronchovascular bundles, the number of bundles demonstrating inflammatory 
infiltrates, and for scoring of the severity of the inflammation in each bundle. The percentage of 
bronchovascular bundles involving inflammation and the overall average inflammation severity 
score were both significantly reduced in mice given sRAGE alongside HDM extract as compared 
to the two other HDM extract-sensitized/challenged groups (MSA or no protein treatment), 
mirroring the BALF cell count and differential data (Figure 27B). 
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Figure 26. Exogenous sRAGE markedly attenuates airway eosinophilia. 
Graphical summaries of cell counts and differentials, of Romanowsky-stained cytospins prepared from BALF from 
mice treated with HDM extract or saline control, alongside sRAGE, MSA, or no additional protein. n=3-4 per 
treatment group. 
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Figure 27. Exogenous sRAGE markedly attenuates peribronchial and perivascular eosinophilic 
infiltrates in response to HDM allergen. 
(A) Representative photomicrographs recorded at 20X magnification and (B) graphical summaries of percentage 
airways involved and mean inflammation severity scores across all bronchovascular bundles (0 = no inflammatory 
infiltrate, 1 = mild inflammatory infiltrate, 2 = moderate inflammatory infiltrate, 3=severe inflammatory infiltrate), 
of H&E stained lung sections from mice treated with HDM extract or saline control, alongside sRAGE, MSA, or no 
additional protein. n=3-4 per treatment group. 
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4.16 BONE MARROW CHIMERIC MICE LACKING RAGE DEVELOP ALLERGIC 
AIRWAY DISEASE IN RESPONSE TO HDM ALLERGEN 
One of the most important questions arising from studies of RAGE’s role in allergic airway 
disease/asthma is the relative importance of pulmonary RAGE versus hematopoietic RAGE. 
Although localization studies discussed above suggested that eosinophils and helper T 
lymphocytes do not express any RAGE, and that macrophages express the protein at low levels, 
the literature is replete with studies suggesting expression of RAGE by inflammatory cells, and 
particularly by monocytes-macrophages. Thus, the possibility that macrophage RAGE rather 
than pulmonary parenchymal RAGE is responsible for the effects seen in models of allergic 
airway disease/asthma cannot be easily dismissed. To elucidate this mechanistic question, bone 
marrow chimeric mice were generated, radioresistant alveolar macrophages were ablated with 
liposomal clodronate, and the chimeric mice were subjected to an HDM model of allergic airway 
disease/asthma (Figure 2A). Contrary to expectation, in response to HDM extract sensitization 
and challenge RAGE KO mice that had received RAGE KO donor bone marrow developed the 
same pulmonary eosinophilia (Figure 28) and peribronchial, perivascular, and interstitial 
eosinophilic inflammation (Figure 29) as wild type mice. Furthermore, no distinction could be 
made between wild type recipient mice with RAGE KO donor bone marrow and RAGE KO 
recipient mice with wild type donor bone marrow: all groups demonstrated exuberant pulmonary 
eosinophilic inflammation in response to HDM allergen and normal quiescent lung when treated 
with saline vehicle control. Unsurprisingly, neither could any distinction be made between the 
four HDM extract-treated groups with regard to pulmonary function parameters (results not 
shown). 
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KO (KO BM), saline-treated KO (KO BM), HDM extract-treated 
 
Figure 28. Bone marrow chimeric mice develop airway eosinophilia in response to HDM allergen, 
regardless of pulmonary epithelial or hematopoietic RAGE expression status. 
Representative photomicrographs recorded at 40X magnification of Romanowsky-stained cytospins prepared from 
BALF of chimeric mice treated with HDM extract or saline control. n=3-7 per treatment group. 
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Figure 29. Bone marrow chimeric mice develop peribronchial, perivascular, and interstitial 
eosinophilia in response to HDM allergen, regardless of pulmonary epithelial or hematopoietic RAGE 
expression status. 
Representative photomicrographs recorded at 20X magnification of H&E-stained lung sections from chimeric mice 
treated with HDM extract or saline control. n=3-7 per treatment group. 
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4.17 IN THE ABSENCE OF RAGE, HDM ALLERGEN DOES NOT ELICIT UP-
REGULATION OF VCAM-1 EXPRESSION 
To determine whether the expression levels and localization of VCAM-1 are normal in RAGE 
KO mice at baseline, and to determine how expression and localization are regulated in response 
to HDM allergen, lung sections from mice subjected to an HDM model of allergic airway 
disease/asthma (Figure 2A) were inspected by immunofluorescence microscopy for the 
expression of VCAM-1. VCAM-1 expression was indistinguishable between wild type and 
RAGE KO mice at baseline, and in both cases expression was confined to the vascular 
endothelium. In response to HDM extract sensitization/challenge, whereas wild type mice 
demonstrated up-regulated VCAM-1 expression (notably at bronchovascular bundles with 
marked eosinophilic infiltrates), RAGE KO mice demonstrated no difference from their saline-
treated control counterparts (Figure 30). 
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Figure 30. Mice lacking RAGE do not up-regulate vascular VCAM-1 expression in response to HDM 
allergen. 
Representative immunofluorescence photomicrographs recorded at 10X magnification of sections of lung from mice 
treated with HDM extract or saline control. Green – VCAM-1; blue – nuclei. 
4.18 IN THE ABSENCE OF RAGE, THE HUMORAL IMMUNE RESPONSE TO HDM 
ALLERGEN IS NORMAL 
To determine whether the humoral immune response to HDM allergen is altered in RAGE KO 
mice, ELISA was performed on sera and lung homogenates of wild type and RAGE KO mice 
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subjected to an HDM model of allergic airway disease/asthma (Figure 2A) to evaluate the levels 
of HDM-specific immunoglobulin. Interestingly, significantly elevated levels of HDM-specific 
IgG1 in serum (Figure 31A) and lung homogenate (Figure 31B) of both wild type and RAGE KO 
mice that had been sensitized and challenged with HDM extract were observed. To test whether 
there were broad differences between the HDM antigen binding profiles of serum IgG from 
allergen-primed and -challenged wild type versus RAGE KO mice, HDM extracts separated by 
SDS-PAGE under either reducing or non-reducing conditions and transferred to membranes 
were probed with sera from sensitized and challenged wild type and RAGE KO mice (Figure 
31C), indicating no demonstrable difference in antigen binding profiles between the two strains 
and suggesting that RAGE is not directly involved in antigen recognition. 
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Figure 31. Mice lacking RAGE develop competent IgG antibody responses against HDM antigens 
indistinguishable from those of wild type mice. 
ELISA shows levels of HDM antigen-specific IgG1 antibodies in (A) sera and (B) lung homogenates from mice 
treated with HDM extract or saline control. (C) Left, SDS-PAGE separation under reducing and non-reducing 
conditions, membrane transfer, and Ponceau S stain (serves as loading control) of HDM extracts used to detect 
HDM-specific IgG. Right, immunoblot demonstrating HDM antigen binding by serum IgG from wild type or RAGE 
KO mice treated with HDM extract. n=3-10 per strain/treatment group. 
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To determine whether IgE production is intact in RAGE KO mice, ELISA was performed 
on sera of wild type and RAGE KO mice subjected to an HDM model of allergic airway 
disease/asthma (Figure 2A) to evaluate the levels of total and HDM-specific IgE. Remarkably, 
the levels of both HDM-specific and total IgE (Figure 32) were significantly elevated in the sera 
of both wild type and RAGE KO mice sensitized and challenged with HDM extract, 
demonstrating that isotype class switching is unaffected by the absence of RAGE. 
 
Figure 32. Mice lacking RAGE develop total and HDM antigen-specific IgE antibody responses to 
HDM sensitization and challenge indistinguishable from those of wild type mice. 
ELISA shows levels of (A) total and (B) HDM antigen-specific IgE antibody in sera from mice treated with HDM 
extract or saline control. n=3-10 per strain/treatment group. 
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4.19 IN THE ABSENCE OF RAGE, IL-17 DEMONSTRATES COMPLEX 
REGULATION 
Despite the lack of prominent neutrophilia in response to HDM allergen – in contrast to the florid 
neutrophilia in response to fungal (Aspergillus)304,305 or cockroach fecal306,307 allergen – analysis 
of IL-17 regulation in an HDM model of allergic airway disease/asthma (Figure 2A) was pursued 
in the interest of completeness. Because IL-17 is undetectable in BALF (results not shown), lung 
homogenates were tested for IL-17 levels by ELISA (Figure 33). Interestingly, IL-17 appears to 
have significantly heightened baseline expression in RAGE KO mice as compared to wild type 
mice. However, while the wild type mice demonstrate induction of IL-17 expression in response 
to HDM extract sensitization and challenge, the RAGE KO mice do not, maintaining IL-17 at 
baseline levels. 
 
Figure 33. Mice lacking RAGE demonstrate elevated IL-17 at baseline, but do not up-regulate IL-17 
expression in response to HDM allergen. 
ELISA shows levels of IL-17 in lung homogenates from mice treated with HDM extract or saline control. n=3-6 per 
strain/treatment group. 
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4.20 IN THE ABSENCE OF RAGE, IL-4 EXPRESSION IN RESPONSE TO HDM 
ALLERGEN IS NORMAL 
IL-4 is one of the classic triad of Th2 cytokines thought to play a pivotal role in allergic airway 
disease/asthma. To characterize the expression pattern of this cytokine in the absence of RAGE, 
ELISA was performed on BALF from wild type and RAGE KO mice subjected to an HDM 
model of allergic airway disease/asthma (Figure 2A). As anticipated and in concordance with the 
antibody data, IL-4 expression is up-regulated from baseline in response to sensitization and 
challenge with HDM extract in both wild type and RAGE KO mice, with no significant 
difference between the two strains (Figure 34). 
 
Figure 34. Mice lacking RAGE secrete IL-4 in response to HDM allergen at levels indistinguishable 
from those of wild type mice. 
ELISA shows levels of IL-4 in BALF from mice treated with HDM extract or saline control. n=3-6 per 
strain/treatment group. 
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4.21 IN THE ABSENCE OF RAGE, EXPRESSION OF EOSINOPHIL CHEMOKINES 
IN RESPONSE TO HDM ALLERGEN IS ABROGATED 
Because of the notable defect in eosinophil recruitment to the lung in HDM extract-treated 
RAGE KO mice, ELISA was performed on BALF from wild type and RAGE KO mice subjected 
to an HDM model of allergic airway disease/asthma (Figure 2A) to assess the levels of eotaxins. 
HDM allergen-induced expression of both eotaxin and especially eotaxin-2 was severely 
diminished in RAGE KO mice as compared to wild type counterparts (Figure 35). This indicates 
that the effect of RAGE’s absence on allergic airway disease is likely not direct and local (e.g. 
RAGE directly binding to eosinophils and mediating their ingress from the circulation into the 
tissue), but is rather mediated by defects in canonical eosinophil chemokine networks. 
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Figure 35. Mice lacking RAGE demonstrate abolished eotaxin and eotaxin-2 expression in response 
to HDM allergen. 
ELISA shows levels of (A) eotaxin and (B) eotaxin-2 in BALF from mice treated with HDM extract or saline 
control. n=3-6 per strain/treatment group. 
4.22 IN THE ABSENCE OF RAGE, IL-5 EXPRESSION IN RESPONSE TO HDM 
ALLERGEN IS ABROGATED 
To characterize the expression pattern of IL-5 in RAGE’s absence, ELISA was performed on 
BALF from wild type and RAGE KO mice subjected to an HDM model of allergic airway 
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disease/asthma (Figure 2A). Severe impairment in HDM allergen-driven IL-5 protein expression 
in RAGE KO mice, as compared to wild type counterparts, was observed (Figure 36A). Due to 
the centrality of IL-5 to the eosinophilic component of asthma, and in order to test whether the 
defect was secretory or synthetic, qRT-PCR was performed on lung homogenate transcript from 
the same group of mice; the IL-5 defect in RAGE KO mice occurs at the level of mRNA 
synthesis (Figure 36B). 
 
Figure 36. Mice lacking RAGE demonstrate abolished IL-5 expression in response to HDM allergen. 
(A) ELISA on BALF and (B) qRT-PCR (GAPDH used as housekeeping control) on lung homogenate mRNA shows 
levels of IL-5 in mice treated with HDM extract or saline control. n=3-6 per strain/treatment group. 
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4.23 IN THE ABSENCE OF RAGE, IL-13 EXPRESSION IN RESPONSE TO HDM 
ALLERGEN IS ABROGATED 
To characterize the expression of IL-13 in the absence of RAGE, ELISA was performed on 
BALF from wild type and RAGE KO mice subjected to an HDM model of allergic airway 
disease/asthma (Figure 2A). To test whether the effects seen occur at the level of protein 
secretion or mRNA synthesis, qRT-PCR was performed on lung homogenate transcript from the 
same group of mice. IL-13 induced in response to HDM allergen is abrogated in RAGE KO mice 
at both the transcript and protein levels (Figure 37). 
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Figure 37. Mice lacking RAGE demonstrate abolished IL-13 expression in response to HDM 
allergen. 
(A) ELISA on BALF and (B) qRT-PCR (GAPDH used as housekeeping control) on lung homogenate mRNA shows 
levels of IL-13 in mice treated with HDM extract or saline control. n=3-6 per strain/treatment group. 
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4.24 EXPRESSION OF TSLP IS UNALTERED IN RESPONSE TO HDM ALLERGEN 
To understand the apparently discoordinate Th2 response in RAGE’s absence, in which IL-4 and 
IgE secretion are intact but IL-5, IL-13, and downstream chemokines are abrogated, study of 
stroma-secreted cytokines was undertaken. As TSLP could not be detected in BALF, lung 
homogenate protein and transcript from wild type and RAGE KO mice subjected to an HDM 
model of allergic airway disease/asthma (Figure 2A) were analyzed for levels of TSLP by 
ELISA and qRT-PCR, respectively. Both assays demonstrate no up-regulation of TSLP in either 
wild type or RAGE KO mice in response to HDM allergen (Figure 38). 
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Figure 38. Both wild type mice and mice lacking RAGE demonstrate no increase in TSLP expression 
in response to HDM allergen. 
(A) ELISA on protein and (B) qRT-PCR (GAPDH used as housekeeping control) on transcript isolated from lung 
homogenate shows levels of TSLP in mice treated with HDM extract or saline control. n=3-6 per strain/treatment 
group. 
 114 
4.25 IN THE ABSENCE OF RAGE, IL-25 EXPRESSION IN RESPONSE TO HDM 
ALLERGEN IS NORMAL 
To assay the levels of IL-25 in the absence of RAGE, ELISA was performed on BALF from wild 
type and RAGE KO mice subjected to an HDM model of allergic airway disease/asthma (Figure 
2A). IL-25 was up-regulated in BALF of both wild type and RAGE KO mice in response to 
HDM allergen, and no distinction between the two strains could be made in this regard (Figure 
39). 
 
Figure 39. Mice lacking RAGE secrete IL-25 in response to HDM allergen at levels indistinguishable 
from those of wild type mice. 
ELISA shows levels of IL-25 (IL-17E) in BALF from mice treated with HDM extract or saline control. n=3-4 per 
strain/treatment group. 
 115 
4.26 IL-33 IS UNDETECTABLE IN BALF FOLLOWING TREATMENT WITH HDM 
EXTRACT 
Because IL-33 is constitutively expressed in lung tissue, BALF from mice subjected to an HDM 
model of allergic airway disease/asthma (Figure 2A) was assayed by ELISA for IL-33 levels. No 
IL-33 was detectable in BALF (results not shown). Because of the possibility that released IL-33 
is very short-lived in the lung compartment, and in parallel with studies by others showing that 
Alternaria extract induced IL-33 release into BALF within 1 hour of treatment followed by rapid 
decay within 6 hours,308 IL-33 release studies were attempted. Increasing doses of HDM extract 
were administered intratracheally in a single dose to wild type mice and BALF was harvested at 
several time points thereafter. ELISA and immunoblot assays demonstrated no release of IL-33 
into BALF in response to any of the doses of HDM extract at any of the time points examined 
(Figure 40). 
 
Figure 40. IL-33 release in response to increasing doses of HDM extract is undetectable. 
(A) ELISA and (B) immunoblot fail to detect any release of IL-33 into the BALF in response to increasing doses of 
HDM extract administered i.t., at various time points after treatment. Ponceau S stain serves as loading control, and 
lung homogenate serves as IL-33 positive control. n=1 per dose/time point group. 
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4.27 IN THE ABSENCE OF RAGE, HDM ALLERGEN-INDUCED EXPRESSION OF 
IL-33 IS ABROGATED 
As it was impossible to detect (by BALF ELISA) the release of constitutively-expressed IL-33 
into airspace lining fluid in response to HDM allergen applied in a single dose i.t., or 
administered chronically i.n., total pulmonary IL-33 was assessed instead. Lung homogenate 
proteins from wild type or RAGE KO mice subjected to an HDM model allergic airway 
disease/asthma (Figure 2A) were analyzed by immunoblot to detect IL-33. IL-33 was markedly 
increased in wild type mice in response to HDM allergen, while no increase in IL-33 from 
baseline was observed (Figure 41A); on the contrary, a small but statistically-significant decrease 
in total IL-33 was observed in RAGE KO mice treated with HDM extract. Interestingly, RAGE 
KO mice had a somewhat elevated expression of IL-33 at baseline (compared to wild type mice), 
although this difference was not statistically significant. To determine whether IL-33 protein 
expression in lung was mirrored by transcript expression, qRT-PCR was performed on lung 
homogenate mRNA from the same group of mice. IL-33 transcript expression parallels (Figure 
41B) total IL-33 protein expression, suggesting that differences between strain/treatment groups 
with respect to protein were due to differences in synthesis, rather than differences in extent of 
secretion (e.g. HDM extract promoting retention of IL-33 within lung cells of wild type mice but 
driving secretion of IL-33 from these cells into the circulation in RAGE KO mice). 
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Figure 41. Mice lacking RAGE do not up-regulate IL-33 protein or transcript expression in lung in 
response to HDM allergen. 
(A) Immunoblot (β-actin serves as loading control) and (B) qRT-PCR (GAPDH used as housekeeping control) 
probing for IL-33, in whole lung homogenates from mice treated intranasally with HDM extract or saline control. 
Densitometry analysis shows normalized IL-33:β-actin ratios for each strain/treatment group. n=3-6 per 
strain/treatment group. 
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4.28 IL-33 IS LOCALIZED TO SMOOTH MUSCLE AND TYPE II ALVEOLAR 
EPITHELIAL CELLS 
As IL-33 is a potential causal antecedent to IL-5 and IL-13 expression, which is disrupted in the 
absence of RAGE, defining the cellular sources of pulmonary IL-33 is a first step towards 
establishing a structural-functional link to epithelial RAGE. To identify the sources of IL-33 in 
the pulmonary compartment, lung sections from mice subjected to an HDM model of allergic 
airway disease/asthma (Figure 2A) were inspected by immunofluorescence microscopy for the 
expression of IL-33. Bronchial epithelium, type I alveolar epithelium, and most endothelium 
(Figure 42A-C) did not express IL-33. Some endothelial expression of IL-33 was apparent in 
what appear to be venules or lymphatic vessels, but no IL-33 could be detected in arterioles or 
alveolar capillaries. 
Contrastingly, smooth muscle cells and type II alveolar epithelial cells clearly express 
high levels of IL-33. Peculiarly, smooth muscle cell IL-33 is most prominent in peribronchial 
smooth muscle, but also in vascular smooth muscle, and appears to be primarily cytoplasmic in 
localization (Figure 43A). Type II alveolar epithelial cell IL-33 – the bulk of pulmonary IL-33, it 
seems – is primarily nuclear in localization, consistent with previous reports (Figure 43B). 
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Figure 42. IL-33 is not expressed in bronchial epithelium, type I alveolar epithelium, or most 
endothelium. 
Representative immunofluorescence photomicrographs recorded at 20X magnification of pulmonary (A) bronchial 
epithelial cells, (B) type I alveolar epithelial cells, and (C) endothelial cells. Green – CCSP/uteroglobin (bronchial 
epithelium), AQP5 (type I alveolar epithelium), PECAM-1/CD31 (endothelium); red – IL-33; blue – nuclei; pink – 
nuclear co-localization. 
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Figure 43. IL-33 is expressed in smooth muscle and type II alveolar epithelial cells. 
Representative immunofluorescence photomicrographs recorded at 20X magnification of pulmonary (A) smooth 
muscle cells and (B) type II alveolar epithelial cells. Green – α-SMA (smooth muscle), proSP-C (type II alveolar 
epithelial cells); red – IL-33; blue – nuclei; yellow – cellular co-localization; pink – nuclear co-localization. 
4.29 HDM ALLERGEN-INDUCED EXPRESSION OF IL-33 IS ATTRIBUTABLE TO 
INCREASED EXPRESSION OF IL-33 ON A PER CELL BASIS 
The marked increase in pulmonary IL-33 expression in mice treated with HDM extract as 
compared to saline-treated control counterparts (and the notable difference in IL-33 expression at 
 121 
baseline between wild type and RAGE KO mice) can conceivably arise from one of two 
mechanisms. In the first scenario, IL-33 expression is increased in response to HDM allergen due 
to increased numbers of IL-33+ cells, whether due to increased proliferation of IL-33-expressing 
cell types (e.g. type II alveolar epithelial cells) or due to HDM-mediated recruitment of novel IL-
33-expressing cells (e.g. a larger fraction of smooth muscle cells expresses IL-33, or additional 
cell types are induced to express IL-33). In the second scenario, IL-33 expression is not up-
regulated in response to HDM allergen by recruiting new cells to express IL-33; it is rather the 
IL-33 expression on a per cell basis that is altered. To address this question, immunofluorescence 
microscopy was performed on lung sections from wild type and RAGE KO mice subjected to an 
HDM model of allergic airway disease/asthma (Figure 2A). Sections were inspected for changes 
in IL-33 localization with reference to both treatment and strain. No difference in the spectrum of 
cell types expressing IL-33 was observed between wild type and RAGE KO mice, nor between 
HDM extract-treated and saline control-treated mice (Figure 44A). A quantitation method was 
implemented to determine the average density of IL-33+ cells per section for each 
strain/treatment group (Figure 44B), taking into account the cellularity of the specimens assayed 
by normalizing to a nuclear stain. No significant difference in the density of IL-33+ cells between 
groups was detectable, indicating that the marked up-regulation of IL-33 protein and transcript in 
response to HDM allergen in wild type mice, as well as the difference in baseline expression of 
IL-33 between wild type and RAGE KO mice, was attributable to an increase in IL-33 
expression on a per cell basis. Indeed, this is easily seen on visual inspection, as the intensity of 
type II alveolar epithelial cell IL-33 signal was substantially greater in HDM-treated wild type 
mice than in the other strain/treatment groups (Figure 44A, left lower panel). 
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Figure 44. No difference in the distribution or density of IL-33-expressing cells is observable between 
strains or treatments in an HDM model of allergic airway disease/asthma. 
(A) Representative immunofluorescence photomicrographs recorded at 10X magnification and (B) normalized 
density of IL-33+ cells per section, in lung sections from mice treated intranasally with HDM extract or saline 
control. n=3-4 per strain/treatment group. Red – IL-33; blue – nuclei; pink – nuclear co-localization. 
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5.0  DISCUSSION 
5.1 SOLUBLE RAGE BIODISTRIBUTION AND CLEARANCE 
Of the three common routes of administration tested – intravenous, intraperitoneal, and 
intratracheal, sRAGE can be delivered to the pulmonary compartment solely via intratracheal 
instillation. These findings cast doubt on studies suggesting a therapeutic effect of 
intraperitoneally-administered sRAGE in mouse models of lung disease.309 It is possible that in 
the sRAGE preparations used by other investigators there are contaminants present, such as LPS, 
which could ameliorate pulmonary disease by rerouting pathogenic cell populations away from 
the lung and to the peritoneum, or by inducing such populations in the lung to deviate to a less 
pernicious phenotype. Alternatively, it is also possible that the low doses (hundreds of 
nanograms) of radiolabeled proteins given here failed to recruit low-affinity transport receptors 
in the pulmonary vasculature that become relevant when much higher doses (dozens of 
micrograms) of sRAGE are given i.p. or i.v. 
A secondary consideration to this set of experiments’ primary aim of determining the 
efficacious route(s) of pulmonary delivery of sRAGE was that these studies also afforded the 
opportunity to probe for potential receptors for sRAGE. Indeed, the MSA treatment controls 
were incorporated with this in mind, to distinguish between specific preferential organ 
biodistribution due to sRAGE binding partners (where the measure of biodistribution is 
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radioactivity per unit mass) and nonspecific preferential organ biodistribution due to greater 
vascular density or more leaky vessels. At first glance, the biodistribution of sRAGE and MSA 
following i.p. or i.v. administration would seem to suggest preferential retention of sRAGE (as 
compared to MSA) in a number of organs, including kidneys, liver, spleen, stomach, small 
intestine, colon, pancreas, skeletal muscle, bone, and brain. However, when these two 
administration routes were compared to each other and to i.t. instillation, no consistent 
preferential organ biodistribution emerged except for the kidneys. Indeed, this phenomenon (of 
sRAGE apparently distributing more effectively than MSA to many organs) was likely not due to 
latent sRAGE binding sites present in these organs, but rather to more rapid kinetics of transport 
of sRAGE (roughly half the molecular weight of MSA, with a reported Stokes radius of 2.81 nm 
for human sRAGE310 as compared to a Stokes radius of 3.55 nm for bovine serum albumin311) 
across the medium-sized (~4-5.5 nm in diameter) and largest (~25 nm in diameter) pores of the 
peritoneal membrane.312 In turn, with peritoneally-delivered sRAGE entering the circulation 
more rapidly than MSA, a transient discrepancy in distribution between the two radiolabeled 
proteins arises, which resolves as the proteins are excreted. The preferential biodistribution of 
sRAGE to the kidneys appears to have been a bona fide effect and likely relates to the size and 
charge properties of sRAGE and MSA. sRAGE binds with high affinity to heparin and heparan 
sulfate (the latter is abundant in renal basement membranes) and is sufficiently small to traverse 
the glomerular barrier during filtration (the effective glomerular pore size being ~8 nm) and thus 
be excreted intact. In contrast, albumin’s negative charge and larger size preclude it from being 
filtered intact, and therefore this protein must be eliminated via other pathways. In retrospect, a 
more suitable protein control for sRAGE may have been irrelevant Fab fragment, which is closer 
in size to sRAGE and is physiologically more inert than serum albumin. 
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Exogenously-administered sRAGE is rapidly cleared from the lung with clearance 
kinetics similar to that of MSA. Moreover, sRAGE remains intact in the lung and effectively 
distributes to the alveoli, from whence it translocates into the circulation. These results are 
surprising, as the lung is rich with many RAGE binding partners, including heparin,37 heparan 
sulfate,36 collagen I and IV,38 and RAGE itself310 (RAGE and specifically sRAGE displays 
homo-oligomerization at low concentrations), all of which are also present in the alveolar 
basement membrane and/or pulmonary interstitium. This would suggest that despite the 
abundance of RAGE binding partners in the lung, in the healthy state these do not act as effective 
sites of sRAGE sequestration. It is important to note, however, that a number of previous studies 
have found an inverse relationship between molecular size and clearance rate from the lung of a 
variety of molecules.313,314 Therefore, as a significantly smaller molecule than albumin, sRAGE 
would be expected to demonstrate more rapid clearance. That sRAGE clearance parallels that of 
MSA, and is thus less rapid than predicted, may suggest retardation of sRAGE transport by 
transient interactions between sRAGE and its ligands. However, it is also important to note that 
an alveolar receptor involved in albumin uptake and transcytosis, gp60, has been identified,315 
and it is possible that such a designated system for return of protein into the circulation does not 
exist for sRAGE. If sRAGE clears predominantly or exclusively via slower, nonspecific 
mechanisms such as paracellular transport and fluid-phase endocytosis,316 albumin may thus not 
serve as a suitable control to infer a subtle ligand-mediated retardation in sRAGE egress. 
Regardless of the microscopic details of protein clearance from the lung, it is evident from these 
biodistribution and clearance studies that, should sRAGE be used as a therapeutic in pulmonary 
disease – assuming no additional functionalization, such as PEGylation to increase half-life – it 
must be administered frequently (one or more times daily) and via the airways. These studies 
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utilized an i.t. instillation approach, but they also imply that intranasal and nebulized aerosol 
administration would exhibit substantial efficacy of sRAGE delivery. 
5.2 EOSINOPHIL RECRUITMENT STUDIES 
No specific eosinophil-recruiting capacity of exogenous lung-administered sRAGE could be 
detected. In these studies, care was taken to use species-matched endotoxin-depleted proteins so 
as to avoid both an allergic response to foreign epitopes and neutrophil chemotaxis in response to 
LPS. Multiple-dose experiments were incorporated to accommodate the possibility that an 
induction dose of sRAGE was necessary to elicit an appreciable response to a second application 
of sRAGE. This would simulate a scenario in which a disease process first causes epithelium to 
shed sRAGE, which then acts in an autocrine, paracrine, or endocrine fashion on local or distant 
intermediary actors or terminal effectors to up-regulate responders on which subsequently-shed 
sRAGE acts. No specific eosinophil ingress in response to sRAGE was seen in the multiple-dose 
experiments, either. Thus, it may be concluded that sRAGE does not have the capacity to induce 
eosinophil chemotaxis when delivered at high doses to the lung. Other investigators have 
suggested that exogenous sRAGE (~100 µg, twice what was delivered in the studies described 
herein) induces pulmonary influx of monocytes and neutrophils; while this may certainly be a 
genuine effect of supraphysiologic doses of sRAGE, it is also possibly a consequence of residual 
LPS in the preparations used. The finding that bovine sRAGE was previously shown to be 
effective at inducing eosinophil chemotaxis may be reflective of an allergic phenomenon, as 
there is substantial discrepancy in amino acid sequence between bovine and murine RAGE. 
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5.3 RAGE AND ASTHMA PHENOTYPE 
The results of this study suggest that RAGE is a key mediator in the disease mechanisms that 
eventuate in airway hyperresponsiveness, mucus secretion and airway remodeling, and 
pulmonary eosinophilia in the HDM model of allergic airway disease/asthma. Taking into 
consideration the great difference in response between wild type and RAGE KO mice to HDM 
allergen, it is perhaps surprising that RAGE levels and localization in the pulmonary 
compartment are essentially unchanged between allergen- and saline control-treated groups. This 
suggests the possibility that it is not RAGE itself, but rather a protein whose expression is tightly 
linked to RAGE, that is responsible for the effects seen in RAGE KO mice. While this possibility 
cannot be definitively excluded, given the observation that treatment with sRAGE – a decoy for 
RAGE ligands – specifically and markedly reduces bronchovascular inflammation in response to 
HDM allergen, it would seem that the lack of RAGE itself, rather than a compensatory process 
occurring in genetic knockouts, is responsible for the effect seen. The lack of sRAGE 
ameliorating effect on pulmonary function measures is likely attributable to incomplete ablation 
of pulmonary eosinophilia (or, more directly, residual allergy-promoting cytokine expression). 
Furthermore, the sRAGE treatment studies point to the membrane protein being the pro-
inflammatory isoform, consistent with much of the RAGE literature. The sRAGE treatment 
studies also indicate that manipulation of the RAGE signaling axis via administration of sRAGE, 
antagonistic antibodies, or small molecule inhibitors, may have promise in the treatment of 
allergic airway disease/asthma. 
Significant sRAGE shedding has been noted in models of acute lung injury, and a 
number of studies have suggested that sRAGE is either increased or decreased in BALF of 
human asthmatics. sRAGE shedding may be a phenomenon unrelated to disease pathogenesis, as 
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the synthesis and release of parenchymal or inflammatory cell proteases during injury can 
account for nonspecific shedding of bystander proteins. In addition, in the absence of aggressive 
protease inhibition, the estimated relative abundance of the various RAGE isoforms on 
immunoblot is progressively shifted towards sRAGE (unpublished observations). Therefore, the 
observation that there is no sRAGE detected in BALF or serum of mice treated with HDM 
extract is not particularly concerning. It is possible that the BALF and serum preparations 
analyzed were too dilute and required concentrating in order to detect sRAGE, or that a low level 
of detectable sRAGE was cleared from the lung between the last allergen challenge and sacrifice. 
It is also possible that in asthma models the disease milieu is insufficiently proteolytic to induce 
nonspecific sRAGE shedding. Indeed, in the OVA model, challenge with allergen does not 
induce shedding of detectable sRAGE into BALF or serum (results not shown). 
Due to its multivalency, RAGE has for some time been considered by many to be a 
pattern recognition receptor (PRR).45,317-319  To date, however, no exogenous ligand has been 
discovered. In our own studies addressing this question, milligram-scale quantities of HDM 
extract were passed over an sRAGE-activated matrix; only nanogram-scale quantities of 
sRAGE-bound protein were eluted, and among the identified species were none that have been 
characterized as important molecular mediators of allergy. Towards deciphering the relevance of 
allergen identity to the RAGE effects seen, the ovalbumin model of allergic airway 
disease/asthma was used for comparison. The findings recapitulated those of the HDM model: 
RAGE KO mice sensitized and challenged with ovalbumin do not develop the airway 
hyperresponsiveness, pulmonary eosinophilia, or goblet cell hyperplasia seen in wild type mice 
thus sensitized and challenged. That two very different models of allergic airway disease/asthma 
point to the same conclusion regarding RAGE function suggests the general applicability of the 
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findings and provides added incentive to explore the role of RAGE in human asthma, in which 
allergen triggers are diverse. Whereas in the HDM model, a physiologic allergen with intrinsic 
protease activity is applied intranasally to effect sensitization and challenge, in the OVA model 
sensitization occurs in the mesentery: the ovalbumin (which is not a particularly relevant allergen 
in clinical asthma) requires LPS contamination to have adequate immunogenicity, and is given 
with alum adjuvant intraperitoneally; challenge then occurs via the intranasal route. Given the 
substantial differences in the sensitization process between the HDM and OVA models, both as 
to location and mechanism, and the lack of structural homology between HDM proteins and 
ovalbumin motifs, it is reasonable to conclude that RAGE is not directly acted upon by allergen. 
Rather, allergen likely induces expression and release of one or more endogenous mediators that 
then act as activating ligands on the RAGE signaling axis. 
To evaluate the plausibility of the endogenous RAGE ligand hypothesis, lung 
homogenates were passed over an sRAGE-activated matrix and sRAGE-bound proteins were 
eluted, a large proportion of which are unlikely to be of biologic significance, e.g. histones and 
protein translation factors, which likely associate with RAGE via large bridging molecules and 
nonspecific electrostatic interactions. Although broadly termed “RAGE ligands” in this 
discussion, such species would technically not be RAGE ligands in either the biochemical  or 
physiologic sense. The identification of several binding partners known to be dysregulated in 
human asthma or murine models of the disease, such as biglycan and decorin, confers a degree of 
validity to the affinity chromatography approach and suggests that more stringent methods of 
discovering RAGE-ligand interactions, such as co-immunoprecipitation, may provide further 
mechanistic insight into the initiating triggers of allergic airway disease/asthma. 
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Immunoglobulin data lend further support to the notion of endogenous RAGE ligands 
acting as intermediaries between allergen and RAGE signaling cascades. The notable 
immunoglobulin response in serum and lung homogenate rules out the possibility that RAGE 
KO mice suffer from global shutdown of adaptive immunity or are somehow ignorant or anergic 
to antigen, and suggests that antibody homing to the site of allergenic insult – the lung – is intact. 
That effective immunoglobulin production in response to antigens occurs in the absence of 
RAGE, despite the lack of other features associated with allergic airway disease, is consistent 
with prior studies suggesting that B cell deficiency (and hence antibody production) does not 
affect the physiologic and pathologic changes seen in response to allergen in an OVA model of 
allergic airway disease/asthma.320 It also underscores the overall picture of RAGE – not as an 
antigen-sensing initiator of allergic immunity (which, if true, would be reflected in RAGE KO 
mice with markedly lower HDM-specific immunoglobulin levels and perhaps immunologic 
ignorance of one or more HDM epitopes) – but as a post-sensitization pathogenetic mediator of 
allergic airway disease/asthma. Additionally, the fact that in the presence of high levels of IgE 
the RAGE KO mice do not develop airway hypersensitivity, eosinophilia, or remodeling would 
seem to indicate that IgE by itself does not play a major role in the development of frank allergic 
disease, at least in this mouse model. However, in this regard it must be noted that changes in 
airway physiology were assayed using methacholine rather than allergen as the challenge agent. 
Which of pulmonary or hematopoietic RAGE are critical for the effects seen in mouse 
models of asthma is a question that could not be clarified by these studies. Immunofluorescence 
microscopy indicated that two key populations in asthma, eosinophils and helper T lymphocytes, 
do not express RAGE. Macrophages appeared to express RAGE at low levels in naïve mice, 
primarily at the surface. In response to HDM treatment, macrophage RAGE appears to be 
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localized to the cell interior, and is notably more punctate. Whether macrophage RAGE protein 
expression is reflective of gene expression or phagocytic uptake of shed epithelial sRAGE is 
unclear. To clarify the relative importance of hematopoietic or pulmonary RAGE, bone marrow 
chimeric mice were generated and macrophages were depleted using liposomal clodronate prior 
to initiating the allergic airway disease/asthma protocol. This approach had successfully 
demonstrated the importance of parenchymal TLR4 in HDM models of allergic airway 
disease/asthma.321 Contrary to expectation, RAGE KO mice that received RAGE KO bone 
marrow developed the same peribronchial, perivascular, and interstitial eosinophilic 
inflammation in response to HDM extract that wild type mice did. There are several potential 
explanations of this phenomenon. First, this may be a simple consequence of greater age: the 
bone marrow chimeric mice were considerably older than non-chimeric mice, because of waiting 
times between the transplantation and macrophage ablation, and between the macrophage 
ablation and commencement of the HDM treatment protocol. Lack of RAGE does lead to 
spontaneous pulmonary fibrosis in aging mice, which no doubt arises from altered gene and 
protein expression. Second, it may be a consequence of the irradiation itself, which is known to 
lead to changes in protein expression in lung.322-325 Third, it may be an off-target effect due 
specifically to the clodronate treatment. Fourth, it may reflect a peculiarity of the bone marrow 
engraftment, wherein hematopoietic stem cells transplanted into adult animals are primed to 
differentiate into cells that respond to allergen differently (in this case, presumably an enhanced 
sensitivity) than cells arising from a hematopoietic compartment that initially developed in 
embryonic life. At any rate, a different approach – namely, RAGE deletion specifically in either 
lung or bone marrow – must be used to answer important questions regarding the relative 
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importance of hematopoietic vs. parenchymal RAGE in the development of allergic airway 
disease/asthma. 
5.4 RAGE AND LYMPHOCYTE-DERIVED CYTOKINES IN ASTHMA 
In the absence of RAGE, the response to antigen under conditions that foster a Th2 allergic-type 
response is markedly discoordinate: while robust IgG and IgE responses against allergen were 
generated, this was not associated with pulmonary eosinophilic inflammation, mucus 
hypersecretion, or airway hyperresponsiveness to methacholine challenge. To understand this 
complex phenotype, attention was turned to the more proximal element in the chain of causality: 
the network of T lymphocyte-derived cytokines and downstream effectors. 
IL-17 has been suggested to play a role in allergy and asthma; in the HDM model of 
asthma/AAD, IL-17 is up-regulated in response to allergen sensitization and challenge in wild 
type mice.326 That RAGE KO mice demonstrate no IL-17 induction in response to HDM extract, 
and furthermore show heightened baseline expression of IL-17 in the absence of antigen, 
suggests that RAGE plays an important role in basal IL-17 regulation. RAGE may actively 
inhibit the secretion of IL-17, either in a direct fashion or by disrupting precursor cytokines such 
as IL-23. Conversely, the absence of RAGE may lead to compensatory induction of other factors 
that in turn drive IL-17 expression. As discussed previously, IL-17 has a complex role in asthma 
in that it promotes the neutrophilic subtype while also negatively regulating established allergic 
asthma by shifting the immune response away from Th2-type inflammation. The baseline 
elevation of IL-17 in RAGE KO mice may thus impede the initiation of a primary asthmatic 
response; moreover, it may account for the subtle differences in airway responsiveness to 
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methacholine challenge between naïve saline-treated wild type and RAGE KO mice (RAGE KO 
mice treated with saline demonstrated an elevated Rn parameter as compared to wild type mice 
thus treated), as a number of studies have indicated a role for IL-17 in promoting airway 
hyperresponsiveness.240,241,327,328 As a full allergic/asthmatic response is not initiated in the 
RAGE KO mice treated with HDM extract, it is not particularly surprising that in this strain there 
is no allergen-induced up-regulation in IL-17 secretion from baseline. 
Innate and adaptive immune response mechanisms that drive humoral immunity are 
intact in the absence of RAGE, including antigen recognition, processing, and presentation; B 
lymphocyte production of immunoglobulin; and isotype class switching, this latter phenomenon 
being driven by IL-4. Consistent with this, IL-4 was elevated in both wild type and RAGE KO 
mice in response to HDM allergen. While T lymphocytes are thought to be the major source of 
IL-4, IL-5, and IL-13, other cell types have been linked to the production of one or more 
members of this triad. Thus, IL-4 induction by HDM allergen could be reflective of a partial T 
lymphocyte response, or of the recruitment of other cell types that produce IL-4, such as 
macrophages329 or basophils.330 
Eosinophil chemotaxis is mediated by a diverse group of chemokines, including eotaxin, 
eotaxin-2, RANTES, MCP-3, MCP-4, and MIP-1α, among others. This network of eosinophil-
recruiting chemokines coordinates both the ingress of eosinophils into the tissues as well as 
many other features of the immune response, including recruitment and activation of 
lymphocytes, basophils, macrophages, and neutrophils. Because of this specificity of effect of 
eotaxin and eotaxin-2, this pair of chemokines was investigated in an HDM model of allergic 
airway disease/asthma. The expression of both chemokines was abrogated in the absence of 
RAGE. This implies that RAGE’s effect on eosinophilia is not a direct one (i.e. such that RAGE 
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expressed on eosinophils acts as a chemokine receptor, as has been suggested by others,60 or that 
pulmonary RAGE binds surface-expressed RAGE ligands on eosinophils to assist their 
trafficking into the lung), but rather is mediated via the canonical cytokine-mediated pathways of 
eosinophil recruitment. 
To address the possibility of a local effect of pulmonary epithelial RAGE on secretion of 
eotaxins, the antecedent link in the chain of causality, collectively the Th2 cytokines IL-5 and 
IL-13, was assessed. A pivotal role for RAGE in the induction of these two cytokines was 
demonstrated. IL-5 is known to drive many aspects of eosinophil generation, maturation, 
function, and survival; IL-13 mediates many of the structural changes in the lung, such as mucus 
hypersecretion and goblet cell hyperplasia, as well as induction of eotaxins. The finding that 
synthesis of IL-5 and IL-13 is abolished in RAGE’s absence is thus consistent with the 
physiologic and histologic analyses of phenotype previously described. However, this also 
invokes difficult questions regarding the integrity of the IL-4 response in the absence of RAGE, 
and how this may be understood given the lack of IL-5 and IL-13 expression. Clearly, the 
absence of signaling along the RAGE axis does not eventuate in global suppression of Th2 
immunity, as would be expected in the absence of the Th2 transcription factor GATA-3, or in the 
context of immunosuppressive therapy. Of course, this presupposes that classic T lymphocytes 
are indeed the major source of IL-5 and IL-13 in the asthmatic lung, and, conversely, that non-T 
cell sources do not account for much of the IL-4 detected in BALF. Apart from the trivial 
explanation of T cells expressing IL-4 but not IL-5 and IL-13 in the absence of RAGE, one 
potential resolution of this conundrum is the postulation of a substantially more significant role 
for non-classic (non T-cell) sources of IL-4, IL-5, and IL-13 than hitherto recognized. 
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The fundamental sub-cellular mechanisms by which IL-4 and IL-5/IL-13 secretion are 
decoupled are beyond the scope of this discussion. While each of these cytokines has multiple, 
overlapping, and synergistic effects with other Th2 and non-Th2 cytokines, it is worth noting that 
IL-4 has a pivotal role in antibody isotype class switching and T cell priming, which thus links 
this cytokine inextricably with the adaptive immune system. In contrast, in allergic airway 
disease/asthma, IL-5 and IL-13 appear to be primarily involved in shaping the eosinophilic 
inflammatory response and mediating changes in airway structure and function, respectively. 
Furthermore, they are not critical for T cell priming. Therefore, these two cytokines mediate the 
two major pre-adaptive arms of anti-microbial defense: innate immunity (i.e. the eosinophil 
granulocyte response) and physical barriers to pathogen entry and colonization (i.e. augmented 
mucus secretion to assist in expulsion of parasites). In light of this, it is not surprising that it has 
previously been noted by others that IL-4 production is regulated specifically by the 
cyclosporine-sensitive T cell receptor (TCR)/calcineurin/NFAT pathway.331-333 By contrast, the 
calcineurin/NFAT pathway is not required for IL-5 and IL-13 induction, which rely on other 
signaling pathways, such as the p38 MAPK and NF-κB pathways.333 The encoding of IL-5 and 
IL-13 regulation in these latter pathways (which are ubiquitous, not restricted to T cells, and are 
in fact linked to RAGE14) suggests that other cell types could be responsible for IL-5 and IL-13 
production. Indeed, a recently-identified major source of IL-5 and IL-13, but not IL-4, are the 
nuocytes, an innate helper T cell population that resides in the normal lung, primed for rapid 
responses to pathogenic stimuli before T cell priming has occurred. 
From a phenomenological point of view, questions proceeding from the apparent 
discoordination amongst the Th2 cytokines IL-4, IL-5, and IL-13, may be addressed in part by 
characterizing the expression of upstream cytokines and intracellular mediators. However, 
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fundamental mechanistic insight will likely require full dissection of the lung and draining 
lymphoid tissues into component cell populations and subsequent characterization of their 
RAGE expression status and signaling capacity, profiling of their cytokine synthetic capacity, 
and in vitro experimentation to parse out the underlying intracellular signaling pathways 
involved. 
5.5 RAGE AND STROMA-DERIVED CYTOKINES IN ASTHMA 
Stroma-derived cytokines in allergic airway disease/asthma have been the subject of intense 
scrutiny over the past several years. As previously noted, this is largely rooted in the presently 
poor understanding of the etiology of allergic disease. Each of the emerging triad of stroma-
derived cytokines was evaluated in an HDM model of chronic allergic airway disease/asthma. 
Thymic stromal lymphopoietin (TSLP) was not found to demonstrate increased expression in 
response to allergen in either strain, suggesting that either the detection methods used were 
insufficiently sensitive or specific, or that TSLP does not play a significant role in the chronic 
phase of the disease. By contrast, allergen-driven expression of IL-25 is intact in the absence of 
RAGE. One possible explanation of this effect is that RAGE is involved in the recognition and 
response to IL-25, either directly or via one of the downstream mediators of the latter. Another is 
that endogenous IL-25 is insufficient to effect eosinophilic inflammation in the absence of one or 
more co-factors (which are disrupted in RAGE’s absence). Although prior studies convincingly 
demonstrate that Th2 inflammation is blunted in IL-25 knockout mice,334,335 these do no more 
than suggest that IL-25 is a permissive factor in the allergic immune response. Hence, studies 
demonstrating marked eosinophilic inflammation in response to potentially supraphysiologic 
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exogenous IL-25250,253 may be of limited relevance to understanding the role of IL-25 in more 
physiologic models of allergic airway disease/asthma as well as the human condition itself: high 
doses of exogenous IL-25 may suffice to drive Th2 immunity in the absence of co-factors 
otherwise important in initiating allergic disease. Questions regarding the role of IL-25 in the 
absence of RAGE may be addressed by administering increasing doses of IL-25 to wild type and 
RAGE KO mice and evaluating the eosinophilic inflammatory response: demonstration of a 
markedly diminished response in RAGE KO mice would suggest that RAGE lies downstream of 
IL-25, whereas similar responses in both strains would suggest a non-physiologic effect of 
exogenous IL-25 and would indicate that endogenous allergen-elicited IL-25 is permissive but 
not sufficient for the development of a Th2 immune response. 
Characterization of IL-33 expression in response to HDM allergen in wild type and 
RAGE KO mice was of particular importance because IL-33 has previously been linked to 
specific induction of IL-5 and IL-13 (but not IL-4). This complements the finding that absence of 
RAGE prevents induction of specifically IL-5 and IL-13 (but not IL-4) in response to allergen. 
Because IL-33 is constitutively expressed in the interior of structural cells of the lung (in which it 
serves as a transcription repressor), detection of released BALF was attempted in order to restrict 
the scope of investigation solely to the portion of IL-33 that acts as an extracellular cytokine  
Release of IL-33 into BALF was not observed in a chronic HDM model of allergic airway 
disease/asthma, nor acutely following single dose administration of HDM extract. Although no 
IL-33 could be detected in either instance, it is possible that this was the case because of a 
narrow time window during which IL-33 secretion is appreciable in response to stimulus. 
The increase in total IL-33 at both transcript and protein levels in wild type mice treated 
with allergen is consistent with increased turnover of IL-33 from intracellular stores and shunting 
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into secretory pathways. As IL-33 has an additional role in regulating transcription, tight control 
of IL-33 levels, such that steady state is maintained, is critical (with synthesis, regulated 
secretion in response to allergen stimulus, and transcriptional regulation in the balance). Up-
regulation in global IL-33 expression could be attributed to recruitment of novel cell populations 
into the pool of IL-33-expressing cells, proliferation of established IL-33-expressing cells, or 
increased mean IL-33 expression on a per cell basis. The former two scenarios would be 
compatible with a bystander increase in the levels of IL-33, perhaps induced by the inflammatory 
state in the lungs of wild type mice; the latter scenario would be most consistent with 
compensatory up-regulation of IL-33 release due to induced secretion. Immunofluorescence 
microscopy studies suggest that IL-33 is increased in wild type mice in response to HDM extract 
on a per cell basis, lending support to the notion that allergen induces enhanced IL-33 synthesis 
and secretion from structural cells of the lung. RAGE KO mice do not demonstrate enhanced IL-
33 expression in response to allergen, suggesting that the abrogation of IL-5 and IL-13 
expression may be attributed to a deficient IL-33 response in RAGE’s absence. 
As in the case of IL-25, it is unclear whether RAGE lies upstream or downstream of IL-
33. Conceivable mechanistic scenarios include but are not limited to: RAGE signaling induces 
the expression and secretion of IL-33, RAGE acts as a receptor or co-receptor for IL-33 on 
responding immune cells, and RAGE is involved in recruiting IL-33 responsive cells, such as 
nuocytes, to the lung compartment. The latter two hypothetical mechanisms would require 
RAGE to take part in an autoregulatory positive feedback loop driving reciprocal IL-33 synthesis 
and secretion; in the absence of RAGE, this loop would be broken and thus RAGE KO mice 
would not demonstrate elevated IL-33 in response to allergen. The first of the proposed 
mechanisms, that of RAGE inducing IL-33, is the simplest and most attractive: the lack of 
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elevated allergen-induced IL-33 expression in the absence of RAGE easily explains the 
downstream effects on IL-5, IL-13, airway physiology, and pulmonary histology seen in RAGE 
KO mice administered allergen. The observation that the major source of IL-33 in mouse lung 
appears to be the type II pneumocyte, in structural and functional proximity to and lineage 
antecedent of the major source of RAGE (the type I pneumocyte), further supports a mechanism 
in which alveolar epithelial RAGE signaling promotes the release of IL-33 from neighboring 
alveolar epithelium, which in turn drives downstream cytokine expression. Questions concerning 
the place of IL-33 in the chain of causality may be readily addressed by administration of 
exogenous IL-33 in RAGE KO mice in a dosing regimen known to elicit pulmonary eosinophilic 
inflammation in wild type mice. If RAGE KO mice reproduce this inflammation, it would be 
reasonable to conclude that RAGE is an inducer of IL-33, and that IL-33 sensing and response 
systems are intact; if the inflammatory response is blunted in RAGE’s absence, a mechanism in 
which RAGE is involved in detection and response to IL-33 (as a receptor, a co-receptor, or as a 
more distant permissive factor) would be more likely. 
5.6 SUMMARY AND FUTURE DIRECTIONS 
The results presented herein suggest a vital role for RAGE in the pathogenesis of allergic airway 
disease/asthma. What emerges is a complex picture of mixed phenotype, in which the absence of 
RAGE abolishes allergen-induced eosinophilic inflammation, mucus hypersecretion, and airway 
hyperresponsiveness, even as the immunoglobulin response remains fully intact. These 
phenotypic data are paralleled by the cytokine profile, with IL-5, IL-13, and eotaxins linked to 
inflammation, airway physiology, and airway structure, and IL-4 linked to immunoglobulin. 
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Investigation of stroma-derived cytokines demonstrated no role for TSLP in the animal models 
studied and no difference between wild type and RAGE KO mice with respect to IL-25 
secretion. IL-33, a potent inducer of IL-5 and IL-13 (but not IL-4) was found to have disrupted 
regulation in response to allergen in RAGE’s absence, consistent with the phenotypic and overall 
cytokine data. Given the fact that RAGE demonstrates the same essential role in the generation 
of Th2 immunity in mouse models of asthma with markedly different antigens (HDM extract vs. 
ovalbumin) and routes of sensitization, and given the very low affinity of RAGE for proteins 
present in HDM extract, it seems likely that designated endogenous RAGE ligands serve to link 
exogenous allergens and their associated danger signals with signaling pathways downstream 
from RAGE. 
On the basis of these studies and in conjunction with observations made by others, a 
working model of RAGE function in allergic airway disease/asthma emerges. Allergens and their 
associated danger signals provoke the release of one or more RAGE ligands from one or more 
cell sources in the lung. With reference to this, it is important to note that ovalbumin requires 
traces of LPS to have adequate immunogenicity336 and that protease activity of HDM extract is 
crucial for development of the full asthmatic phenotype.337-339 Interestingly, one study also 
suggested that TLR4 signaling is vital in inducing disease in an HDM model of asthma.321 This 
suggests that, while foreign antigen may suffice to drive immunoglobulin production, associated 
danger signals (e.g. LPS together with T cell-mediated damage in the ovalbumin model or 
protease-mediated necrosis in the HDM model) are required for the development of a mature 
Th2 immune response. Indeed, the requirement for LPS as well as tissue damage (whether by 
allergen proteases in the HDM model or cytotoxic T lymphocytes and antibody-mediated 
complement deposition in the ovalbumin model) may suggest a two-pronged initiation of the 
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fully-fledged Th2 immune response: canonical PAMPS, such as LPS, drive T cell priming and 
differentiation and B cell antibody secretion, whereas low-level tissue damage and elaboration of 
specific endogenous DAMPS skews the lymphocyte response towards specifically Th2. 
Following endogenous RAGE ligand release, said ligands activate RAGE on type I alveolar 
epithelium and/or other cell types. Although the compartment and specific cell population that 
expresses RAGE critical to the phenotype seen in allergic airway disease/asthma was never 
definitively identified, for purposes of this discussion it is assumed that this is lung and 
specifically type I alveolar epithelial cells. The activated RAGE-expressing cells then induce IL-
33-expressing cells to release that cytokine and also up-regulate basal levels of stored IL-33. 
This is likely mediated by autocrine, paracrine, or juxtacrine signaling: for example, type I 
pneumocytes may signal to neighboring type II pneumocytes via receptor-membrane ligand 
interactions, gap junctions, or secreted factors. Released IL-33, in turn, may then act on the 
resident innate nuocytes and recruited T lymphocytes to potently induce IL-5 and IL-13 
secretion, which eventuates in most of the major manifestations of allergic airway 
disease/asthma. This is summarized graphically below (Figure 45). 
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Figure 45. A schematic representation depicting a model of the role of RAGE in asthma. 
Allergen along with danger signals elicits release of endogenous RAGE ligands, which then activate signaling 
cascades in RAGE-expressing cells. Activated RAGE-expressing cells, in turn, induce IL-33-expressing cells to up-
regulate and release IL-33. Released IL-33 acts on responding cells such as nuocytes and T lymphocytes to drive 
expression of IL-5 and IL-13, resulting in physiologic and structural changes in lung consistent with asthma. 
 
These studies suggest many new questions and avenues of future investigation. The most 
immediate set of questions regards the role of other cytokines, chemokines, and adhesion 
molecules in animal models of asthma, including but not limited to IL-9 expression, Th1 and 
other Th17 cytokines, the PSGL-1/P-selectin interaction, and eosinophil chemotaxins other than 
eotaxin and eotaxin-2. As the stroma-derived cytokine TSLP appears to have been irrelevant in 
the chronic HDM model of allergic airway disease/asthma assessed, implementation of more 
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acute models to assess the role of RAGE in the regulation of this cytokine may be necessary. 
Methods to assess IL-33 secretion specifically (rather than whole tissue levels), perhaps by use 
of ex vivo explants of lung, are required to demonstrate that not only basal expression but also 
secretion of IL-33 in response to allergen stimulus is impaired in RAGE’s absence. Furthermore, 
the role of RAGE in IL-25 and especially IL-33 function is somewhat murky and must be 
clarified with administration of cytokines to wild type and RAGE KO mice and assessment of 
inflammatory phenotype. If RAGE KO mice demonstrate an impaired inflammatory response to 
IL-25 and/or IL-33, it is reasonable to conclude that RAGE lies downstream of these cytokines 
(e.g. as a receptor, co-receptor, nuocyte maintenance factor, etc.). Contrariwise, if RAGE KO 
mice demonstrate similar inflammation in response to IL-25 and/or IL-33 as their wild type 
counterparts, RAGE being positioned functionally antecedent to these cytokines is the more 
likely possibility. 
A second line of potential investigation concerns unresolved questions regarding 
localization of RAGE and Th2 cytokine expression. Bone marrow chimeric studies failed to 
demonstrate whether pulmonary or hematopoietic RAGE is responsible for the phenotypic 
effects seen in RAGE KO mice. This may be addressed by tissue-specific knockout mice, in 
which hematopoietic or pulmonary RAGE is selectively eliminated from the system. 
Additionally, whole lung single cell suspension followed by immunostaining for lineage markers 
and separation of the various populations by flow cytometry would permit rigorous assessment 
of RAGE and cytokine expression status, via culturing and subsequent ELISA on conditioned 
media, intracellular cytokine staining, qRT-PCR on extracted RNA, and/or immunoblotting on 
purified cell lysates. In particular, the IL-33-expressing population chiefly responsible for IL-33 
secretion in response to HDM allergen is unclear, i.e. type II pneumocytes vs. smooth muscle 
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cells; furthermore, the respective roles of T lymphocytes vs. non-T cell sources such as nuocytes 
in the global expression of IL-5 and IL-13 in animal models of asthma is unclear and requires 
elucidation via the preparative and analytical approaches discussed previously. 
A third set of questions concerns the signal transduction mechanism between allergen and 
RAGE. Affinity chromatography approaches to detecting endogenous RAGE ligands generated 
numerous identifications, but their biological significance remains unclear. A more physiologic 
approach to ligand identification is needed. One approach is to use sRAGE conjugated to a 
functionalized photoactivatable cross-linker to probe for RAGE ligands. Whole lung single cell 
suspensions from mice previously sensitized and challenged with HDM extract or saline vehicle 
control could be prepared and cultured in serum-free media, with or without HDM extract. 
sRAGE conjugated to photoactivatable cross-linker functionalized with a fluorophore (such as 
sulfosuccinimidyl 2-(7-azido-4-methylcoumarin-3-acetamido)ethyl-1,3’-dithiopropionate (sulfo-
SAED)) could then be introduced to the whole lung cell culture, under non-permeabilizing or 
membrane permeabilizing conditions. Non-permeabilizing conditions would assess for surface-
expressed RAGE ligands, whereas saponin-mediated membrane permeabilization (perhaps in 
conjunction with application of brefeldin A, to block secretion) would assess for secreted or 
intracellular RAGE ligands. Non-covalent sRAGE interactions with cognate ligands would be 
rendered covalent via photoactivation of the cross-linker with exposure to UV light. Cell sorting 
on the fluorescently labeled cells (with appropriate controls for nonspecific binding) or 
inspection by immunofluorescence microscopy would indicate the major cellular sources of 
RAGE ligands. With this information in hand, these in vitro experiments could be repeated in 
lung cells pre-sorted according to unique lineage markers (based on RAGE ligand expression, 
determined previously), using sRAGE conjugated to a biotinylated non-fluorescent cross-linker 
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(such as sulfosuccinimidyl-2-[6-(biotinamido)-2-(p-azidobenzamido) hexanoamido]ethyl-1,3’-
dithiopropionate) (sulfo-SBED)). Identification of RAGE ligands in various cell types could be 
made by isolation of biotinylated species from cell lysates using solid phase streptavidin, 
followed by release of the sRAGE/RAGE ligand complexes from streptavidin-bound biotin by 
reduction of disulfide bonds, separation by SDS-PAGE, and mass spectrometry. Determination 
of physiologic relevance could be made by quantitative proteomics (perhaps by using methods 
such as two-dimensional difference gel electrophoresis (DIGE)), comparing HDM extract-treated 
samples with saline-treated samples to confirm up-regulation of putative ligands in the allergic 
state. Further corroboration of relevance may be attained by expression profiling of identified 
RAGE ligands using standard immunodetection methods and through use of anti-ligand 
antagonistic antibodies in animal models of allergic airway disease/asthma to assess the effect on 
disease phenotype and cytokine expression. 
A fourth line of inquiry concerns the signal transduction mechanism that connects RAGE 
to IL-33 synthesis and secretion. Elucidation would mandate characterization of physiologic 
RAGE ligands involved in allergy, identification of the source(s) of RAGE (e.g. type I alveolar 
epithelial cells or alveolar macrophages, etc.) relevant to the phenotypic effects seen in animal 
models of disease, as well as identification of the cell type(s) whose allergen-induced up-
regulation and release of IL-33 is aberrantly regulated in RAGE’s absence (e.g. type II alveolar 
epithelial cells or smooth muscle cells). With these data available, in vitro experiments may be 
devised that explore the relationship between RAGE and IL-33 in detail. For instance, if it 
appears that type I pneumocyte RAGE and type II pneumocyte IL-33 are most relevant to the 
effects seen, and that S100A13 is the dominant RAGE ligand involved, studies employing 
primary mixed co-cultures of type I and type II epithelial cells (with S100A13 used as an 
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agonist) may be used to probe the intra- and intercellular networks mediating RAGE’s effect on 
IL-33. Using RAGE agonist as the input and IL-33 secretion as the output, small molecule 
inhibitors of surface receptors or gap junctions, or antagonistic antibodies against cell surface 
adhesion molecules and secreted proteins, could be used to parse out the most relevant autocrine, 
paracrine, and juxtacrine interactions. Once these are delineated, additional experiment may be 
performed on cultures of a single cell population to characterize the intracellular signaling 
cascades linking RAGE ligation to downstream cell responses and, separately, IL-33 secretion to 
upstream extracellular stimuli. 
Laying aside mechanistic questions, findings regarding the role of RAGE in animal 
models of asthma may have substantial bearing on other models of disease. First, results in the 
ovalbumin and HDM extract models of asthma may be confirmed using other antigens (e.g. 
cockroach feces) and other strains (e.g. BALB/c). Furthermore, RAGE’s role in the early phase 
of allergic airway disease/asthma must be elucidated using more acute models of disease. 
Second, it was observed that wild type, but not RAGE KO, mice treated with HDM extract 
develop prominent vascular smooth muscle hyperplasia, a histologic phenotype remarkably 
similar to that seen in pulmonary hypertension. Although smooth muscle hyperplasia may 
represent merely a reaction to the inflammatory milieu in the lung, it is worth exploring the 
feasibility of using HDM extract to develop mouse models of pulmonary hypertension, 
especially as RAGE has recently been found to be critically involved in vascular remodeling.340 
Finally, RAGE’s prominent role in the maladaptive allergic response suggests that it may be 
involved in the adaptive response to helminth infection. Indeed, from the pharmacologic 
standpoint, RAGE affinity for glycans makes it a prime candidate for a pattern recognition 
receptor for parasites and helminths, which are rich in glycoproteins and glycolipids and whose 
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glycans are increasingly recognized as profoundly immunomodulatory.341-343 Investigation of the 
role of RAGE in animal models of nematode (e.g. Nippostrongylus) and trematode (e.g. 
Schistosoma) infection would address some of these questions. 
It must be stated that these studies of the role of RAGE in asthma were conducted 
exclusively using mouse models of allergic airway disease/asthma, with well-controlled 
application of allergen and inbred mouse strains. The human disease is far more complex, with 
substantial genetic heterogeneity, varied environmental triggers, and variable phenotype and 
responsiveness to treatment. Bearing in mind these not uncommon discrepancies between animal 
disease models and the human conditions they attempt to model, the studies conducted thus far 
strongly suggest that RAGE is a potential therapeutic target in the treatment of asthma. Small 
molecule RAGE inhibitors, such as the recently developed compound TTP488 (already in 
clinical trials in Alzheimer’s disease patients), may be tested in mice to lend further support to 
the conclusions drawn from the sRAGE therapeutic studies, as well as to assess for possible side 
effects of RAGE inhibition. Use of such inhibitors would also provide an answer to the question 
of whether RAGE inhibition in frank allergic airway disease/asthma has the capacity to 
ameliorate disease phenotype (to test this, anti-RAGE therapy would commence after allergic 
airway disease was fully established). Finally, confirmatory studies on human lung tissue 
explants, primary culture cells, and on BALF and serum samples will be necessary to establish 
the degree to which the results in mice apply in humans. With regard to this, the elucidation of 
the signaling circuits by which a disease process initiating in the distal alveolus progresses 
proximally to result in a predominantly bronchial disease will constitute an important aim of 
future research. 
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APPENDIX 
Table 1. RAGE binding partners detected in HDM extract, identified by mass spectrometry. 
Accession 
No. Protein Name Mass kDa Score 
Coverage 
% emPAI 
gi|49066042 RecName: Full=Calmodulin-alpha; Short=CaM A 16.037 1597 23.2 0.92 
gi|2353266 tropomyosin [Dermatophagoides pteronyssinus] 32.953 1482 49.3 4.08 
gi|162532787 calmodulin 1 [Crassostrea ariakensis] 5.657 232 75 0.76 
gi|196476746 calmodulin 2 [Amblyomma americanum] 4.294 210 42.1 3.15 
gi|136050 RecName: Full=Troponin C 17.422 190 20.3 0.22 
gi|308476320 hypothetical protein CRE_18007 [Caenorhabditis remanei] 41.642 149 5.6 0.19 
gi|62825408 calmodulin [Orthopyxis integra] 11.94 127 32.7 0.77 
gi|20385544 group 14 allergen protein [Dermatophagoides pteronyssinus] 191.455 122 3.1 0.06 
gi|219815476 troponin C [Tyrophagus putrescentiae] 17.68 91 15 0.22 
gi|156336944 
hypothetical protein 
NEMVEDRAFT_v1g150407 
[Nematostella vectensis] 
7.062 79 29.7 0.59 
gi|15072346 ferritin heavy chain-like protein [Dermatophagoides pteronyssinus] 20.875 65 5.6 0.18 
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Table 1 (continued). 
gi|48112268 PREDICTED: hypothetical protein LOC409648 [Apis mellifera] 22.995 63 4 0.17 
gi|2347119 thioredoxin peroxidase [Dirofilaria immitis] 22.336 61 5.5 0.17 
gi|241999902 bridging integrator, putative [Ixodes scapularis] 75.409 58 1.7 0.05 
gi|321462817 
hypothetical protein 
DAPPUDRAFT_215354 [Daphnia 
pulex] 
61.061 56 1.7 0.06 
 
 
 
Table 2. RAGE binding partners, identified by mass spectrometry, detected in lung homogenates 
from WT or RAGE KO mice treated with HDM extract or saline control. 
Accession 
No. Protein Name Mass kDa Score 
Coverage 
% emPAI 
WT, saline-treated 
P43277 Histone H1.3 22.1 3015 28.1 5.8 
P43274 Histone H1.4 21.977 2928 28.3 5.87 
P43276 Histone H1.5 22.576 1248 27.4 3.1 
P09405 Nucleolin 76.723 1086 16.1 0.76 
Q9CZX8 40S ribosomal protein S19 16.085 907 37.9 3.55 
Q8CGP5 Histone H2A type 1-F 14.162 845 15.4 1.08 
P67984 60S ribosomal protein L22 14.759 795 28.9 1.56 
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Table 2 (continued). 
P28653 Biglycan 41.639 761 9.2 0.41 
P60710 Actin, cytoplasmic 1 41.737 738 14.1 0.53 
Q64475 Histone H2B type 1-B 13.952 730 33.3 1.69 
P43275 Histone H1.1 21.785 728 17.4 1.25 
P10922 Histone H1.0 20.861 486 16 0.96 
P62751 60S ribosomal protein L23a 17.695 476 16 0.81 
P62852 40S ribosomal protein S25 13.742 438 26.4 1.12 
Q6ZWV7 60S ribosomal protein L35 14.553 436 22 1.59 
A2ASQ1 Agrin 207.539 428 2.9 0.07 
P62889 60S ribosomal protein L30 12.784 383 31.3 1.22 
Q62151 Advanced glycosylation end product-specific receptor 42.669 331 3.5 0.18 
P28654 Decorin 39.809 322 12.1 0.43 
P62806 Histone H4 11.367 303 29.1 1.47 
P97352 Protein S100-A13 11.158 299 19.4 0.85 
Q05793 
Basement membrane-specific 
heparan sulfate proteoglycan core 
protein 
398.294 299 1.6 0.05 
O54724 Polymerase I and transcript release factor 43.954 287 6.6 0.39 
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Table 2 (continued). 
P68433 Histone H3.1 15.404 252 13.2 0.56 
P63017 Heat shock cognate 71 kDa protein 70.871 246 6 0.17 
Q8VCC9 Spondin-1 90.821 227 3.7 0.12 
Q9JHL1 Na(+)/H(+) exchange regulatory cofactor NHE-RF2 37.403 204 8 0.21 
Q8VCT4 Carboxylesterase 3 61.788 202 4.8 0.19 
P62900 60S ribosomal protein L31 14.463 194 16.8 1.05 
P62204 Calmodulin 16.838 185 15.4 0.51 
P20029 78 kDa glucose-regulated protein 72.422 175 3.5 0.11 
Q8BP67 60S ribosomal protein L24 17.779 174 8.3 0.22 
P62264 40S ribosomal protein S14 16.273 174 15.9 0.53 
P10649 Glutathione S-transferase Mu 1 25.97 171 13.8 0.5 
P47738 Aldehyde dehydrogenase, mitochondrial 56.538 171 3.7 0.13 
O08553 Dihydropyrimidinase-related protein 2 62.278 168 5.2 0.19 
P62862 40S ribosomal protein S30 6.648 168 16.9 0.63 
Q9CR57 60S ribosomal protein L14 23.564 168 6 0.16 
P68372 Tubulin beta-2C chain 49.831 165 8.3 0.24 
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Table 2 (continued). 
P61255 60S ribosomal protein L26 17.258 164 17.2 0.84 
P15532 Nucleoside diphosphate kinase A 17.208 161 17.1 0.5 
P29341 Polyadenylate-binding protein 1 70.671 159 3.5 0.11 
P62082 40S ribosomal protein S7 22.127 155 18 0.89 
Q63918 Serum deprivation-response protein 46.764 153 6.9 0.26 
P97351 40S ribosomal protein S3a 29.885 146 7.6 0.27 
P47911 60S ribosomal protein L6 33.51 146 9.5 0.38 
P50404 Pulmonary surfactant-associated protein D 37.688 145 4.8 0.21 
P62908 40S ribosomal protein S3 26.674 137 12.8 0.49 
P62320 Small nuclear ribonucleoprotein Sm D3 13.916 130 15.1 0.64 
P10126 Elongation factor 1-alpha 1 50.114 128 2.4 0.07 
P62141 
Serine/threonine-protein 
phosphatase PP1-beta catalytic 
subunit 
37.187 126 3.1 0.1 
Q62093 Serine/arginine-rich splicing factor 2 25.476 125 3.6 0.15 
A2AJK6 Chromodomain-helicase-DNA-binding protein 7 334.061 116 0.2 0.01 
P12970 60S ribosomal protein L7a 29.977 115 10.5 0.43 
P97315 Cysteine and glycine-rich protein 1 20.583 114 7.8 0.18 
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Table 2 (continued). 
P24549 Retinal dehydrogenase 1 54.468 114 5 0.22 
P61358 60S ribosomal protein L27 15.798 112 5.9 0.25 
Q8CCK0 Core histone macro-H2A.2 40.092 111 2.4 0.09 
Q8CI43 Myosin light chain 6B 22.749 105 6.3 0.17 
O35381 
Acidic leucine-rich nuclear 
phosphoprotein 32 family member 
A 
28.538 105 9.7 0.45 
P32067 Lupus La protein homolog 47.756 103 2.4 0.08 
P30115 Glutathione S-transferase A3 25.361 100 7.2 0.32 
P47915 60S ribosomal protein L29 17.587 98 6.9 0.22 
P39447 Tight junction protein ZO-1 194.742 96 0.6 0.02 
P01942 Hemoglobin subunit alpha 15.085 95 16.9 0.58 
Q9JJH1 Ribonuclease 4 17.025 90 7.4 0.22 
P97429 Annexin A4 35.916 88 6.3 0.22 
P84099 60S ribosomal protein L19 23.466 86 4.6 0.16 
P62242 40S ribosomal protein S8 24.205 86 6.3 0.16 
P14069 Protein S100-A6 10.051 85 9 0.4 
P20152 Vimentin 53.688 85 8.6 0.22 
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Table 2 (continued). 
P26041 Moesin 67.767 85 2.9 0.11 
P62270 40S ribosomal protein S18 17.719 79 13.2 0.48 
P05064 Fructose-bisphosphate aldolase A 39.356 78 3 0.09 
P16858 Glyceraldehyde-3-phosphate dehydrogenase 35.81 77 4.5 0.1 
P70441 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 38.6 76 3.1 0.1 
Q9Z204 Heterogeneous nuclear ribonucleoproteins C1/C2 34.385 75 6.1 0.23 
Q8BH43 Wiskott-Aldrich syndrome protein family member 2 54.074 75 3.6 0.14 
Q61937 Nucleophosmin 32.56 74 4.5 0.12 
P63101 14-3-3 protein zeta/delta 27.771 74 5.7 0.14 
Q9EQU5 Protein SET 33.378 73 3.5 0.11 
Q6IFZ6 Keratin, type II cytoskeletal 1b 61.359 72 2.1 0.06 
P48036 Annexin A5 35.752 72 6.6 0.22 
P26040 Ezrin 69.407 71 2.9 0.11 
Q62376 U1 small nuclear ribonucleoprotein 70 kDa 51.992 69 1.6 0.07 
Q06318 Uteroglobin 10.519 67 10.4 0.37 
P35979 60S ribosomal protein L12 17.805 67 5.5 0.21 
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Table 2 (continued). 
Q62465 Synaptic vesicle membrane protein VAT-1 homolog 43.097 66 4.9 0.18 
P11247 Myeloperoxidase 81.182 66 1.3 0.05 
P35242 Pulmonary surfactant-associated protein A 26.157 63 5.2 0.14 
Q7TMK9 Heterogeneous nuclear ribonucleoprotein Q 69.633 62 1.3 0.05 
Q60972 Histone-binding protein RBBP4 47.656 62 1.6 0.08 
Q9JJW6 RNA and export factor-binding protein 2 23.73 61 5 0.16 
Q03265 ATP synthase subunit alpha, mitochondrial 59.753 61 1.8 0.06 
Q3TEA8 Heterochromatin protein 1-binding protein 3 60.867 61 3.4 0.13 
Q9CQI7 U2 small nuclear ribonucleoprotein B'' 25.323 59 3.6 0.15 
Q8C119 Protein NDNF 65.027 59 1.9 0.06 
P97447 Four and a half LIM domains protein 1 31.889 59 3.9 0.11 
Q9CYR0 Single-stranded DNA-binding protein, mitochondrial 17.319 59 5.3 0.22 
P40936 Indolethylamine N-methyltransferase 29.46 57 4.2 0.13 
P11499 Heat shock protein HSP 90-beta 83.281 57 1.4 0.04 
P62918 60S ribosomal protein L8 28.025 55 4.3 0.13 
Q60737 Casein kinase II subunit alpha 45.134 54 1.8 0.08 
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Table 2 (continued). 
O08709 Peroxiredoxin-6 24.871 52 8 0.33 
Q9Z1P7 KN motif and ankyrin repeat domain-containing protein 3 84.186 52 2.3 0.09 
P62702 40S ribosomal protein S4, X isoform 29.598 51 2.7 0.13 
P62754 40S ribosomal protein S6 28.681 50 3.2 0.13 
Q9DCW4 Electron transfer flavoprotein subunit beta 27.623 48 4.3 0.14 
P97822 
Acidic leucine-rich nuclear 
phosphoprotein 32 family member 
E 
29.622 48 5.4 0.13 
P08074 Carbonyl reductase [NADPH] 2 25.958 47 4.5 0.15 
P58252 Elongation factor 2 95.314 46 1 0.04 
Q8VHE6 Dynein heavy chain 5, axonemal 527.558 46 0.2 0.01 
P40630 Transcription factor A, mitochondrial 27.988 46 4.5 0.13 
P17563 Selenium-binding protein 1 52.514 46 2.3 0.07 
P47962 60S ribosomal protein L5 34.401 45 4.4 0.11 
Q9WVE8 Protein kinase C and casein kinase substrate in neurons protein 2 55.833 45 1.9 0.07 
Q9CXW4 60S ribosomal protein L11 20.252 44 5.1 0.19 
P60867 40S ribosomal protein S20 13.373 44 5.9 0.29 
P70279 Surfeit locus protein 6 41.235 43 2.3 0.09 
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Table 2 (continued). 
Q99K48 Non-POU domain-containing octamer-binding protein 54.541 43 1.7 0.07 
P07724 Serum albumin 68.693 43 1.6 0.05 
O55142 60S ribosomal protein L35a 12.554 42 6.4 0.31 
Q6ZWN5 40S ribosomal protein S9 22.591 41 4.1 0.17 
P27048 Small nuclear ribonucleoprotein-associated protein B 23.656 40 3 0.16 
WT, HDM extract-treated 
P09405 Nucleolin 76.723 1804 18 0.76 
Q64475 Histone H2B type 1-B 13.952 1192 31.7 1.69 
P28653 Biglycan 41.639 1064 19.5 0.82 
P62204 Calmodulin 16.838 1031 55 1.29 
Q62151 Advanced glycosylation end product-specific receptor 42.669 966 24.6 0.52 
Q8CGP5 Histone H2A type 1-F 14.162 924 21.5 0.63 
P67984 60S ribosomal protein L22 14.759 923 49.2 2.24 
P62082 40S ribosomal protein S7 22.127 828 29.9 1.61 
Q9CZX8 40S ribosomal protein S19 16.085 786 40 3.55 
P43274 Histone H1.4 21.977 732 21.9 1.23 
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Table 2 (continued). 
P62751 60S ribosomal protein L23a 17.695 704 16 0.81 
P43277 Histone H1.3 22.1 688 21.7 1.22 
Q61937 Nucleophosmin 32.56 460 12.3 0.39 
P62889 60S ribosomal protein L30 12.784 424 31.3 0.7 
P62737 Actin, aortic smooth muscle 42.009 385 9.3 0.18 
P99024 Tubulin beta-5 chain 49.671 366 9.9 0.33 
P68372 Tubulin beta-2C chain 49.831 338 9.9 0.33 
P62852 40S ribosomal protein S25 13.742 333 20.8 1.12 
P32067 Lupus La protein homolog 47.756 324 5.8 0.16 
P62320 Small nuclear ribonucleoprotein Sm D3 13.916 301 15.1 0.64 
O54724 Polymerase I and transcript release factor 43.954 294 13.3 0.28 
P16254 Signal recognition particle 14 kDa protein 12.51 288 12.7 0.31 
P16110 Galectin-3 27.515 282 5.7 0.14 
Q922U2 Keratin, type II cytoskeletal 5 61.767 282 2.1 0.06 
P62900 60S ribosomal protein L31 14.463 253 21.6 1.05 
P62309 Small nuclear ribonucleoprotein G 8.496 251 17.1 0.48 
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Table 2 (continued). 
P97315 Cysteine and glycine-rich protein 1 20.583 248 7.8 0.18 
P62862 40S ribosomal protein S30 6.648 230 18.6 1.66 
P97352 Protein S100-A13 11.158 228 17.3 0.36 
Q9Z204 Heterogeneous nuclear ribonucleoproteins C1/C2 34.385 222 6.7 0.23 
P62315 Small nuclear ribonucleoprotein Sm D1 13.282 211 16.8 0.3 
P62305 Small nuclear ribonucleoprotein E 10.804 206 29.3 1.56 
Q6ZWV7 60S ribosomal protein L35 14.553 204 22 0.61 
Q8VCC9 Spondin-1 90.821 198 4.3 0.12 
P24369 Peptidyl-prolyl cis-trans isomerase B 23.713 198 7.9 0.35 
P62806 Histone H4 11.367 196 17.5 0.83 
P27048 Small nuclear ribonucleoprotein-associated protein B 23.656 186 9.5 0.56 
Q9EQU5 Protein SET 33.378 185 3.5 0.11 
P26040 Ezrin 69.407 179 4.1 0.11 
P68369 Tubulin alpha-1A chain 50.136 159 3.3 0.07 
P97351 40S ribosomal protein S3a 29.885 152 11.7 0.43 
Q8BP67 60S ribosomal protein L24 17.779 130 8.3 0.22 
 160 
Table 2 (continued). 
P62843 40S ribosomal protein S15 17.04 128 15.2 0.23 
P28654 Decorin 39.809 124 5.9 0.2 
P28656 Nucleosome assembly protein 1-like 1 45.345 120 4.3 0.08 
P68433 Histone H3.1 15.404 118 5.1 0.25 
P63325 40S ribosomal protein S10 18.916 114 5.5 0.2 
Q60972 Histone-binding protein RBBP4 47.656 112 5.4 0.25 
P63017 Heat shock cognate 71 kDa protein 70.871 108 5.3 0.11 
P02104 Hemoglobin subunit epsilon-Y2 16.137 105 6.8 0.24 
P10922 Histone H1.0 20.861 101 8.8 0.4 
P29341 Polyadenylate-binding protein 1 70.671 98 3.5 0.05 
Q9CXW4 60S ribosomal protein L11 20.252 97 7.9 0.19 
P01942 Hemoglobin subunit alpha 15.085 94 6.3 0.26 
Q3UPL0 Protein transport protein Sec31A 133.569 91 0.6 0.03 
Q63918 Serum deprivation-response protein 46.764 87 6.2 0.17 
P61255 60S ribosomal protein L26 17.258 84 10.3 0.5 
P16858 Glyceraldehyde-3-phosphate dehydrogenase 35.81 79 3.6 0.1 
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Table 2 (continued). 
A2BDX3 Adenylyltransferase and sulfurtransferase MOCS3 49.375 77 2 0.07 
P10126 Elongation factor 1-alpha 1 50.114 68 2.4 0.07 
P12970 60S ribosomal protein L7a 29.977 67 4.1 0.13 
P30115 Glutathione S-transferase A3 25.361 65 12.2 0.15 
Q62376 U1 small nuclear ribonucleoprotein 70 kDa 51.992 64 1.6 0.07 
Q62093 Serine/arginine-rich splicing factor 2 25.476 62 3.6 0.15 
O35381 
Acidic leucine-rich nuclear 
phosphoprotein 32 family member 
A 
28.538 59 2.4 0.13 
P62307 Small nuclear ribonucleoprotein F 9.725 57 9.3 0.41 
Q7TMK9 Heterogeneous nuclear ribonucleoprotein Q 69.633 55 1.3 0.05 
P84104 Splicing factor, arginine/serine-rich 3 19.33 53 5.5 0.2 
Q8BH43 Wiskott-Aldrich syndrome protein family member 2 54.074 47 1.6 0.07 
Q8VEK3 Heterogeneous nuclear ribonucleoprotein U 87.918 45 0.9 0.04 
P62702 40S ribosomal protein S4, X isoform 29.598 34 3.4 0.13 
RAGE KO, saline-treated 
P09405 Nucleolin 76.723 2307 27.9 1.57 
Q8VCC9 Spondin-1 90.821 1922 25.7 0.94 
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Table 2 (continued). 
P43274 Histone H1.4 21.977 1912 28.3 3.98 
P15864 Histone H1.2 21.267 1609 33.5 3.46 
Q9CZX8 40S ribosomal protein S19 16.085 1362 57.9 7.7 
P62204 Calmodulin 16.838 1213 41.6 1.29 
P28653 Biglycan 41.639 1176 23 0.98 
P67984 60S ribosomal protein L22 14.759 1147 40.6 2.24 
P60710 Actin, cytoplasmic 1 41.737 1136 22.1 0.82 
Q8R1M2 Histone H2A.J 14.045 1130 43.4 1.69 
P10922 Histone H1.0 20.861 1029 34 2.86 
Q6GSS7 Histone H2A type 2-A 14.095 1016 43.1 1.67 
Q64475 Histone H2B type 1-B 13.952 960 43.7 6.23 
P62889 60S ribosomal protein L30 12.784 857 60 9.87 
P68372 Tubulin beta-2C chain 49.831 850 21.1 0.77 
Q9ERD7 Tubulin beta-3 chain 50.419 776 15.8 0.53 
P63017 Heat shock cognate 71 kDa protein 70.871 774 22.9 0.58 
P62806 Histone H4 11.367 738 45.6 5.1 
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Table 2 (continued). 
P43276 Histone H1.5 22.576 687 25.6 2 
P62751 60S ribosomal protein L23a 17.695 616 23.7 2.28 
O08583 THO complex subunit 4 26.94 501 12.5 0.48 
O35381 
Acidic leucine-rich nuclear 
phosphoprotein 32 family member 
A 
28.538 499 15.4 1.11 
Q6ZWV7 60S ribosomal protein L35 14.553 488 22 0.61 
P43275 Histone H1.1 21.785 469 11.7 0.63 
P62082 40S ribosomal protein S7 22.127 467 26.8 1.61 
P47962 60S ribosomal protein L5 34.401 454 20.5 0.68 
P62900 60S ribosomal protein L31 14.463 444 24.8 1.61 
P62852 40S ribosomal protein S25 13.742 392 32 1.73 
P97352 Protein S100-A13 11.158 372 19.4 0.85 
Q61937 Nucleophosmin 32.56 368 13 0.39 
Q9Z204 Heterogeneous nuclear ribonucleoproteins C1/C2 34.385 366 15 0.87 
Q62151 Advanced glycosylation end product-specific receptor 42.669 338 6.5 0.29 
P62320 Small nuclear ribonucleoprotein Sm D3 13.916 334 17.5 1.1 
O08553 Dihydropyrimidinase-related protein 2 62.278 331 10.8 0.41 
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Table 2 (continued). 
P28654 Decorin 39.809 327 9.9 0.31 
Q9EST5 
Acidic leucine-rich nuclear 
phosphoprotein 32 family member 
B 
31.079 312 10.3 0.58 
Q9EQU5 Protein SET 33.378 309 9.3 0.24 
Q9JHL1 Na(+)/H(+) exchange regulatory cofactor NHE-RF2 37.403 304 8 0.21 
P62305 Small nuclear ribonucleoprotein E 10.804 300 29.3 0.87 
Q60972 Histone-binding protein RBBP4 47.656 292 11.8 0.35 
Q9CXW4 60S ribosomal protein L11 20.252 258 19.7 0.68 
P16110 Galectin-3 27.515 255 15.2 0.47 
P42669 Transcriptional activator protein Pur-alpha 34.884 253 11.2 0.23 
P16858 Glyceraldehyde-3-phosphate dehydrogenase 35.81 241 3.6 0.1 
P97351 40S ribosomal protein S3a 29.885 238 37.1 1.04 
P32067 Lupus La protein homolog 47.756 236 8.9 0.25 
P70441 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 38.6 230 5.9 0.2 
P01942 Hemoglobin subunit alpha 15.085 229 21.8 0.99 
P68433 Histone H3.1 15.404 221 20.6 0.96 
P97315 Cysteine and glycine-rich protein 1 20.583 208 7.8 0.18 
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Table 2 (continued). 
Q05793 
Basement membrane-specific 
heparan sulfate proteoglycan core 
protein 
398.294 203 1.1 0.04 
P62862 40S ribosomal protein S30 6.648 203 18.6 1.66 
P97822 
Acidic leucine-rich nuclear 
phosphoprotein 32 family member 
E 
29.622 198 9.6 0.61 
P68369 Tubulin alpha-1A chain 50.136 188 8.6 0.15 
Q8VEK3 Heterogeneous nuclear ribonucleoprotein U 87.918 187 8.5 0.23 
Q62465 Synaptic vesicle membrane protein VAT-1 homolog 43.097 185 7.9 0.28 
P62309 Small nuclear ribonucleoprotein G 8.496 179 17.1 0.48 
Q61074 Protein phosphatase 1G 58.728 172 4.4 0.06 
P24369 Peptidyl-prolyl cis-trans isomerase B 23.713 166 7.9 0.35 
P28656 Nucleosome assembly protein 1-like 1 45.345 163 6.9 0.17 
P62307 Small nuclear ribonucleoprotein F 9.725 160 24.4 1 
Q8BP67 60S ribosomal protein L24 17.779 158 8.3 0.22 
P63325 40S ribosomal protein S10 18.916 155 11.5 0.45 
O54724 Polymerase I and transcript release factor 43.954 152 13.3 0.28 
P16254 Signal recognition particle 14 kDa protein 12.51 151 21.8 0.72 
Q9CR57 60S ribosomal protein L14 23.564 150 6 0.16 
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Table 2 (continued). 
P10126 Elongation factor 1-alpha 1 50.114 147 4.3 0.15 
P27048 Small nuclear ribonucleoprotein-associated protein B 23.656 145 9.5 0.56 
P57776 Elongation factor 1-delta 31.293 143 7.8 0.25 
Q91VM5 Heterogeneous nuclear ribonucleoprotein G-like 1 42.162 141 8.5 0.19 
Q9WVE8 Protein kinase C and casein kinase substrate in neurons protein 2 55.833 139 7 0.14 
P26040 Ezrin 69.407 134 2.9 0.05 
Q9CQI7 U2 small nuclear ribonucleoprotein B'' 25.323 133 9.3 0.32 
P62702 40S ribosomal protein S4, X isoform 29.598 132 9.9 0.43 
Q9DBR7 Protein phosphatase 1 regulatory subunit 12A 114.996 119 3.6 0.1 
Q922U2 Keratin, type II cytoskeletal 5 61.767 116 3.3 0.06 
P02104 Hemoglobin subunit epsilon-Y2 16.137 116 6.8 0.24 
Q8CCK0 Core histone macro-H2A.2 40.092 115 2.4 0.09 
Q62093 Serine/arginine-rich splicing factor 2 25.476 114 3.6 0.15 
P24549 Retinal dehydrogenase 1 54.468 113 2 0.07 
Q7TMK9 Heterogeneous nuclear ribonucleoprotein Q 69.633 113 1.3 0.05 
A2ASQ1 Agrin 207.539 107 0.6 0.02 
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Table 2 (continued). 
P47911 60S ribosomal protein L6 33.51 105 9.5 0.38 
Q8C4U3 Secreted frizzled-related protein 1 35.413 102 12.4 0.22 
P61255 60S ribosomal protein L26 17.258 100 17.2 0.84 
Q9DCT8 Cysteine-rich protein 2 22.727 99 10.6 0.16 
Q9D0J8 Parathymosin 11.43 98 11.9 0.35 
O55126 Protein NipSnap homolog 2 32.933 97 3.9 0.11 
P29341 Polyadenylate-binding protein 1 70.671 96 3.1 0.05 
Q8BH43 Wiskott-Aldrich syndrome protein family member 2 54.074 92 3.6 0.14 
P10649 Glutathione S-transferase Mu 1 25.97 91 8.7 0.31 
P08074 Carbonyl reductase [NADPH] 2 25.958 89 4.5 0.15 
P20152 Vimentin 53.688 89 6.4 0.07 
O09118 Netrin-1 67.81 87 4.5 0.05 
Q63918 Serum deprivation-response protein 46.764 81 9.3 0.17 
Q8VE97 Serine/arginine-rich splicing factor 4 55.979 80 1.8 0.07 
P57784 U2 small nuclear ribonucleoprotein A' 28.357 80 4.3 0.13 
Q62376 U1 small nuclear ribonucleoprotein 70 kDa 51.992 76 1.6 0.07 
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Table 2 (continued). 
Q3TEA8 Heterochromatin protein 1-binding protein 3 60.867 75 6.7 0.19 
P84104 Splicing factor, arginine/serine-rich 3 19.33 73 5.5 0.2 
P61358 60S ribosomal protein L27 15.798 69 5.9 0.25 
P62245 40S ribosomal protein S15a 14.84 66 20 0.59 
P50404 Pulmonary surfactant-associated protein D 37.688 62 2.1 0.1 
P35700 Peroxiredoxin-1 22.176 60 5.5 0.17 
P12970 60S ribosomal protein L7a 29.977 59 4.1 0.13 
P30115 Glutathione S-transferase A3 25.361 58 10.9 0.32 
P14152 Malate dehydrogenase, cytoplasmic 36.511 55 3.6 0.1 
O35295 Transcriptional activator protein Pur-beta 33.901 51 5.2 0.23 
P47955 60S acidic ribosomal protein P1 11.475 51 14 0.34 
Q6ZWN5 40S ribosomal protein S9 22.591 51 4.1 0.17 
Q7TNV0 Protein DEK 43.159 50 1.6 0.09 
Q3UPL0 Protein transport protein Sec31A 133.569 50 0.6 0.03 
P48036 Annexin A5 35.752 49 6.3 0.11 
Q9JKB3 DNA-binding protein A 38.814 45 2.2 0.1 
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Table 2 (continued). 
Q8CI43 Myosin light chain 6B 22.749 44 6.3 0.17 
P47738 Aldehyde dehydrogenase, mitochondrial 56.538 44 1.9 0.07 
Q8R1B4 Eukaryotic translation initiation factor 3 subunit C 105.531 43 1 0.03 
P97447 Four and a half LIM domains protein 1 31.889 42 5.4 0.11 
Q9CQV8 14-3-3 protein beta/alpha 28.086 41 6.5 0.13 
Q9CWL8 Beta-catenin-like protein 1 64.98 41 1.4 0.06 
P15532 Nucleoside diphosphate kinase A 17.208 41 13.8 0.22 
P15626 Glutathione S-transferase Mu 2 25.717 41 3.2 0.15 
P60867 40S ribosomal protein S20 13.373 40 16 0.29 
P40630 Transcription factor A, mitochondrial 27.988 37 6.2 0.13 
P47915 60S ribosomal protein L29 17.587 35 5.6 0.22 
RAGE KO, HDM extract-treated 
P09405 Nucleolin 76.723 2168 19.8 0.94 
P28653 Biglycan 41.639 1604 19.5 0.82 
Q6GSS7 Histone H2A type 2-A 14.095 1459 43.8 1.09 
Q8VCC9 Spondin-1 90.821 1292 24.4 0.66 
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Table 2 (continued). 
P68372 Tubulin beta-2C chain 49.831 1276 25.2 1.05 
Q8CGP5 Histone H2A type 1-F 14.162 1267 30 1.08 
Q64475 Histone H2B type 1-B 13.952 1221 31.7 1.69 
P62082 40S ribosomal protein S7 22.127 1098 34 2.06 
P62204 Calmodulin 16.838 1053 41.6 1.29 
Q9CZX8 40S ribosomal protein S19 16.085 1033 46.2 6.01 
P43274 Histone H1.4 21.977 973 22.4 1.62 
P43277 Histone H1.3 22.1 963 22.6 2.06 
P67984 60S ribosomal protein L22 14.759 952 40.6 2.24 
Q7TMM9 Tubulin beta-2A chain 49.907 827 17.1 0.54 
Q61937 Nucleophosmin 32.56 798 14.7 0.55 
P60710 Actin, cytoplasmic 1 41.737 794 22.1 0.82 
P62751 60S ribosomal protein L23a 17.695 773 16 0.81 
P62889 60S ribosomal protein L30 12.784 725 41.7 2.76 
P32067 Lupus La protein homolog 47.756 561 13 0.35 
O35381 
Acidic leucine-rich nuclear 
phosphoprotein 32 family member 
A 
28.538 470 21.5 0.64 
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Table 2 (continued). 
Q62151 Advanced glycosylation end product-specific receptor 42.669 464 9.2 0.18 
P97352 Protein S100-A13 11.158 403 19.4 0.85 
P62900 60S ribosomal protein L31 14.463 403 24.8 1.61 
Q6ZWV7 60S ribosomal protein L35 14.553 401 22 0.61 
P28654 Decorin 39.809 396 9.9 0.31 
P62806 Histone H4 11.367 390 34 3.51 
Q9Z204 Heterogeneous nuclear ribonucleoproteins C1/C2 34.385 361 12.5 0.87 
P68369 Tubulin alpha-1A chain 50.136 347 9.3 0.24 
P63017 Heat shock cognate 71 kDa protein 70.871 341 10.7 0.23 
P62320 Small nuclear ribonucleoprotein Sm D3 13.916 316 15.1 0.64 
P62305 Small nuclear ribonucleoprotein E 10.804 314 29.3 0.87 
P62852 40S ribosomal protein S25 13.742 302 20.8 0.65 
P16254 Signal recognition particle 14 kDa protein 12.51 301 12.7 0.72 
P47962 60S ribosomal protein L5 34.401 282 9.4 0.23 
P16110 Galectin-3 27.515 275 5.7 0.14 
P97351 40S ribosomal protein S3a 29.885 271 25 1.29 
 172 
Table 2 (continued). 
P97315 Cysteine and glycine-rich protein 1 20.583 246 7.8 0.18 
Q9EQU5 Protein SET 33.378 245 9.7 0.38 
Q9EST5 
Acidic leucine-rich nuclear 
phosphoprotein 32 family member 
B 
31.079 243 9.9 0.26 
P16858 Glyceraldehyde-3-phosphate dehydrogenase 35.81 223 3.6 0.1 
P62862 40S ribosomal protein S30 6.648 218 18.6 1.66 
P62309 Small nuclear ribonucleoprotein G 8.496 218 17.1 0.48 
O54724 Polymerase I and transcript release factor 43.954 215 7.1 0.18 
Q922U2 Keratin, type II cytoskeletal 5 61.767 215 2.1 0.06 
P97822 
Acidic leucine-rich nuclear 
phosphoprotein 32 family member 
E 
29.622 205 11.9 0.27 
Q61074 Protein phosphatase 1G 58.728 199 4.8 0.13 
P24369 Peptidyl-prolyl cis-trans isomerase B 23.713 174 7.9 0.35 
P28656 Nucleosome assembly protein 1-like 1 45.345 171 4.3 0.08 
P26040 Ezrin 69.407 163 4.1 0.11 
Q8BP67 60S ribosomal protein L24 17.779 156 8.3 0.22 
P10126 Elongation factor 1-alpha 1 50.114 145 4.3 0.15 
P47911 60S ribosomal protein L6 33.51 139 9.5 0.24 
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Table 2 (continued). 
Q60972 Histone-binding protein RBBP4 47.656 134 9.2 0.25 
Q9CXW4 60S ribosomal protein L11 20.252 133 12.9 0.68 
P62702 40S ribosomal protein S4, X isoform 29.598 133 7.2 0.27 
P27048 Small nuclear ribonucleoprotein-associated protein B 23.656 133 9.5 0.56 
P61255 60S ribosomal protein L26 17.258 128 16.6 0.84 
P68433 Histone H3.1 15.404 127 13.2 0.56 
P70441 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 38.6 124 3.1 0.1 
P10922 Histone H1.0 20.861 123 8.8 0.4 
O08583 THO complex subunit 4 26.94 122 11.4 0.3 
P29341 Polyadenylate-binding protein 1 70.671 115 3.5 0.11 
Q62093 Serine/arginine-rich splicing factor 2 25.476 115 3.6 0.15 
P63325 40S ribosomal protein S10 18.916 111 5.5 0.2 
P02104 Hemoglobin subunit epsilon-Y2 16.137 108 6.8 0.24 
O55126 Protein NipSnap homolog 2 32.933 100 3.9 0.11 
Q7TMK9 Heterogeneous nuclear ribonucleoprotein Q 69.633 100 1.3 0.05 
Q9CR57 60S ribosomal protein L14 23.564 97 6 0.16 
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Table 2 (continued). 
P24549 Retinal dehydrogenase 1 54.468 94 2 0.07 
P20029 78 kDa glucose-regulated protein 72.422 85 2.1 0.05 
Q8C4U3 Secreted frizzled-related protein 1 35.413 85 7.3 0.1 
A2ASQ1 Agrin 207.539 82 0.6 0.02 
P61358 60S ribosomal protein L27 15.798 82 5.9 0.25 
P47955 60S acidic ribosomal protein P1 11.475 80 14 0.34 
P50404 Pulmonary surfactant-associated protein D 37.688 76 2.1 0.1 
P62307 Small nuclear ribonucleoprotein F 9.725 71 9.3 0.41 
P84104 Splicing factor, arginine/serine-rich 3 19.33 69 5.5 0.2 
Q3UPL0 Protein transport protein Sec31A 133.569 69 0.6 0.03 
P10649 Glutathione S-transferase Mu 1 25.97 67 8.7 0.31 
Q8VE97 Serine/arginine-rich splicing factor 4 55.979 65 1.8 0.07 
P01942 Hemoglobin subunit alpha 15.085 64 11.3 0.58 
P12970 60S ribosomal protein L7a 29.977 63 4.1 0.13 
Q63918 Serum deprivation-response protein 46.764 62 6.2 0.17 
Q8CCK0 Core histone macro-H2A.2 40.092 61 2.4 0.09 
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Table 2 (continued). 
Q62376 U1 small nuclear ribonucleoprotein 70 kDa 51.992 60 1.6 0.07 
Q8BH43 Wiskott-Aldrich syndrome protein family member 2 54.074 59 1.6 0.07 
P07901 Heat shock protein HSP 90-alpha 84.788 58 1.6 0.04 
P18760 Cofilin-1 18.56 57 8.4 0.21 
Q9QZZ6 Dermatopontin 23.995 56 5.5 0.16 
Q9JKB3 DNA-binding protein A 38.814 55 2.2 0.1 
P62245 40S ribosomal protein S15a 14.84 54 20 0.26 
P08113 Endoplasmin 92.476 53 1 0.04 
P40630 Transcription factor A, mitochondrial 27.988 49 6.2 0.13 
P47738 Aldehyde dehydrogenase, mitochondrial 56.538 48 1.9 0.07 
Q8VEK3 Heterogeneous nuclear ribonucleoprotein U 87.918 46 2 0.09 
Q62465 Synaptic vesicle membrane protein VAT-1 homolog 43.097 44 4.9 0.09 
Q3TEA8 Heterochromatin protein 1-binding protein 3 60.867 41 3.2 0.06 
Q9R0Q7 Prostaglandin E synthase 3 18.721 38 4.4 0.2 
P14211 Calreticulin 47.995 37 1.7 0.08 
P63101 14-3-3 protein zeta/delta 27.771 36 7.8 0.14 
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Table 2 (continued). 
O08553 Dihydropyrimidinase-related protein 2 62.278 36 3.1 0.06 
 
 
 
Table 3. Comparison of normalized emPAI values of RAGE binding partners in HDM extract-
treated vs. saline-treated WT or RAGE KO mice. 
Accession 
No. Protein Name 
Normalized emPAI (HDM extract-treated) > 
normalized emPAI (saline-treated)? (Y/N) 
 WT RAGE KO 
A2ASQ1 Agrin N Y 
A2BDX3 Adenylyltransferase and sulfurtransferase MOCS3 Y N 
O08583 THO complex subunit 4 N Y 
O35381 
Acidic leucine-rich nuclear 
phosphoprotein 32 family member 
A 
N Y 
O54724 Polymerase I and transcript release factor Y Y 
O55126 Protein NipSnap homolog 2 N Y 
P02104 Hemoglobin subunit epsilon-Y2 Y Y 
P07901 Heat shock protein HSP 90-alpha N Y 
P08113 Endoplasmin N Y 
P09405 Nucleolin Y N 
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Table 3 (continued). 
P10126 Elongation factor 1-alpha 1 Y Y 
P10649 Glutathione S-transferase Mu 1 N Y 
P12970 60S ribosomal protein L7a N Y 
P14211 Calreticulin N Y 
P16110 Galectin-3 Y N 
P16254 Signal recognition particle 14 kDa protein Y Y 
P16858 Glyceraldehyde-3-phosphate dehydrogenase Y Y 
P18760 Cofilin-1 N Y 
P20029 78 kDa glucose-regulated protein N Y 
P24369 Peptidyl-prolyl cis-trans isomerase B Y Y 
P24549 Retinal dehydrogenase 1 N Y 
P26040 Ezrin Y Y 
P27048 Small nuclear ribonucleoprotein-associated protein B Y Y 
P28653 Biglycan Y Y 
P28654 Decorin N Y 
P28656 Nucleosome assembly protein 1-like 1 Y N 
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Table 3 (continued). 
P29341 Polyadenylate-binding protein 1 N Y 
P32067 Lupus La protein homolog Y Y 
P40630 Transcription factor A, mitochondrial N Y 
P43277 Histone H1.3 N Y 
P47738 Aldehyde dehydrogenase, mitochondrial N Y 
P47911 60S ribosomal protein L6 N Y 
P47955 60S acidic ribosomal protein P1 N Y 
P50404 Pulmonary surfactant-associated protein D N Y 
P60710 Actin, cytoplasmic 1 N Y 
P61255 60S ribosomal protein L26 N Y 
P61255 60S ribosomal protein L26 N Y 
P61358 60S ribosomal protein L27 N Y 
P62082 40S ribosomal protein S7 Y Y 
P62204 Calmodulin Y Y 
P62305 Small nuclear ribonucleoprotein E Y Y 
P62307 Small nuclear ribonucleoprotein F Y N 
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Table 3 (continued). 
P62309 Small nuclear ribonucleoprotein G Y Y 
P62315 Small nuclear ribonucleoprotein Sm D1 Y N 
P62320 Small nuclear ribonucleoprotein Sm D3 Y N 
P62702 40S ribosomal protein S4, X isoform Y Y 
P62737 Actin, aortic smooth muscle Y N 
P62751 60S ribosomal protein L23a Y N 
P62806 Histone H4 N Y 
P62843 40S ribosomal protein S15 Y N 
P62852 40S ribosomal protein S25 Y N 
P62862 40S ribosomal protein S30 Y Y 
P62900 60S ribosomal protein L31 Y N 
P63017 Heat shock cognate 71 kDa protein Y N 
P63101 14-3-3 protein zeta/delta N Y 
P63325 40S ribosomal protein S10 Y N 
P67984 60S ribosomal protein L22 Y Y 
P68369 Tubulin alpha-1A chain Y Y 
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Table 3 (continued). 
P68372 Tubulin beta-2C chain Y Y 
P84104 Splicing factor, arginine/serine-rich 3 Y Y 
P97315 Cysteine and glycine-rich protein 1 Y Y 
P97351 40S ribosomal protein S3a Y Y 
P97352 Protein S100-A13 N Y 
P99024 Tubulin beta-5 chain Y N 
Q3UPL0 Protein transport protein Sec31A Y Y 
Q60972 Histone-binding protein RBBP4 Y Y 
Q61074 Protein phosphatase 1G N Y 
Q61937 Nucleophosmin Y Y 
Q62093 Serine/arginine-rich splicing factor 2 Y Y 
Q62151 Advanced glycosylation end product-specific receptor Y Y 
Q62376 U1 small nuclear ribonucleoprotein 70 kDa Y Y 
Q63918 Serum deprivation-response protein Y Y 
Q64475 Histone H2B type 1-B Y N 
Q6GSS7 Histone H2A type 2-A N Y 
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Table 3 (continued). 
Q6ZWV7 60S ribosomal protein L35 N Y 
Q7TMK9 Heterogeneous nuclear ribonucleoprotein Q Y Y 
Q7TMM9 Tubulin beta-2A chain N Y 
Q8BP67 60S ribosomal protein L24 Y Y 
Q8CCK0 Core histone macro-H2A.2 N Y 
Q8CGP5 Histone H2A type 1-F N Y 
Q8VCC9 Spondin-1 Y Y 
Q8VE97 Serine/arginine-rich splicing factor 4 N Y 
Q8VEK3 Heterogeneous nuclear ribonucleoprotein U Y N 
Q922U2 Keratin, type II cytoskeletal 5 Y Y 
Q9CR57 60S ribosomal protein L14 N Y 
Q9CXW4 60S ribosomal protein L11 Y Y 
Q9CZX8 40S ribosomal protein S19 Y Y 
Q9EQU5 Protein SET Y Y 
Q9JKB3 DNA-binding protein A N Y 
Q9QZZ6 Dermatopontin N Y 
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Table 3 (continued). 
Q9R0Q7 Prostaglandin E synthase 3 N Y 
Q9Z204 Heterogeneous nuclear ribonucleoproteins C1/C2 Y Y 
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